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Thesis Summary 
 
The blood brain barrier (BBB) poses a significant hurdle to brain drug delivery.  
However, the location of the olfactory mucosa, within the nasal cavity, is a viable target 
site for direct nose-to-brain (N2B) delivery, thereby bypassing the BBB.  To exploit this 
target site innovative nasal formulations are required for targeting and increasing 
residency within the olfactory mucosa. We developed and characterised three 
formulation systems for N2B delivery, (i) thermoresponsive mucoadhesion nasal gels 
sprays; (ii) mesoporous silica nanoparticles and (iii) nasal pMDI devices.  
We developed an optimal mucoadhesive formulation system incorporating 
amantadine as a model, water-soluble anti-Parkinson’s drug using carboxymethy 
cellulose and chitosan as mucoadhesives. Formulations demonstrated droplet sizes of 
< 130µm and stability over 8-weeks when stored at refrigeration conditions with no 
significant cellular toxicity against olfactory bulb (OBGF400) and nasal epithelial (RPMI 
2650) cells.   
Mesoporous silica nanoparticles (MSNP) were prepared (~220nm) and 
demonstrated cellular uptake into OBGF400 within 2-hours of incubation with minimal 
toxicity.  MSNP were loaded with two novel phytochemicals known to possess CNS 
activity, curcumin and chrysin, with loading efficiencies of ~12% confirmed through 
TGA, DSC and HPLC-UV analysis.  Furthermore, a pH dependant release profile was 
identified with curcumin with greater release at nasal cavity pH 5.5 compared to pH 7.4. 
Furthermore, successful incorporation of MSNP into nasal gels was demonstrated 
through rheological studies with a decrease in Tsol-gel.  
 A pilot study was conducted to assess the feasibility of modified existing pulmonary 
pMDI to deliver diazepam intranasally, targeting the olfactory mucosa.  Diazepam was 
formulated with HFA134a and using ethanol as a co-solvent, and demonstrated stability 
in formulation over 3 months. Deposition studies within a nasal cast model 
demonstrated 5-6% deposition onto the olfactory mucosa under optimal administration 
conditions in the absence of any nozzle attachments. 
Our studies have provided a basis for the development to innovative intranasal 
formulation systems potentially capable of targeting the olfactory mucosa for both water 
soluble and poorly soluble drugs. 
Key words: Olfactory, mucoadhesive, mesoporous silica nanoparticles, pMDI, 
 
 
 
 3
 
 
 
To 
 
My wife Madhu, daughter Urvee 
& 
Ma, Aba, Amar, Didi, Padu Bhavaji, Deepu, 
Shraddha, Premveer & Preetam. 
  
 4
Acknowledgements 
Firstly, I would like to express my sincere gratitude to my supervisor Dr. Raj K Singh 
Badhan for his invaluable guidance, encouragement, constant support and patience 
throughout this journey for the past few years, especially during the writing of my thesis, 
thank you for everything. 
I am thankful to my associate supervisor Dr James Bowen (Birmingham University, now 
Open University) for showing interest in my project, training & letting me use the 
Rheometer for my project. I would also like to thank Dr Gail Scherba (University of 
Illinois) for providing the neuronal cell lines for my project. 
I must also like to thank all the lab technicians: Jit, Tom, Christine for providing all the 
lab and technical support throughout my project. Special thanks to Mike Davis for being 
such a kind person apart from his enormous help in the medicinal chemistry lab, 
unfortunately he is not with us today. 
I would like to thank my only group colleague Manjit and other group colleagues/ fellow 
researchers Swapnil, Sameer, Ali, Craig, Amr, Eman, Affiong, Jas, Liz, Tom, Mandeep, 
Hamad, Ehsan, Floren, Pranav, Shibu for their direct or indirect help.   
Thanks to ARCHA and Charlie for the training and letting us use their facility.  
I would like to thanks Aston University for giving the bursary for this PhD. 
I would like to thank Dr Keith Hallam for conducting the BET analysis 
I would like to thank 3M Healthcare Ltd. for collaborating with Chapter 4 and providing 
assistance and materials. 
Finally, I reserve my greatest expression of gratitude to my wife Madhu, who has always 
been there for me and my daughter Urvee and for tolerating my absence.  
 
 
 
 5
List of Publications 
Peer Reviewed Articles 
                 
                                                                                             
1. Lungare, S., Hallam, K., & Badhan, R. K. S. (2016). Phytochemical-loaded 
mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery. International 
Journal of Pharmaceutics, 513(1-2), 280-293. 
 
 
2. Lungare, S., Bowen, J. & Badhan, R. (2016). Development and Evaluation of a 
Novel Intranasal Spray for the Delivery of Amantadine. J Pharm Sci, 105, 1209-20. 
 
 
3. Badhan RK, Kaur M, Lungare S and Obuobi S., (2014). Improving brain drug 
targeting through exploitation of the nose-to-brain route: a physiological and 
pharmacokinetic perspective. Current Drug Delivery.11 (4):458-71. 
 
 
Abstracts 
                                                                                                                                                  
 
1. Shital Lungare, James Bowen and Raj K Singh Badhan, 2015. Development 
of drug delivery system to target the brain via olfactory route. LHS PG Research day, 
Aston University, Birmingham, UK. 
 
2. Shital Lungare, James Bowen and Raj K Singh Badhan., 2014.Exploiting nose 
to brain delivery route using flavonoid loaded mesoporous nanoparticles. M5 
Biomedical imaging conference, University of Nottingham, Nottingham, UK. 
 
3. Shital Lungare, James Bowen and Raj k Singh Badhan., 2013. Overcoming 
Parkinson’s disease: direct nose-to-brain delivery of amantadine. UKICRS. The 
University of Reading, Reading. UK. 
 
4. Shital Lungare, James Bowen, Raj K Singh Badhan. 2014. Optimisation of 
Mesoporous nanoparticles for delivering flavonoids to the brain via olfactory route. APS 
Pharmasci University of Hertfordshire, Hatfield, UK. 
 
5. Shital Lungare, James Bowen, Raj K Singh Badhan. 2015. Mesoporous 
nanoparticles for nose to brain drug delivery via olfactory route. 1st Annual Keele 
Nanopharmaceutics Symposium. Keele University, Keele, UK. 
  
 6
Table of Contents 
Acknowledgements 4 
List of Publications 5 
Peer Reviewed Articles 5 
Chapter 1: Introduction 18 
1.1 Background 19 
1.2 Blood-brain barriers: functional role in limiting CNS drug disposition 19 
1.3 The nasal route as an administration route for CNS drug delivery 21 
1.3.1 The nasal cavity anatomy and physiology 21 
1.3.2 Nose-to-brain pathways 23 
1.3.2.1 Olfactory pathways 24 
1.3.2.2 Trigeminal nerve pathways 26 
1.4 Pharmacokinetic aspects of nose-to-brain delivery 26 
1.4.1 Absorption considerations 27 
1.4.2 Distribution considerations 27 
1.5 Olfactory delivery of macromolecules 29 
1.6 Human studies demonstrating olfactory drug delivery 30 
1.7 Formulation factors influencing olfactory drug delivery 32 
1.7.1 Nasal solutions/sprays 33 
1.7.2 Nasal Gels 34 
1.7.3 Nanoparticulate drug carriers for olfactory drug delivery 39 
1.7.4 Pressure metered dose inhaler 42 
1.8 Novel CNS drug candidates: phytochemicals 43 
1.9 Models for studying nasal drug delivery 46 
1.9.1 Models for studying nasal drug delivery: ex-vivo models 46 
1.9.2 Models for studying nasal drug delivery: cell culture models 46 
1.10 Aims and Objectives 48 
Chapter 2: Development of thermosensitive mucoadhesive polymer hydrogel formulations 
for olfactory drug delivery 50 
2.1. Introduction 51 
2.2. Aims and objectives 53 
2.3. Materials and Methods 54 
2.3.1. Materials 54 
2.3.2. Formulation development 54 
2.3.3. Assessment of sol-gel transition (Tsol-gel): visually 55 
2.3.4. Assessment of formulation mucoadhesion 56 
2.3.4.1. Texture analysis 56 
2.3.4.2. Displacement method 57 
2.3.5. Pre-column derivatisation of AMT and HPLC detection 58 
2.3.6. Stability of formulations 59 
2.3.7. Membrane-less release kinetics 60 
2.3.8. Human nasal epithelial cell culture: RPMI 2650 61 
2.3.8.1. Human nasal epithelial airway cell culture model 62 
2.3.9. Porcine olfactory bulb neuroblastoma cell culture: OBGF400 64 
2.3.10. Formulation cellular viability: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide (MTT) assay 65 
2.3.11. AMT release and transport across an in-vitro human nasal epithelial cell culture 
model 66 
2.3.12. Nasal spray systems: droplet size distribution 66 
2.3.13. Nasal spray system: human nasal cast deposition 67 
2.3.14. Statistical analysis 68 
2.4 Results 69 
2.4.1. Formulation development and optimisation 69 
2.4.1.1. Optimisation of thermoresponsive polymer content 69 
2.4.2. The impact of mucoadhesive polymers on formulation Tsol-gel. 72 
2.4.3. Formulation characterisation 73 
 7
2.4.3.1. Sol-gel transition (Tsol-gel) by rheology 73 
2.4.3.2. Assessment of formulation mucoadhesion: texture analysis 79 
2.4.3.3. Assessment of formulation mucoadhesion: displacement method 80 
2.4.3.4. Validation of a pre-column derivatisation method to detect AMT 81 
2.4.3.5. Human nasal epithelial cell culture model: MTT assay 85 
2.4.3.6. Porcine olfactory bulb cell culture model: MTT assay 87 
2.4.3.7. The development of a human nasal epithelial airway cell culture model 89 
2.4.3.8. Human nasal epithelial airway cell culture model: AMT transport 90 
2.4.4. Stability and AMT release from optimised formulations 91 
2.4.5. Nasal spray systems: droplet size distribution 97 
2.4.5.1. Nasal spray system: human nasal cast deposition 101 
2.5. Discussion 104 
2.5.1. Development of thermosensitive mucoadhesive hydrogel formulations 106 
2.5.2. Rheological assessment of thermosensitive formulations 109 
2.5.3. Evaluation of in-vitro mucoadhesion 112 
2.5.4. Cellular toxicity associated with formulation exposure 114 
2.5.5. AMT release and transport across a permeable insert model of the human nasal 
epithelia 115 
2.5.6. Stability and release of AMT from optimised formulations 117 
2.5.7. Nasal spray system 119 
2.6.  Conclusion 122 
 
Chapter 3: Development and characterisation of mesoporous nanoparticles for olfactory drug 
delivery               123 
3.1. Introduction 124 
3.2. Aims and objectives 128 
3.3. Materials and Methods 129 
3.3.1. Fluorescent bead uptake in porcine olfactory bulb neuroblastoma (OBGF400) cells 
 129 
3.3.2. Preparation of mesoporous nanoparticles (MSNP) 130 
3.3.2.1. Synthesis of MSNPs: template removal by calcination (Gul-MSNP) 130 
3.3.2.2. Synthesis of MSNPs: charged template approach (Pro-2-MSNPs) 131 
3.3.2.3. Synthesis of MSNPs: template removal by refluxing (Fan-MSNPs) 131 
3.3.3. Assessment of MSNP particle size distribution and zeta-potential (ζ) 131 
3.3.4. Scanning electron microscopy based assessment of the morphology of MSNP 132 
3.3.5. Porosity assessments using nitrogen adsorption/desorption isotherm analysis 132 
3.3.6. Thermogravimetric analysis (TGA) of MSNP 132 
3.3.7. Loading of fluorescein isothiocynate (FITC) and targettng to OBGF400 133 
3.3.8. Differential scanning calorimetry (DSC) 134 
3.3.9. Fourier transform infrared (FT-IR) 134 
3.3.10. HPLC analytical detection of curcumin 134 
3.3.11. HPLC method for chrysin 135 
3.3.12. Toxicity of MSNP towards olfactory cells 135 
3.3.13. Cellular toxicity of phytochemicals 136 
3.3.14. Live cell imaging: Cell-IQ® 136 
3.3.15. Phytochemical loading of MSNP Drug loading 136 
3.3.16. In-vitro drug release studies 137 
3.3.17. Incorporation of Fan-MSNP into thermoresponsive nasal gel systems 138 
3.3.18. Statistical analysis 138 
3.4. Results 139 
3.4.1. Fluorescent bead uptake 139 
3.4.2. Synthesis and characterisation of MSNP 141 
3.4.2.1. Scanning electron microscopy based assessment of the morphology of MSNP
 141 
3.4.2.2. Surface porosity of MSNP using nitrogen adsorption-desorption studies 145 
3.4.2.3. FTIR assessment of MSNP 147 
 8
3.4.3. FITC loading of MSNPs for cellular uptake studies 150 
3.4.4. FITC release from Fan-MSNP 150 
3.4.5. Cellular uptake of FITC-Fan-MSNP 151 
3.4.6. Phytochemical loading of Fan-MSNP 155 
3.4.7. HPLC-UV detection of curcumin 165 
3.4.8. HPLC-UV detection of chrysin 169 
3.4.9. Cytotoxicity study 173 
3.4.10. Cellular toxicity of MSNP: live-cell time-lapse phase-contrast microscopy 176 
3.4.11. Drug release study from the mesoporous silica nanoparticles 180 
3.4.12. Incorporation of Fan-MSNP into thermoresponsive nasal gel 182 
3.5. Discussion 190 
3.5.1. Target MSNP size range for olfactory uptake 191 
3.5.2. Formulation of MSNP 192 
3.5.3. Surface porosity and pore size determination 193 
3.5.4. FT-IR assessment of Fan-MSNP 194 
3.5.5. FITC loading and release in Fan-MSNP 195 
3.5.6. FITC-MSNP cellular uptake 195 
3.5.7. Phytochemical loading into Fan-MSNP 196 
3.5.8. HPLC-UV detection of phytochemicals 199 
3.5.9. Cellular toxicity of MSNP 200 
3.5.10.  Phytochemical release from MSNP 202 
3.5.10.1. Curcumin             202 
3.5.10.2. Chrysin              206 
3.5.11.  Incorporation of Fan-MSNP into the thermoresponsive nasal gel 206 
3.6. Conclusion 208 
 
Chapter 4: Adaptation of a pMDI spray device for targeted delivery onto the olfactory mucosa: 
a feasibility study              209 
4.1. Introduction 210 
4.2. Aims and objectives 212 
4.3. Materials and Methods 213 
4.3.1. Materials 213 
4.3.2. Assessment of diazepam solubility in ethanol 213 
4.3.3. Assessment of diazepam solubility in propellant 213 
4.3.4. HPLC-UV detection of diazepam 214 
4.3.5. Canister stability studies 214 
4.3.6. Nasal pMDI spray: droplet size distribution 215 
4.3.7. Nasal pMDI spray deposition within a nasal cast model: brilliant blue visualisation 
  216 
4.3.8. Nasal pMDI spray deposition within a nasal cast model: diazepam localisation 218 
4.3.9. Cellular toxicity of diazepam 218 
4.4. Results 219 
4.4.1. Assessment of diazepam solubility in ethanol 219 
4.4.2. Assessment of diazepam solubility in propellant 219 
4.4.3. HPLC-UV detection of diazepam 220 
4.4.4. Canister stability studies 223 
4.4.5. Nasal pMDI spray: droplet size distribution 224 
4.4.6. Nasal pMDI spray deposition within a nasal cast model: brilliant blue visualisation
 225 
4.4.7. Diazepam deposition in a nasal cast model 228 
4.4.8. Cellular toxicity of diazepam 229 
4.5. Discussion 231 
4.6. Conclusion 235 
 
Chapter 5: Conclusion                        236 
 9
References: 241 
 
List of Figures  
Figure 1-1: The blood-brain barrier (BBB) is formed from brain microvascular endothelial cells, 
astrocytes and pericytes (Chen and Liu, 2012). ............................................................................ 20 
Figure 1-2: Anatomy and histology of human nasal cavity (Pires et al., 2009). .................................... 22 
Figure 1-3: Drug transfer routes to the brain, adapted from (Chen et al., 2016). ................................. 24 
Figure 1-4: Olfactory area showing epithelium, bulb and tract (Mistry et al., 2009). ............................ 25 
Figure 1-5: Nasal (solution) formulation. ............................................................................................... 33 
Figure 1-6: Chemical structure of widely used thermoresponsive polymers ........................................ 36 
Figure 1-7: The gelation of poloxamer 407 in water ............................................................................. 37 
Figure 1-8: Schematic representation of mesoporous silica nanoparticles. Taken from(Yuan et al., 
2011). ............................................................................................................................................. 41 
Figure 1-9: Stöber reaction for preparation of mesoporous silica nanoparticles {Yan, 2014 #814}. .... 42 
Figure 1-10: Example of pMDI systems used for pulmonary and nasal (olfactory) drug delivery. ....... 43 
Figure 1-11: The structure of flavonoid (Heim et al., 2002). ................................................................. 44 
Figure 2-1: Tensile strength apparatus ................................................................................................. 57 
Figure 2-2: Displacement measurement apparatus .............................................................................. 58 
Figure 2-3: FMOC reaction and complex formation with amines (Bahrami and Mohammadi, 2007). .. 59 
Figure 2-4: Morphology of RPMI 2650 cells .......................................................................................... 62 
Figure 2-5: Morphology of OBGF400 cells............................................................................................ 65 
Figure 2-6: Assessment of nasal deposition in a human nasal cast model using a multidose nasal 
spray ............................................................................................................................................... 68 
Figure 2-7: Impact of differing heating rates on FCMC temperature sweep properties ........................ 74 
Figure 2-8: Temperature sweep of AMT containing formulations ......................................................... 76 
Figure 2-9: Time sweep of AMT containing formulations ...................................................................... 77 
Figure 2-10: Steady shear behaviour of AMT containing formulations ................................................. 78 
Figure 2-11: Assessment of formulation mucoadhesion through tensile strength measurements ....... 80 
Figure 2-12: Assessment of formulation mucoadhesion through displacement measurements .......... 81 
Figure 2-13: HPLC chromatogram of derivatised amantadine at retention time 4.911 min. ................. 82 
Figure 2-14: Linearity plot for a AMT pre-column derivatisation method .............................................. 85 
 10
Figure 2-15: Cellular toxicity of amantadine (A), CMC (B), PEG4000 (C), F127 (D) and CS (E) on 
RPMI-2650 cells. ............................................................................................................................ 86 
Figure 2-16: Cellular toxicity of amantadine (A), CMC (B), PEG4000 (C), F127 (D) and CS (E) on 
OBGF400. ...................................................................................................................................... 88 
Figure 2-17: Monolayer resistance of RPMI 2650 cells grown on permeable inserts. ......................... 89 
Figure 2-18: Release and transport of AMT from formulations ............................................................. 90 
Figure 2-19: Amantadine cumulative% release for optimised formulations at week 0 and stored at 
4°C, (A) FCMC; (B) FCS and (C) FPEG  ........................................................................................ 92 
Figure 2-20: Amantadine cumulative % release for optimised formulations at week 1 and stored at 
4°C, (A) FCMC; (B) FCS and (C) FPEG  ........................................................................................ 93 
Figure 2-21:  Amantadine cumulative % release for optimised formulations at week 8 and stored at 
4°C, (A) FCMC; (B) FCS.  ............................................................................................................... 94 
Figure 2-22: Amantadine cumulative % release for FCS at week 1 and 2 stored at 25°C.  .................. 95 
Figure 2-23: Nasal spray droplet size distribution graph for FPEG ...................................................... 98 
Figure 2-24: Nasal spray droplet size distribution graph for FCS. ........................................................ 99 
Figure 2-25: Nasal spray droplet size distribution graph for FCMC. ................................................... 100 
Figure 2-26: Representative nasal deposition patterns of FCS. ......................................................... 102 
Figure 2-27: Representative nasal deposition patterns of FCMC. ...................................................... 103 
Figure 3-1: Cellular uptake of fluorescent latex beads in OBGF400 .................................................. 140 
Figure 3-2: Scanning electron micrograph of Gul-MSNP.................................................................... 142 
Figure 3-3: Scanning electron micrograph of Pro 2 MSNP ................................................................. 143 
Figure 3-4: Scanning electron micrograph of Fan-MSNP ................................................................... 144 
Figure 3-5: Nitrogen adsorption/desorption isotherms of Fan-MSNP. ................................................ 146 
Figure 3-6: BJH pore radius distribution of Fan-MSNP. ...................................................................... 146 
Figure 3-7: BJH pore width distribution of Fan-MSNP. ....................................................................... 147 
Figure 3-8: FT-IR spectra of Fan-MSNP. ............................................................................................ 148 
Figure 3-9: FT-IR spectra of Fan-MSNP prior to CTAB removal (green) and immediately after CTAB 
removal (red). ............................................................................................................................... 149 
Figure 3-10: FT-IR spectra of FITC-MSNP ......................................................................................... 150 
Figure 3-11: Release of FITC from FITC-MSNP. ................................................................................ 151 
Figure 3-12: Cellular localisation of FITC-MSNP ................................................................................ 152 
Figure 3-13: z-dimension cellular localisation of FITC-MSNP (stage 1) ............................................. 153 
 11
Figure 3-14: z-dimension cellular localisation of FITC-MSNP (stage 2) ............................................. 154 
Figure 3-15: FTIR spectra of (A) Fan-MSNP; (B) and (C) Curc-MSNP .............................................. 156 
Figure 3-16: DSC thermograms of curcumin, Fan-MSNP and Curc-MSNP ....................................... 157 
Figure 3-17: TGA thermograms of curcumin, Fan-MSNP and Curc-MSNP. ...................................... 158 
Figure 3-18: Fan-MSNP size and PDI before and after loading with curcumin .................................. 159 
Figure 3-19: Fan-MSNP zeta potential before and after loading of flavonoid curcumin ..................... 160 
Figure 3-20: FTIR spectra of chrysin, blank MSNPs and Chry-MSNPs ............................................. 161 
Figure 3-21: DSC thermograms of chrysin, Fan-MSNP and Chry-MSNP .......................................... 162 
Figure 3-22: TGA thermograms of chrysin, Fan-MSNP and Chry-MSNP. ......................................... 163 
Figure 3-23: Fan-MSNP size and PDI before and after loading with chrysin ..................................... 164 
Figure 3-24: Zeta potential before and after loading of flavonoid chrysin ........................................... 165 
Figure 3-25: HPLC chromatogram of curcumin .................................................................................. 166 
Figure 3-26: Linearity plot for curcumin ............................................................................................... 169 
Figure 3-27: Chrysin HPLC chromatogram ......................................................................................... 170 
Figure 3-28: Linearity plot for chrysin .................................................................................................. 173 
Figure 3-29: Cellular toxicity of Fan-MSNPs on OBGF400 cells. ....................................................... 174 
Figure 3-30: Cellular toxicity of curcumin on OBGF400 cells ............................................................. 175 
Figure 3-31: Cellular toxicity of chrysin on OBGF400 cells. ................................................................ 175 
Figure 3-32: Cell-IQ live cell imaging of OBGF400 cells (top) and Fan-MSNP at 150µg/mL (middle) 
and 50µg/mL (bottom). ................................................................................................................. 177 
Figure 3-33: Cell-IQ live cell imaging of OBGF400 cells (top) and Chry-MSNP at 150µg/mL (middle) 
and 50µg/mL (bottom). ................................................................................................................. 178 
Figure 3-34: Cell-IQ live cell imaging of OBGF400 cells (top), Curc-MSNP at 150µg/mL (middle) and 
50µg/mL (bottom). ........................................................................................................................ 179 
Figure 3-35: Cumulative percentage release of curcumin from Curc-MSNP...................................... 180 
Figure 3-36: Cumulative percentage release of chrysin from Chry-MSNP ......................................... 181 
Figure 3-37: Temperature sweep of FCMC following incorporation of Fan-MSNP ............................ 183 
Figure 3-38: Temperature sweep of FCS following Incorporation of Fan-MSNP. .............................. 184 
Figure 3-39: Temperature sweep of FPEG following Incorporation of Fan-MSNP ............................. 185 
Figure 3-40: Steady shear behaviour of FCMC incorporating Fan-MSNP. ........................................ 187 
Figure 3-41: Steady shear behaviour of FCS incorporating Fan-MSNP. ............................................ 188 
 12
Figure 3-42: Steady shear behaviour of FPEG incorporating of Fan-MSNP. ..................................... 189 
Figure 3-43: Chemical structures of (A) curcumin, (B) demethoxycurcumin and (C) and 
bisdemethoxycurcumin. ................................................................................................................ 200 
Figure 3-44: Curcumin degradation products ..................................................................................... 203 
Figure 3-45: HPLC-UV chromatogram of curcumin at pH 7.4. ........................................................... 204 
Figure 3-46: HPLC-UV chromatogram of curcumin at pH 5.5. ........................................................... 205 
Figure 4-1: A pressured metered dose inhaler (Lavorini, 2013). ........................................................ 211 
Figure 4-2: The 3M fabricated nasal pMDI actuator (termed the ‘Aardvark’ system). ........................ 215 
Figure 4-3: Spray angle used within the nasal pMDI actuators. ......................................................... 216 
Figure 4-4: Nozzle attachments .......................................................................................................... 217 
Figure 4-5: Stability of diazepam formulated in 5% or 10% w/w ethanol and HF134a following 3-week 
storage.......................................................................................................................................... 219 
Figure 4-6: Diazepam HPLC chromatogram. ...................................................................................... 220 
Figure 4-7: Linearity plot for diazepam. ............................................................................................... 223 
Figure 4-8: Diazepam content assay of 5 and 10% w/w ethanol canisters. ....................................... 224 
Figure 4-9: Spray particle size distribution. ......................................................................................... 225 
Figure 4-10: Nasal cast deposition of BB pMDI under static and dynamic airflow. ............................ 226 
Figure 4-11: Nasal cast deposition of BB pMDI under static air flow and with the ‘short’ and ‘long’ 
nozzle attachments. ..................................................................................................................... 227 
Figure 4-12: Olfactory deposition of diazepam. .................................................................................. 229 
Figure 4-13: Cellular toxicity of diazepam on OBGF400 cells. ........................................................... 230 
 
 
 
 
 
 
 
 
 
 
 13
 
List of Tables 
Table 2-1: Impact of PF127 on Tsol-gel, indicating the inverse relationship between concentration and 
Tsol-gel in Pluronic only formulations. ............................................................................................... 69 
Table 2-2: Effect of addition of amantadine and excipients on gelation temperature ........................... 70 
Table 2-3: Effect of addition of CMC on gelation temperature .............................................................. 70 
Table 2-4: Effect of addition of amantadine on gelation temperature ................................................... 71 
Table 2-5: Effect of Increase in PF127 content on gelation temperature .............................................. 71 
Table 2-6: Optimised formulation based on CMC as mucoadhesive .................................................... 72 
Table 2-7: Impact of mucoadhesive polymers on formulation gelation ................................................. 72 
Table 2-8: Power law rheological analysis of AMT at ambient and nasal temperatures ....................... 79 
Table 2-9: System precision assessment for AMT pre-column derivitisation method ........................... 83 
Table 2-10: Method precision assessment for AMT pre-column derivitisation method ......................... 84 
Table 2-11: Drug release kinetics analysis of formulations stored at refrigerated (4°C) and ambient 
(25°C) temperature for up to 8 weeks.  ........................................................................................... 96 
Table 2-12: Laser diffraction particle size analysis ................................................................................ 97 
Table 3-1: Particle size and zeta-potential of different MSNPs ........................................................... 141 
Table 3-2: Nitrogen adsorption desorption data for Fan-MSNP .......................................................... 145 
Table 3-3: System precision assessment for curcumin HPLC-UV detection ...................................... 167 
Table 3-4: Method precision assessment for curcumin ....................................................................... 168 
Table 3-5: System precision assessment for chrysin HPLC-UV detection ......................................... 171 
Table 3-6: Method precision assessment for chrysin .......................................................................... 172 
Table 4-1: pMDI canister composition ................................................................................................. 214 
Table 4-2: Dimensions of nozzle attachments .................................................................................... 217 
Table 4-3: System precision assessment for diazepam ...................................................................... 221 
Table 4-4: Method precision assessment for diazepam ...................................................................... 222 
 
 
 
 14
 
List of abbreviations  
AD   Alzheimer’s disease 
AEP  Auditory-evoked brain potentials 
ALI  air liquid interface 
AMT  Amantadine  
ANE  Artificial nasal electrolyte solution 
ANOVA  Analysis of variance 
API  Active pharmaceutical ingredient 
AUC  Area under the curve 
BB   Brilliant blue 
BBB  Blood brain barrier 
BCRP  Breast cancer resistance protein 
BCS  Biopharmaceutical classification system 
BCS  Bovine calf serum 
BCSFB  Blood cerebrospinal fluid barrier  
BLK  Benzalkonium chloride 
CBF  Ciliary beat frequency 
Chry-MSNP Crysin loaded MSNP 
CNS  Central nervous system  
CO2   Carbon dioxide 
CS   Chitosan 
CSF  Cerebrospinal fluid 
CST  Critical solution temperature 
CTAB  Cetyltrimethylammonium bromide 
 15
Curc-MSNP Curcumin loaded MSNP 
DFT  density functional theory 
DMEM  Dulbecco’s Modified Eagle Medium 
DMEM-F12 Dulbecco’s Modified Eagle Medium: Nutrient Mixture F12 
DMF  Dimethylformamide 
DMSO  Dimethylsulphoxide 
DSC  Differential scanning calorimetry 
DUSA  Dosage unit sampling apparatus 
DZP  Diazepam 
EE   Entrapment efficiency 
Fan-MSNP Fan method Mesoporous Nanoparticles 
FBS  Foetal bovine serum 
FDA  US Food and Drug Administration 
FITC  Fluorescein isothiocynate- Dextran 
FMOC  9-Fluorenylmethyl chloroformate 
FTIR  Fourier transform infrared 
HBSS  Hank's Balanced Salt Solution 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid   
HFA  Hydrofluroalkanes 
HPC  Hydroxypropyl cellulose 
HPLC  High performance liquid chromatography 
HPMC  Hydroxypropyl methylcellulose 
HRP  Horseradish peroxidase 
IGF-1  Insulin like growth factor-1 
IN   Intra-nasal 
LC   loading content 
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LCST  Low critical solution temperature 
LOB  Left olfactory bulb 
LOD  Limit of detection 
LOQ  Limit of quantification 
LY   Lucifer yellow  
MCC  Mucocilliary clearance 
MCI  Mild cognitive impairment 
ME  Microemulsion 
MEM  Eagle’s minimal essential medium 
MSNP  Mesoporous nanoparticles 
MTB  Sodium metabisulphate 
MTT  3-(4, 5-dimethylthiazol-2-yl)-2,-5-diphenyl tetrazolium bromide 
Na CMC  Sodium carboxymethyl cellulose 
NEAA  Non-essential amino acid 
NP   nanoparticles 
OB   Olfactory bulb 
OE   olfactory epithelium 
OEC  olfactory ensheathing cells 
ORN  olfactory receptor neurons 
PAA  poly (acrylic acid) 
PBS  posphate buffered saline 
PD   Parkinson’s disease 
PDI  Polydispersity index 
PEG  Polyethylene glycol 
PEO  Poly (ethylene oxide) 
PF127  Pluronic F127 
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PHE  Phenylephrine 
pMDI  Pressurised meter dose inhaler  
PNIPAAm  Poly (N-isopropyleacrylamide) 
PPO  Poly (propylene oxide) 
PVP  Polyvinylpyrrolidone  
QS   Quantity sufficient 
RCF  Relative centrifugal force   
RH   Relative humidity 
ROB  right olfactory bulb 
RPM  Revolutions per minute 
RT   Room temperature 
SD   Standard deviation 
SEM  Scanning electron microscopy 
SFM  Serum free media 
TEER  Transendothelial electrical resistance 
TEOS  Tetraethoxysilane 
TGA  Thermogravimetric analysis 
TJ   Tight junction 
UCST  Upper critical solution temperature 
UV   Ultraviolet 
WGA-HRP Wheatgerm agglutin-horseraddish peroxidase 
WHO  World Health Organisation 
  
 18
 
 
 
 
 
Chapter 1  
Introduction  
 19
1.1 Background 
The World Health Organisation (WHO) have highlighted that neurological disorders are one of 
the biggest threats to public health (WHO, 2006).  Furthermore with an increasingly ageing 
population, by the year 2020 one in every three people alive will suffer from a central nervous 
system (CNS) related disorders (WHO, 2006). Disorders of the CNS account for approximately 
1% of deaths but this is associated with a worldwide disease burden of almost 11%, and it is 
thought that approximately 1.5 billion people worldwide suffer from some kind of brain or CNS 
disorder.  Less than 8% of CNS-indicated drugs successfully enter clinical trials and this has 
been accompanied by an overall drop in the success rate of delivering a candidate to market 
(Kola and Landis, 2004), with the US Food and Drug Administration (FDA) only approving 
between 15-25 new compounds per year (Kola and Landis, 2004). 
Despite advances in drug delivery technologies, CNS drug targeting and delivery is still a 
limiting factor with less than 1% of all CNS-targeted compounds showing activity against CNS 
diseases (Pardridge, 2005, Lipinski, 2000).  This is despite many of these compounds 
possessing physicochemical properties that would normally predispose them to good 
membrane permeability (e.g, molecular weight < 500 and highly lipid soluble) (Pardridge, 1998). 
Blood-brain barriers: functional role in limiting CNS drug disposition 
The brain is a very highly vascularised organ with a microvascular surface area of 150-200cm2 
g. tissue (12-18m2) in humans (Abbott and Romero, 1996).  However, the primary cause of 
poor brain disposition of therapeutics is often associated with highly selective barrier termed 
as the blood-brain barrier (BBB), formed from brain microvascular endothelial cells which are 
highly selective in controlling the entry of endogenous and exogenous compounds into the 
brain (Figure 1-1).   
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Figure 1-1: The blood-brain barrier (BBB) is formed from brain microvascular endothelial cells, astrocytes and 
pericytes (Chen and Liu, 2012). 
The three key features of the BBB which specifically govern and restrict passage of therapeutic 
drugs are: 1) an extensive network of tight junction (TJ) proteins limiting the transfer of 
molecules between endothelial cells; 2) Limited transcellular transport of molecules due to a 
lack of fenestrations and limited transcytosis; 3) An extensive network of membrane drug 
transporter proteins which hinder molecular trafficking across the BBB but also provide a 
mechanism to deliver or remove required substances such as amino acids and glucose into 
the brain (Dauchy et al., 2008, Dutheil et al., 2010). 
Conventional drug therapy targeting the CNS has largely failed to yield successful results, and 
this is thought to be a result of the impermeable nature of the BBB in hindering molecular flux, 
and hence limiting the extent to which therapeutic agents can accumulate within the brain 
biophase before yielding a clinical response (Pardridge, 2012, Pardridge, 2010, Pardridge, 
2007a, Pardridge, 2007c, Pardridge, 2005, Neuwelt et al., 2008, Abbott et al., 2010a).   
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1.2 The nasal route as an administration route for CNS drug delivery 
Although the nasal route has traditionally been used to treat local symptoms, many studies 
have demonstrated the systemic delivery of therapeutic agents through intranasal (IN) drug 
delivery.  A major advantage of the nasal route is the highly perfused nature of the nasal cavity 
which allows the rapid systemic delivery of drug, and which further offers the ability to bypass 
first-pass metabolism and extraction of drugs, posing as an attractive route for drugs otherwise 
delivered through parenteral or oral routes (Illum, 2012, Bitter et al., 2011).  The first recorded 
success in the delivery of a therapeutic agent into the brain in humans, following IN 
administration, was in a patent application by William Frey II (Frey, 1997a),(Frey, 1997b) 
reporting the successful delivery of neurological agents and macromolecules (insulin) (Frey, 
2001) targeting Alzheimer’s disease. These reports established a novel approach to target 
CNS drug delivery through potentially bypassing the BBB. 
1.2.1 The nasal cavity anatomy and physiology 
The surface area of the human nasal cavity is approximately 150cm2 with a total volume of 15-
20mL (Morrison and Costanzo, 1992). The primary function of the nasal cavity is respiration 
and olfaction, and is divided into two symmetrical halves with each half further divided into four 
areas termed the vestibules, atrium, respiratory region and olfactory region (Figure 1-2). 
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Figure 1-2: Anatomy and histology of human nasal cavity (Pires et al., 2009). 
Nasal vestibule: the nasal vestibules cover an area of approximately 0.6cm2 and forms part of 
the anterior area of the nasal cavity (Figure 1-2). The vestibules are formed from stratified 
squamous and keratinised epithelium and sebaceous glands, and the absorption of drugs is 
difficult.  
Atrium: the area close to vestibules is comprised of stratified squamous epithelium whereas 
the area close to respiratory region has pseudostratified columnar cells with microvilli.  
Respiratory region: this is the largest region within the nasal cavity and is the primary target 
for systemic drug delivery (Figure 1-2). It is divided into the superior, middle and inferior 
turbinates which project from the lateral wall. A range of cell types are present here and include 
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pseudostratified columnar epithelial cells, goblet cells, basal cells, mucous and serous glands. 
Basal cells are thought to provide a source of stem cells for the replenishing of olfactory or 
supporting cell structure within the nasal region (Mackay-Sim and Kittel, 1991, Leung et al., 
2007, Carter et al., 2004). Furthermore, the nasal epithelium in this region has a thick layer of 
mucous which is secreted by secretory glands and goblet cells. This secreted mucus is high 
in water content (95%) and contains a variety of electrolytes, proteins, lipids, enzymes, 
antibodies, bacterial products and the specific glycoprotein mucin (Pires et al., 2009). 
Olfactory Region:  this regions covers the upper part of the nasal cavity with an approximate 
surface area of 2.5-10cm2 in humans (Figure 1-2) (Gizurarson, 2012).  It is primarily comprised 
of approximately 12 million olfactory receptor cells (Purves, 2007) and is the only known part 
of the CNS which is in direct contact with the external environment (Illum, 2000, Pires et al., 
2009). The olfactory mucosa is a pseudostratified columnar epithelium made up of supporting 
cells, basal cells, microvillar cells and olfactory or receptor cells (Morrison and Costanzo, 
1990a).    The olfacotry region has been the focus of one of the major ‘nose-to-brain’ pathways 
to deliver drugs directly to the brain through olfacotry deposition. 
1.2.2 Nose-to-brain pathways 
Following the IN administration of drug, entry into the brain and CNS primarily occurs through 
either the olfactory or trigeminal nerve pathways (Illum, 2000), and to a lesser extent by 
diffusion into the cerebrospinal fluid (CSF) and lymphatic circulations (Dhuria et al., 2010) 
(Figure 1-3). 
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Figure 1-3: Drug transfer routes to the brain, adapted from (Chen et al., 2016). 
Following therapeutic administration into the nasal cavity, compounds may enter the brain and CNS through at least 
three possible mechanisms: (i) nasal respiratory epithelia-leading to systemic absorption and brain deposition; (ii) 
delivery onto the olfactory epithelium leading to olfactory transfer into the olfactory bulb and diffusion into the brain 
parenchyma; (iii) delivery into the trigeminal network and transfer into the brain 
1.2.2.1 Olfactory pathways 
The olfactory region of the nasal cavity consists of olfactory receptor neurons (ORNs) which 
are responsible for providing information associated with olfaction (smell) from the external 
environment into the CNS (Figure 1-4).  
Beneath the olfactory epithelium lies the lamina propria which contains mucus secreting 
Bowman’s glands, axons, blood vessels, lymphatic vessels and connective tissues. Dendrites 
associated with the ORNs extend into the mucus layer of the olfactory epithelium, and the 
axons of ORN pass through the lamina propria through the gaps in cribriform plate and ethmoid 
bone of the skull (Figure 1-4) before terminating in the olfactory bulb (Djupesland, 2013, 
Leopold et al., 2000, Feron et al., 1998). 
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Figure 1-4: Olfactory area showing epithelium, bulb and tract (Mistry et al., 2009). 
The transfer of therapeutic molecules to the olfactory bulb begins at the olfactory receptor neurons, whose 
endogenous function is to process olfaction signals to the brain in response to odorant stimulation. Therapeutic 
molecules are thought to be able to be endocytosed into olfactory receptor neurons (ORN) or permeate through the 
olfactory epithelium and travel along intracellular or extraceullar (perineural) pathways towards the olfactory bulb. 
 
The olfactory nerve pathway provides a non-invasive route to obtain CNS drug delivery and 
was demonstrated in studies using fluorescent tracers which were tracked as they passed 
through the olfactory nerves, the cribriform plate and finally within the olfactory bulb (OB) 
(Lochhead and Thorne, 2012, Renner et al., 2012).  The process of movement through these 
routes are thought to occur either because of intracellular or extracellular mechanisms. Fast 
extracellular movement (typically within 30 minutes) from the nasal epithelium to the CNS is 
likely to occur as a result of channels created by the olfactory ensheathing cells (OEC) (Thorne 
et al., 2004). Balin et al. (1986) observed that IN administered native horseradish peroxidase 
reached the OB of rats and squirrel monkeys extracellularly within 45-90min. Intracellular 
transport involves passive diffusion, receptor mediated endocytosis or adsorptive endocytosis 
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by which the molecules are taken up into ORNs and then axonal transport taking hours to days 
to take these molecules to different regions of the brain (van Woensel et al., 2013).   
1.2.2.2 Trigeminal nerve pathways 
The trigeminal nerves have been somewhat less investigated as a route for nose to brain 
delivery. Trigeminal nerves are located within the nasal epithelia respiratory region and the 
olfactory epithelium and passes through to the CNS through the pons with some contact with 
the olfactory bulb (Chapman et al., 2012, Dhuria et al., 2010).  
1.3 Pharmacokinetic aspects of nose-to-brain delivery 
There is an increasing interest in exploiting the physiology of the nasal cavity and the olfactory 
pathway route to gain access to the CNS for small-molecular weight compounds.  A key 
advantage of any IN route of administration is the ability to overcome hepatic metabolic 
clearance and first pass metabolism, which hinders the bioavailability of many orally 
administered drugs.  In addition, because of this bypassing effect the doses required to achieve 
comparable clinical outcomes is lower and hence reduces the burden of systemic and central 
adverse drug reactions. 
Demonstration of ‘nose-to-brain’ delivery has been widely conducted in rodents, however it is 
important to highlight that the olfactory region in rodents (13-15cm2) (Gross et al., 1982) is 
larger and more accessible than that found in humans (2-10cm2) (Morrison and Costanzo, 
1990b) although the total number of olfactory receptor cells are thought to be similar (15 million 
and 12 million, respectively).  Furthermore, the transport rates of particles interacting with the 
olfactory epithelia is approximately 14mm/min in both species (Gizurarson, 1990).  Thus, 
despite some differences between humans and rodents, the anatomical similarities would 
suggest that the rat model is a reasonable model for drug delivery studies.  
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1.3.1 Absorption considerations 
A major challenge to CNS disposition is the targeted delivery of drug at the olfactory mucosa 
rather than the entire nasal mucosa. The challenges lie in the fact that the nasal mucosa covers 
most of the nasal surface area with the olfactory mucosa being posterior in the nasal cavity, 
posing difficulties from a formulation/delivery perspective.  
The vascularized nature of the olfactory and nasal mucosa would suggest that small molecular 
weight and highly lipophilic compounds are expected to preferentially be absorbed (Illum, 
2003).  However, as with drug absorption at other absorption sites within the body, larger 
molecular weight compounds (> 500Da) show limited membrane permeation (McMartin et al., 
1987).  An added difficulty is the fact that membrane localized xenobiotic transporter proteins 
at the olfactory bulb and olfactory epithelial may provide a further ‘barrier’, in a similar way to 
their expression at the BBB, and thereby potentially limiting the ability of drug substrate of 
these membrane transporters from utilizing efficient olfactory transport (Thiebaud et al., 2011, 
Molinas et al., 2012, Manzini and Schild, 2003, Kandimalla and Donovan, 2005, Graff and 
Pollack, 2005, Bauer et al., 2010).   
1.3.2 Distribution considerations 
Assuming a drug has been delivered sufficiently high enough into the nasal cavity to deposit 
onto the olfactory mucosa, two specific pathways exist for the subsequent delivery of drug to 
the brain, namely axonal transport and epithelial pathways (Shi and Pardridge, 2000).  Axonal 
transport pathways are slow mechanisms involving endocytic movement into the neurons and 
ante-retrograde transport to transverse along olfactory neurons to the OB and brain, with 
typical distribution rates of 0.1 to 400mm/day (Vallee and Bloom, 1991). This has been 
demonstrated with dopamine where concentrations were found to reach a peak in the olfactory 
bulb 4 hours post dosing in mice (Dahlin et al., 2000) 
Epithelial pathways are faster and drugs pass paracellulary across the olfactory epithelium 
(OE) perineural spaces, followed by diffusion into the brain tissue. This rapid transfer has been 
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demonstrated for cocaine and benzoylecgonine following IN administration to rats with peak 
concentrations attained within 10–15 minutes post-dosing (Chow et al., 1999, Chow et al., 
2001).  The rapid brain delivery of the centrally acting acetylcholinesterase inhibitor tacrine 
was reported in both mice and rabbits following IN administration (Jogani et al., 2007).  
Biodistribution studies in BALB/c mice, using radiolabeled tacrine, showed brain distribution to 
be more rapid following IN administration (tmax=60 minutes) when compared to IV 
administration (tmax=120 minutes). In addition the brain:blood ratio of tacrine and brain tacrine 
concentrations were reported to be higher at all time points during the experiment following IN 
administration (Jogani et al., 2007).   
More direct evidence of the use of olfactory pathways for drug absorption has been 
demonstrated  with morphine, Westin et al (Westin et al., 2005, Westin et al., 2006b) quantified 
right olfactory bulb (ROB) morphine disposition following right-sided nasal administration as a 
marker for olfactory deposition and CNS delivery, and used the left olfactory bulb (LOB) as a 
control for systemic distribution.  They reported that levels of morphine in the ROB were 
significantly higher than those in the LOB following IN administration with similar levels in both 
olfactory bulbs and in the rest of the brain following IV administration.  Furthermore, the 
appearance of morphine in the ROB was rapid and detected in a 5-minute autoradiogram, 
however clear species differences in peak levels were reported in mice (60 minutes) and rats 
(15 minutes).   
This rapid appearance of morphine in the olfactory bulbs was further quantified in rats at 5- 
and 15-minute time points following IN and IV administration of morphine (Westin et al., 
2006b). Brain morphine concentrations were similar at both time points, despite lower plasma 
concentrations following IN administration, and with significantly higher area under the cover 
(AUC0-5 minute) brain:plasma for IN administration compared to IV administration (3 and 0.1 
respectively) indicating that direct olfactory transfer makes a significant early contribution to 
brain morphine concentrations.  This suggests that although IV administration yields delivery 
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of morphine into the systemic circulation and subsequent delivery across the BBB and into the 
brain, IN administration may provide a rapid delivery effect because of combination of 
distribution across the BBB and transfer through the olfactory pathways. 
Interestingly at 0-5, 0-15, 0-60, and 0-240 minutes the right brain hemisphere:plasma morphine 
AUC ratios were 2,200, 348, 91, and 11% higher, respectively, compared to IV administration, 
and the overall proportion of morphine which reached the right hemisphere (as a result of 
olfactory transfer) was 95, 71, 48, and 10% for the studied time points (Westin et al., 2006a).  
This subsequent study by Westin highlights an important aspect of assessing nose-to-brain 
pharmacokinetics, namely that the olfactory transfer effect is potentially rapid and decreases 
with time and is an important experimental consideration in such studies. Furthermore, the 
overall contribution of the olfactory route to brain penetration (following IN administration) may 
well be masked for highly lipophilic drugs where BBB penetration and brain disposition may be 
extensive (Sakane et al., 1991). 
1.4 Olfactory delivery of macromolecules 
The connection between the nasal cavity and brain was first established for solute diffusion 
studies, where dyes were injected into the CSF and were shown to penetrate through the 
cribriform plate and enter the mucosal layers of the nasal cavity (Kristensson and Olsson, 
1971).  The first direct and quantitative study of the exploitation of the nasal route to deliver 
drug into the brain was reported by Thorne et al (1995) (Thorne et al., 1995), who 
demonstrated that delivery of wheatgerm agglutin-horseraddish peroxidase (WGA-HRP) into 
the olfactory bulbs of rats. 
The exact transfer mechanism of macromolecules is thought to occur through axonal transport 
through the olfactory neurone and olfactory bulb or trigeminal nerve and along extracellular 
pathways to the brain.  Dendritic uptake is thought to occur through endocytotic or pinocytotic 
mechanism which internalises the macromolecule (De Lorenzo, 1970, Baker and Spencer, 
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1986).  Once internalised, the macromolecular is thought to be transported axonally along the 
olfactory filaments and passes through the cribriform plate before reaching the olfactory bulb.   
The process of internalisation of the macromolecules is an important factor in governing 
whether it undergoes trans-neuronal transport away from the olfactory bulb or whether it simply 
accumulates within the olfactory bulb (Baker, 2003).   For example, the mechanisms of 
intracellular transport of unconjugated HRP within the olfactory neurones was found to be 
through a lysosomal endocytosis pathway as a result of the lack of HRP binding sites on the 
neurone (Broadwell and Balin, 1985). In contrast, the lectin-conjugated form (WGA-HRP) was 
demonstrated to be capable of binding to cell surface glycoproteins and undergo receptor-
mediated endocytosis followed by trans-neuronal transport and brain deposition (Broadwell 
and Balin, 1985, Baker and Spencer, 1986, Shipley et al., 1985).  As with small molecular 
weight compounds, extracellular transport pathways are also a potential route of entry of 
macromolecules into the brain and CNS (Mathison et al., 1998b, Balin et al., 1986).  
1.5 Human studies demonstrating olfactory drug delivery  
Although the reports presented thus far deal with in-vitro or pre-clinical animal models of IN 
delivery, a number of human clinical trials and studies have also conclusively demonstrated 
the ability to deliver drugs into the brain following IN delivery.   Many of these studies have 
focussed on insulin therapeutic agents for the reversal of Alzheimers-associated neurological 
degeneration with a view to examining either the disposition into the brain tissue or the effects 
on memory function.   
In a double-blind study by Kern et al (1999) (Kern et al., 1999), insulin and vehicle-placebo 
was dosed to 18 fasted healthy male volunteers and evaluated a possible nose-to-brain 
pathway by assessing auditory-evoked brain potentials (AEP).  Whilst no changes were 
observed in systemic concentration (in line with previous reports of poor systemic absorption 
into the blood circulation following IN administration, in the absence of absorption enhancers 
(Watanabe et al., 1992, Illum and Davis, 1992, Aungst et al., 1988)), significant changes were 
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observed in elements of the AEP providing evidence of a direct route of transfer from the site 
of administration (IN) to the brain and CNS. 
Furthermore, a study by Reger et al (Reger et al., 2006), assessed the impact of saline vs 20 
IU insulin vs 40 IU insulin on cognitive tests were examined.  Their results demonstrated no 
significant impact on systemic plasma glucose but significant changes in total story recall and 
total list recall when compared to placebo groups.  In a further study by the same group (Reger 
et al., 2008),  adults with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) along 
with normal healthy adults underwent a dose-escalation study of five intranasal doses of insulin 
(10, 20, 40, or 60 IU) or placebo, followed by a cognitive ability testing 15-minutes post-dosing 
and systemic insulin/glucose levels assessed 45-minutes post-dosing.  Again, plasma and 
blood insulin/glucose levels were unchanged but a dose dependency in outcome was reported, 
with low doses improving verbal memory recall (word and story recall) in AD adults and in MCI 
adults who did not carry the APOEε4 allele. 
The interest in IN delivery as a potential novel route to deliver therapeutic agents to the CNS, 
and thereby bypass the BBB, has gained much interested in recent years.  As a relatively non-
invasive approach, IN delivery (with olfactory/trigeminal nerve targeting) provides a route that 
has been demonstrated to bypass the BBB and target delivery to the brain and CNS.  There 
is clear evidence amongst both small molecular weight compounds and macromolecules, that 
pathways including the olfactory neurons/bulb, trigeminal nerves, perivascular channels, the 
CSF, and lymphatic channels play a key role in transfer to the CNS. 
To fully exploit this delivery approach urgent research is needed to examine the methods to 
enable specific regional delivery of compounds within the brain where treatment is required 
and the underlying mechanisms of which govern onwards distribution of therapeutic agents 
across the brain and wider CNS. Nose-to-brain drug delivery is a rapidly developing area, and 
the existing literature supports the view that olfactory transfer may bypass the BBB to achieve 
CNS delivery. Recent developments in nanotechnology and formulation development are 
 32
aiding the difficult challenge of olfactory-targeted delivery within the nasal cavity (Yang et al., 
2013, Xia et al., 2011, Samia et al., 2012, Ravouru et al., 2013, Perez et al., 2012, Chekhonin 
et al., 2008, Zhao et al., 2013, van Woensel et al., 2013, Vaka et al., 2013, Liu et al., 2013, Liu 
et al., 2012).  
1.6 Formulation factors influencing olfactory drug delivery  
When formulating a dosage form for intranasal administration intended to direct brain delivery, 
a number of aspects should be taken into consideration. Firstly, the olfactory region in man is 
situated higher up in the upper part of the nasal cavity making it difficult to reach with currently 
available nasal spray or powder devices (Ugwoke et al., 2005). Secondly any nasally 
administered drugs will be rapidly cleared into the gastrointestinal tract through mucociliary 
clearance (Illum, 2003). Also, for large molecular weight or highly polar drugs the nasal mucosa 
can hinder the trans- and paracellular transport of polar drugs and also provide a significant 
metabolic barrier to systemic absorption (Costantino et al., 2007, Khafagy el et al., 2007). 
To enhance the residency within the nasal cavity, many groups have developed smart 
polymer-based delivery systems which often employ both a ‘responsive’ polymer which can 
alter the properties of the formulation based on a trigger pH or temperature, coupled with the 
use of mucoadhesive polymers to enhance nasal residency (Agrawal and Maheshwari, 2014, 
Kumari et al., 2012, Shin et al., 2013, Jones et al., 2009).(Ugwoke et al., 2005, Zaki et al., 
2007a, Bhandwalkar and Avachat, 2013)  
 
1.6.1 Nasal solutions/sprays 
Liquid based preparations are the most widely used nasal dosage form and are based on 
aqueous formulation systems with the inclusion of excipients for osmolality and maintenance 
of pH coupled with the use of preservatives for multi-dose containers.   The majority are 
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intended for local effects such as relief of nasal congestion, nasal allergy, and nasal infections 
(Figure 1-5). 
 
Figure 1-5: Nasal (solution) formulation. 
(A) Multi-dose nasal spray; (B) multi-dose liquid drops. 
Solution systems are ideal for scenarios were a rapid onset of action is required.   For example, 
intranasally administered methadone for pain relief in human volunteers has been reported to 
reach maximum plasma concentrations within 7 min and a peak pharmacodynamic response 
within 30 min post administration with a bioavailability of 85% (Dale et al., 2002).  Equally 
poorly soluble drugs can be formulated as their salt forms and administered intranasaly, e.g. 
raloxifene and tamoxifen (Hussain and Dittert, 2001). 
The administration of solution formulations can occur through the use of drops or sprays. The 
use of drops often requires a complex set of manoeuvres to ensure correct administration 
(Vidgren and Kublik, 1998) and often can lead to poor control of the volume delivered in 
addition to rapid clearance through laryngopharynx clearance if the head position is incorrect 
(Vidgren and Kublik, 1998).  On the other hand, sprays can often deposit to a greater extent in 
the anterior regions of the nasal cavity and hence yields slower clearance than drops (Hardy 
et al., 1985). For example the nasal bioavailability of desmopressin was increased following 
intranasal spray administration compared to drops (Harris et al., 1986).  
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One type of approach to improve both residency of the formulation within the nasal cavity but 
to also enhance brain delivery is the use of microemulsions. Kumar et al  (Kumar et al., 2008) 
developed an IN microemulsion risperidone formulation and assessed distribution in rats using 
radiolabelled biodistribution studies.  A significantly larger brain:blood was observed following 
IN administration for risperidone solution and nanoemulsion formulations when compared to 
IV administration at 30 minutes post dosing. A lower tmax,brain (1 hour) compared to blood (2 
hours) also suggested rapid and preferential nose-to-brain delivery.   
Triptan-based drugs are widely prescribed for both headaches and migraines (Jain et al., 
2010). Commonly prescribed types include sumatriptan and zolmitriptan and which are often 
delivered intranasally. Clearly, systemic absorption followed by CNS distribution would be the 
primary route of delivery into the CNS, but nose-to brain delivery has been reported in rats 
(Vyas et al., 2006b, Vyas et al., 2005a) using microemulsion (ME) based delivery systems. 
Such a ME-based system demonstrated drug concentrations in brain following IN 
administration to be significantly higher at all sampling time points compared with IV 
administration, with 2.5-3-fold higher brain:blood at the tmax,brain (0.5 hours) (Vyas et al., 2006a). 
1.6.2 Nasal Gels 
To overcome the rapid and significant removal of solution from the nasal cavity as a result of 
mucocilliary clearance, the use of increased viscosity formulations and/or bioadhesion 
polymers is often employed to prolong the contact time with the nasal epithelia.  Viscosity 
increasing polymers are often utilized in nasal formulations resulting in ‘gel’ like structures, 
often termed hydrogels. These are transparent, viscoelastic and thermodynamically stable 
systems consisting of a polar solvent and a polymer, where polar solvent is the external phase. 
The polymer used is often synthetic or natural in origin and will act to form a 3D- network which 
is capable of absorbing water.  A variety of polymers used in these systems are of the 
‘responsive’ type and the most widely studied for nasal drug delivery has been the 
temperature-sensitive category, of which poloxamer-based hydrogels are the most widely cited 
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(Zaki et al., 2007a, Shin et al., 2013, Nie et al., 2011, Majithiya et al., 2006, Kumari et al., 2012, 
Jones et al., 2009, Attwood et al., 1985, Miller and Drabik, 1984).  
These systems undergo a phase transition, moving from a solid-to-liquid or a liquid-to-solid 
which is triggered by a change in the temperature, this is often termed the critical solution 
temperature (CST) or gelation temperature (Tsol-gel or Tgel-sol).  This transition can be positive or 
negative and the majority of polymers belong to positive temperature sensitive hydrogels, 
which undergo swelling in water as the temperature increases above a critical point (upper 
critical solution temperature (UCST)), and hence become a ‘gel’ with increasing temperature.  
Formulations which shrink with increasing temperate are termed negative hydrogels 
(Soppimath et al., 2002). 
The majority of polymers used in these formulations are hydroxypropyl methylcellulose 
(HPMC), N-isopropylacrylamide copolymers (PNIPAAm), poly(ethylene oxide) (PEO) and 
poly(propylene oxide) (PPO) (poloxamers, Tetronics® or Pluronics®) and poly (acrylic acid) 
(PAA) (Klouda and Mikos, 2008) (Figure 1-6).  Of these polymer system, poloxamers block co-
polymers have been widely used in nasal hydrogel systems.  Poloxamer consist of ethylene 
oxide and propylene oxide units which are arranged in a tri-block formation, with Pluronics ® 
being the most widely incorporated due to their general biocompatibility and stability (Dumortier 
et al., 2006b). 
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Figure 1-6: Chemical structure of widely used thermoresponsive polymers 
Taken from (Klouda and Mikos, 2008) 
Poloxamer 407 (a=101; b=56; molecular weight: 9840-14600) is the most widely used 
poloxamer and is also known as Pluronic F 127® (‘F’ for flakes). Hydrogels formed from these 
systems are thermoreversible and are capable of transferred from liquid-to-gel above the sol-
gel transition temperature (Tsol-gel). In such systems the gelation occurs over two phases, as 
the temperature increases to the critical micelle temperature, poloxamer will aggregate to form 
micelles followed by a second step where the micellar structure will form an ordered system in 
the physical form of a gel (Figure 1-7).  
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Figure 1-7: The gelation of poloxamer 407 in water 
Adapted from (Dumortier et al., 2006a) 
In addition to temperature, the process of gelation is highly dependent on the concentration of 
poloxamer utilised and is related to the selection of a concentration above the critical micellar 
concentration. For poloxamer solutions in the region of 20-30% w/v, a clear liquid is formed at 
refrigerated temperatures (4°C) and a hydrogel form ed at room temperature (~25°C), with 
decreasing poloxamer concentration increasing the Tsol-gel (Schmolka, 1972a). 
To further enhance the residency within the nasal cavity, the use of bioadhesive polymers is 
widespread and often include, amongst others, xanthan gum, tamarind gum, sodium alginate, 
carrageenan, gelatin, pectin, chitosan, hydroxypropylcellulose and sodium carboxymethyl 
cellulose (Lee et al., 2000, Nakamura et al., 1996). Bioadhesion is the process of attachment 
of macromolecular polymer to the mucus network on cellular layers.  Typically this process 
occurs through molecular forces such as covalent attachment, hydrogen bonding or 
electrostatic interactions (Lee et al., 2000) and often through interaction with mucus containing 
proteins such as mucin (and termed ‘mucoadhesion’).  
 
 
 38
The process of bioadhesion/mucoadhesion is not widely understood and is based onnumerous  
theories: 
Electronic theory: The adhesive polymer and mucus layer have opposing charges which 
attract when in close contact (Derjaguin et al., 1977). 
Adsorption theory: Adhesion takes places as a result of forces such as van der Walls, 
hydrogen bonding or hydrophobic interactions (Wake, 1976) (Kaelble and Moacanin, 1977). 
Diffusion theory: Chains of the adhesive and substrate can interact and penetrate one 
another to create a semi-permanent bond (Campion, 1975, Voiutskii, 1963, Wake, 1978). 
Wetting Theory: It is the affinity of a liquid system towards the surface to spread over it 
(Boddupalli et al., 2010). 
Fracture Theory: This theory involves mechanical measurement of mucoadhesion, where 
force required to separate two surfaces is measured (Smart, 2005). 
Examples of successful application of mucoadhesive systems include the use of haluronate 
solutions to enhance the nasal bioavailability of vasopressin in rats (Morimoto et al., 1991), a 
range of mucoadhesive (Carbopol 934, PVP K30, HPMC K4M, sodium alginate, tamarind seed 
gum, and carrageenan) to enhance the bioavailability of venlafaxine in rats (Bhandwalkar and 
Avachat, 2013), natural extract mucoadhesive to enhance zolmitripan absorption (Kumari et 
al., 2012), Carbopol® polymers to enhance sumatriptan absorption (Majithiya et al., 2006), 
This issue of retention and residency time of formulations within the nasal cavity was further 
explored by (Kumar et al., 2008), who demonstrated the added benefit of inclusion of a 
mucoadhesive agent on retention in the nasal cavity and subsequent drug pharmacokinetics, 
with the Cmax
 
(0.11%/g) and AUC (0.48 h %/g) of mucoadhesive  
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ME formulations of risperidone significantly higher than non-mucoadhesive containing 
formulations.   
 Approaches aimed at retaining the drug within the nasal cavity for prolonged periods of 
time would undoubtedly aid in the overall retention and drug release within the nasal cavity.   
(Zaki et al., 2007b) explored approaches to enhance the residency time of the anti-emetic drug 
metoclopramide hydrochloride in the nasal cavity using a combination of thermosensitive and 
mucoadhesive polymers.  The bioavailability of metoclopramide in rabbits was demonstrated 
to be significantly improved when given IN rather than orally (69.1% and 51.7% respectively) 
with more rapid (tmax= 42.5 minutes and 50 minutes respectively) and pronounced (Cmax=3.41 
2.63µgmL-1 and 2.63µgmL-1 respectively) when using a poloxamer 407 thermosensitive gel 
system which incorporated polyethylene glycol (PEG) polymers to aid in mucoadhesion and 
retention within the nasal cavity.  
1.6.3 Nanoparticulate drug carriers for olfactory drug delivery 
The use of nanotechnology for drug delivery has developed significantly over the last decade.  
Principally the application of nanoparticles have focussed on poorly soluble active agents 
(Junghanns and Muller, 2008) with a view to increasing their solubility (Ambrus et al., 2009) 
and to enhance permeability through mucosal barriers(Morgen et al., 2012).  Two basic 
approaches are involved in the production of nanoparticles, the bottom–up technologies 
(controlled precipitation, crystallization) and the top–down (high pressure homogenisation, wet 
milling, co-grinding) technologies. The result of such approaches is a wide variety of different 
types of nanomaterials including lipid systems (liposomes), metallic (gold, silver), polymeric 
and ceramic (silica, titanium)(Moreno-Vega et al., 2012), that consist of a highly homogenous 
system of spherical particles in the nanometer scale range, with the European and other 
International Committees have defining 
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 a nanoparticle as having three dimensions in the order of 100 nm or less, although materials 
up to 1000nm have often been described as ‘nanoparticle’ systems (Lövestam et al., 2010). 
The inclusion of drugs into nanoparticles often aids to enhance the solubility, but also provides 
a vehicle through which the nanoparticle is able to, often, easily transverse mucus barriers 
(Kim et al., 2012, Cario, 2012). 
Of the range of nanocarriers developed for nose-to-brain delivery, example of successful 
delivery have been demonstrated with polymeric nanoparticles such as PLGA for lorazepam 
(Sharma et al., 2014); lipid nanoparticles for delivery for the K3 receptor agonist senktide (De 
Luca et al., 2015), duloxetine (Alam et al., 2014), ondansetron (Devkar et al., 2014); 
polysaccharide chitosan for mitotane (Severino et al., 2013).  In all cases, the inclusion of the 
drug into the nanoparticles has been demonstrated to result in a rapid and quantifying delivery 
into the olfactory bulb and wider CNS following administration. 
The advantages of using formulation approaches to enhance CNS delivery was further 
demonstrated by (Jain et al., 2010), through the development of a micellar nanocarrier for 
zolmitriptan. Significantly higher brain accumulation of zolmitriptan was observed in rats at all 
time points studied (30-240 minutes) compared to either IN solution or IV administration. 
Furthermore, it was reported that in the first 30 minutes post-administration, drug uptake was 
limited to the rostral brain region with limited radioactivity in mid-brain, cerebellum, pons and 
medulla.  From 60-240 minutes an increase in distribution was seen in the midbrain and 
cerebellum regions.  To elucidate the absorption pathway, autoradiographical studies using 
99mTc-zolmitriptan demonstrated transport to the olfactory bulb along the olfactory and 
trigeminal systems with transport of the drug complex to the mid-brain and cerebellum along 
the trigeminal pathways. Finally (Jain et al., 2010) were also able to demonstrate targeting of 
99mTc-zolmitriptan to the axon terminals of the olfactory neurons, where the axon terminals 
of the olfactory receptor neuron contact the dendrites of the mitral and tufted cells.  This 
pathway was able to allow 99mTc-zolmitriptan to distribute further into brain regions such as 
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the hippocampus and diencephalon and frontal cortex. Thereafter the compound was 
demonstrated to travel to the caudaputamen, hippocampus and diencephalon. 
 A class of biocompatible nanomaterials that has gained attention for drug delivery are 
silica based nanoparticles.  Silica is biocompatible and is often used in inorganic nanoparticles 
(Bottini et al., 2007, Gerion et al., 2007).  Silica nanoparticles are highly porous in nature, with 
the pore sizes, density and total surface area being highly tuneable making them excellent 
tools for biomolecule detection, drug delivery systems and for contrast agent protectors (Nehoff 
et al., 2014, Liao et al., 2014, Marzaioli et al., 2014). Mesoporous material was first discovered 
by Mobil Corporation in 1992 (Kresge et al., 1992b) and termed MCM-41, possessing a 
honeycomb-like porous structure with hundreds of pore channels (termed mesopores) that 
have the potential to absorb molecules (Figure 1-8).  
 
Figure 1-8: Schematic representation of mesoporous silica nanoparticles. Taken from(Yuan et al., 2011).  
 
This results in mesoporous nanoparticles (MSNP) having a high surface area (> 900m2/g), 
large pore volume (> 0.9cm3/g) with the added benefit of a tuneable pore size over a very 
narrow size distribution (2–10nm) (Slowing et al., 2008a).   
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Unger, Stucky, and Zhao were one of the first groups to prepare micrometer-sized mesoporous 
silica spheres (Grün et al., 1997, Huo et al., 1997, Qi et al., 1998), and their synthesis was 
based on the well-established Stöber reaction for the synthesis of monodisperse non-porous 
silica spheres. This reaction involves the co-hydrolysis and condensation of tetraethoxysilane 
(TEOS) and an alkyltrialkoxysilane (generating porosity) in a mixture of ethanol (co-solvent to 
form a homogenous solution), water, and aqueous ammonia (morphological catalyst) (Grün et 
al., 1997) (Figure 1-9).  
 
 
Figure 1-9: Stöber reaction for preparation of mesoporous silica nanoparticles (Yan et al., 2014). 
However, this first approach developed micrometer size particles, which are not considered 
suitable for cellular targeting and delivery.  Adaptations of this method has developed 
mesoporous silica nanoparticles through the use of TEOS as a silica source, the cationic 
surfactant cetyltrimethylammonium bromide (CTAB) to act as a structure-directing agent, water 
as a solvent and sodium hydroxide as a morphological catalyst (Huh et al., 2003).  To remove 
the template surfactant a solvent extraction or calcination step is used to generate pores.  
 
Given the relative ease of preparation of MSN and the tuneable nature of the nanomaterials, 
MSNP are an interesting group of nanoparticles which have not fully been exploited for nose-
to-brain delivery. 
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1.6.4 Pressure metered dose inhaler 
Although pressurized metered dose inhalers (pMDIs) have been widely utilized for pulmonary 
delivery of drugs, their use in nasal (and specifically olfactory) delivery has been limited.  A 
pMDI system comprises of a drug dissolved directly into a propellant Hydrofloroalkane (HFA 
134a (1,1,1,2-tetrafluoroethane) or 227 (1,1,1,2,3,3,3-Heptafluoropropane)) and, if solubility 
limitations exist, formulation with a co-solvent (e.g. ethanol).  The formulation is housed under 
pressure within the canister, and a metering value determines the overall spray volume (~60-
100µL/actuation).  For nasal drug delivery,  very few actuator devices exist and are often 
utilized to the local treatment allergic rhinitis conditions (Djupesland, 2013).  Whilst actuator 
devices for nose-to-brain delivery are sparse and include technologies such as g. ArhcerFIsh® 
N2B (www.mysticpharmaceuticals.com), ViaNase® (www.kurvetech.com), POD 
(http://impelnp.com/), however there are no current marketed products based on these inhaler 
technologies (Figure 1-10).   
 
Figure 1-10: Example of pMDI systems used for pulmonary and nasal (olfactory) drug delivery.  
The requirement for localised delivery at the upper-most part of the nasal cavity poses 
significant challenges in directing the spray plume from a pMDI system and this may account 
for the limited progress in clinical translation of this widely used delivery system. 
1.7 Novel CNS drug candidates: phytochemicals 
A novel category of potential therapeutic agents for CNS disorders are phytochemicals, which 
are derived from natural extracts from plants.  Over 8000 compounds have been identified as 
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belonging to the general category of polyphenols (Pandey and Rizvi, 2009).  One of the major 
classes of these polyphenols are flavonoids. There are over 6500 compounds identified as 
flavonoids (Kong et al., 2009). Flavonoids consist of a backbone of two aromatic rings (A and 
C ring) and a heterocyclic benzene ring (B ring) (Figure 1-11). The main subclasses includes: 
flavones (e.g. flavone), flavonols (e.g. quercetin, fistein), flavonones (e.g. flavanone, 
hesperetin and naringin), flavanonol (e.g. taxifolin), isoflavones (e.g. genistein, daidzein), 
flavan-3-ols (e.g. catechin , epicatechin) (Yao et al., 2004).   
 
 
 
Figure 1-11: The structure of flavonoid (Heim et al., 2002). 
Flavonids consist of two aromatic rings (A and B) linked through three carbons that usually form a heterocyclic ring 
(C). Based on the pattern of hydroxylation and substitution (Rx), there are 7 subclasses of flavonoids. 
 
Flavonoids offer a wide range of pharmacological actions which includes anti-inflammatory, 
antineoplastic, antioxidative, antiallergic, hepato- and gastro-protective, antidiabetic, and 
antiviral activities (Arts et al., 2000) (Zand et al., 2002) (Hertog et al., 1993).  These 
physiological actions are mostly believed to be due to their antioxidant and free-radical 
scavenging effects (Chu et al., 2000), however new studies suggest that their mechanism of 
action is beyond these two properties (Nones et al., 2010).   
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Many phytochemicals have been reported to possess CNS indicating effects including the 
protection of neurons from neurotoxins and neuro-inflammation in degenerative disease status 
such as Dementias (Williams and Spencer, 2012, Solanki et al., 2015, Shukitt-Hale, 2012, 
Mecocci et al., 2014, Macready et al., 2009, Cherniack, 2012, Blumberg et al., 2014).  
Furthermore, an increasing body of clinical evidence is supporting the view that flavonoids 
impart a protective function towards dopamine neurons through prevention of oxidative 
damage and apoptosis (Mercer et al., 2005, Meng et al., 2009).  The target site for flavonoids 
is thought to be widespread within the CNS, but much attention has been focussed on the 
ability of phytochemicals to interact with the GABAA receptor, one of the most important 
neurotransmitter sites within the CNS.  Indeed, many phytochemicals demonstrated significant 
inhibitory actions on GABAA in low micromolar concentration, e.g. chrysin (3µM) (Medina et 
al., 1990) and 6 –methylapigenin (495 nM) (Wasowski et al., 2002).  Furthermore, chrysin has 
been demonstrated to result in anxiolytic in mice at an intraperitoneal dose of 1mg/kg (Wolfman 
et al., 1994).  In addition to their action on receptor sites, a range of phytochemicals have been 
demonstrated to modulate the genome and proteome of the promiscuous network of 
membrane transporter proteins localised at the BBB (Kaur, 2016).   
Phytochemical flavonoids are therefore a potentially novel multi-faceted class of molecules 
which show potential for a range of CNS patho-physiologies (Katayama et al., 2007, Breedveld 
et al., 2006b, Allen et al., 2002b, Ashida et al., 2000, Pick et al., 2011, Fleisher et al., 2015, 
Zhang et al., 2004, van Zanden et al., 2007, Zhang et al., 2005, Robey et al., 2004, Ferrandiz 
and Alcaraz, 1991, Breedveld et al., 2006a, Allen et al., 2002a). However, many 
phytochemicals are poorly soluble and are not immediately amenable to direct formulation into 
simple spray, solution or hydrogel based systems.  To overcome this, many groups have 
demonstrated successful loading and delivery of phytochemicals into nanoparticle carrier 
systems to enhance their solubility, with the most commonly studied phytochemical being 
curcumin (Gupta et al., 2009, Gupta and Dixit, 2011b, Gupta and Dixit, 2011a, Krausz et al., 
2015). Mesoporous silica nanoparticles have also recently been used recently to demonstrate 
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loading and release of curcumin (Kim et al., 2015). Furthermore, in another study by   (Du et 
al., 2016) chrysin was encapsulated in PLGA-PEG nanoparticles for local treatment whereas 
other groups (Tamaddon et al., 2015, Guideline, 2005) used β-cyclodextrin to increase the 
solubility of chrysin. 
 
1.8 Models for studying nasal drug delivery   
1.8.1 Models for studying nasal drug delivery: ex-vivo models 
To assess the targeting and delivery of drugs within the nasal cavity, the use of established 
cell culture or ex-vivo tissue models are vital.  Traditional, ex-vivo tissue extracts have been 
used from a range of animals or humans and these are mounted within a vertical Franz 
diffusion cell model to evaluate drug penetration from pharmaceutical preparations (Ng et al., 
2010). In this system, the donor and acceptor compartments are separated by a membrane of 
artificial, animal or human origin.  However a key difficultly in this approach are species 
differences in the quality of the tissue and the associated enzyme activities or cell type 
distribution, particularly as these can differ when compared to humans  (Chien and Chang, 
1987) (Costantino et al., 2007, Horvat et al., 2009). 
1.8.2 Models for studying nasal drug delivery: cell culture models 
Although ex-vivo tissue models may be more historically and anatomically relevant for in-vivo 
delivery studies, in-vitro cell culture models of barrier sites are often utilised due to their ease 
of growth/proliferation and development of permeation assays. To ensure a representative 
nasal epithelial model, it is imperative the chosen cell culture model systems is capable of 
forming confluent cell layers; expresses correct intercellular junctional proteins; possess an 
appropriate functional barrier as measured by the transepithelial electric resistance and 
permeability coefficients for drug or marker molecules. The use of in-vitro cell culture models 
of the human nasal epithelium based on directly isolated cells from freshly extract nasal tissue 
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(primary cell culture) has been previously demonstrated to fulfil these criteria, but the limiting 
proliferation ability of primary cells coupled with batch-to-batch variability is often hinders their 
widespread use (Horvat et al., 2009, Werner and Kissel, 1996). 
Immortalized cell lines have the advantages of being relatively easy to culture and of lower 
costs with a greater level of genetic homogeneity (Werner and Kissel, 1996).  Out of the 
available immortalised nasal epithelial cell line, the RPMI 2650 cell line is derived from a 
spontaneously formed anaplastic nasal septum tumour, but possess properties that are very 
closely related to normal human nasal epithelium (Moorhead, 1965, Moore and Sandberg, 
1964, Moll et al., 1983).  Furthermore, reports have demonstrated that this cell line is suitable 
for drug transporter studies (Salib et al., 2005, Reichl and Becker, 2012b, Lungare et al., 2016, 
Kurti et al., 2013, Kreft et al., 2015, Dolberg and Reichl, 2016). 
The availability of olfactory immortalised cell lines is relatively rare with only one model system 
published that is readily available, and isolated from the olfactory bulb of pigs.  This cell line is 
termed OBGF400 and was originally developed by Dr Gail Scherba (Uebing-Czipura et al., 
2008) and has been used as a continuous source of porcine neuronal-committed progenitors 
that can be used for the development of in-vitro neuropathogenic disease models (Uebing-
Czipura et al., 2009). 
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1.9 Aims and Objectives 
The overall aim of this thesis was to examine approaches that can be used to selectively target 
and deliver drugs onto the olfactory mucosa following intranasal delivery. Thermoresponsive 
nasal gel systems, mesoporous silica nanoparticle carriers and adaptations of existing nasal 
pMDI systems were chosen as administration approaches/vehicles.  Furthermore, the 
formulation of water-soluble (amantainde) and poorly soluble (chrysin, curcumin and 
diazepam) compounds were considered. 
To achieve the aims, the overall objectives where: 
Chapter 2: Thermoresponsive nasal gels 
• To demonstrate successful formualtion of a thermoresponsive nasal gel system for the 
delivery of amantadine 
• To assess the stability of formulations and release mechanisms from gels 
• To investigate the optimal administration techniques to ensure optimal olfactory 
deposition using a human nasal cast model 
• To assess the cellular toxicity of formulation towards nasal epithelia cells and olfactory 
cells in culture 
Chapter 3: Mesoporous silica nanoparticles 
• To demonstrate successful formulation of a mesoporous silica nanoparticle capable of 
penetration into olfactory cells layer 
• To assess the optimal size range for penetration of nanoparticles into OBGF400 cells 
• To characterise the mesoporous material developed using FTIR, DSC, TGA, SEM 
• To investigate the potential for loading and release of the phytochemicals chrysin and 
curcumin 
• To assess the cellular toxicity of formulation towards olfactory cells in culture 
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Chapter 4: Nasal pMDI systems 
• To formulate a pMDI canister containing diazepam for nasal delivery 
• To assess the stability of diazepam in HFA134a 
• To assess the deposition patterns of spray when actuating a nasal pDMI into a silicone 
nasal cast 
• To quantify olfactory deposition of diazepam under optimal administration angles 
• To assess the cellular toxicity of diazepam towards olfactory cells.  
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Chapter 2  
Development of thermosensitive 
mucoadhesive polymer hydrogel 
formulations for olfactory drug 
delivery  
 
  
 51
2.1. Introduction 
Approaches aimed at delivering a drug into the CNS to target CNS disorders are challenging 
due to the significant hurdle that the BBB poses in restricting the entry of xenobiotics across 
into the brain and wider CNS (Abbott, 2005, Abbott et al., 2010b, Abbott and Romero, 1996, 
Pardridge, 2007b). Recently, there has been a growing interest in identifying and exploiting 
alternative pathways which may enable CNS drug delivery through bypassing the BBB, and 
much of this work has focussed on the olfactory mucosa and trigeminal neuronal regions within 
the nasal cavity as target sites which can enable CNS drug delivery, primarily as a virtue of the 
direct exposure of neurones to the external environment within the nasal cavity (Jogani et al., 
2008, Stewart, 1985, Reiss et al., 1998, Sakane et al., 1995).  These regions provide direct 
access to the brain, without the limitation of the BBB to hinder drug delivery (Mathison et al., 
1998a) . 
Although IN drug delivery offers many advantages to targeting the olfactory regions for 
nose-to-brain delivery, a key limitation is the short residence time of the formulation in the nasal 
cavity.  The residency time is key to allow the absorption of the drug across the mucosa and 
the action of mucociliary clearance cycles (MCC) substantially reduces the half-life of 
substances administered intranasally to approximately 15-20 minutes (Vyas et al., 2005b) 
(Soane et al., 1999).  
The optimal design of an olfactory targeting system would be one capable of prolonging the 
residence time of the formulation within the nasal cavity and therefore enhance the 
bioavailability of the drug.  To achieve this goal, the use of intelligent polymer based systems 
have now become more commonplace in this field and particularly the use of responsive 
systems which may respond to the nasal cavity temperature have increased amongst 
researchers (Schmolka, 1972b, Wu et al., 2007, Qian et al., 2014, Nazar et al., 2011, Li et al., 
2010, Li et al., 2014, Jeong et al., 2002, Chen et al., 2013b, Alsarra et al., 2009, Agrawal et 
al., 2010) or at a specific trigger pH (Zaki et al., 2007a, Nakamura et al., 1999, Ikechukwu 
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Ugwoke et al., 1999, Hosny and Banjar, 2013, Basu and Maity, 2012).  Furthermore, the use 
of mucoadhesive polymers to enhance the adhesion of the formulations onto the nasal mucosa 
(Zhou and Donovan, 1996, Ugwoke et al., 1999, Soane et al., 2001, Luessen et al., 1996, Jain 
et al., 2008, Ikechukwu Ugwoke et al., 2000, Basu and Maity, 2012, Basu and Bandyopadhyay, 
2010), has further demonstrated the ability to prolong contact time with the mucosa and hence 
increase drug bioavailability (Ugwoke et al., 2001, Qian et al., 2014, Li et al., 2014, Kumar et 
al., 2015, Ibrahim et al., 2015, Hosny and Hassan, 2014, Zaki et al., 2007a). 
Thus, a thermosensitive polymeric system which undergoes solution-to-gel transition 
associated with a change in temperature, coupled with a mucoadhesive to enhance nasal 
cavity/olfactory residency, may provide a simple yet effective formulation and opportunities for 
drug absorption across the olfactory epithelia to enhance residency and delivery to the brain. 
One of the major complications of PD is the emergence of dysphagia affecting the ability 
to ingest or swallow and is thought to affect between 45% and 95% of PD patients and has 
significant implications for orally dosed therapeutics, such as amantadine (Foltynie et al., 2004) 
and other anti-Parkinsonian therapeutics agents. Furthermore, the occurrence of bradykinesia 
and morning akinesia is often associated with delayed gastric emptying after the oral 
administration of anti-Parkinsonian therapeutics (Leopold and Kagel, 1997). To address these 
issues amatadine was selected as a model drug in these formulations.  
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Aims and objectives 
The aim of this chapter was to develop a novel thermoresponsive and mucoadhesive hydrogel 
drug delivery system using amantadine as a model candidate compound which was capable 
of sol-gel transition at 34°C and stable over prolo nged storage.   
To achieve the aims, the overall objectives were: 
• To identify and develop a thermosensitive nasal gel formulation using amantadine as a 
model drug. 
• Identify the optimal formulation composition to ensure suitable sol-gel transition  
• Understand the thixotropic behaviour of these gel formulations at molecular level both at 
room temperature and nasal temperature using rheology 
• Evaluate and compare the mucoadhesive of the formulation following incorporation of 
different mucoadhesive polymers. 
• Analyse the release kinetics of amantadine release from formulations  
• Determine amantadine and excipient cellular toxicity against human nasal epithelia cells 
(RPMI 2650) and porcine olfactory mucosa cells (OBGF400). 
• Assess the storage stability of formulations.  
• Identify optimal administration parameter from a multi-dose spray system for olfactory 
deposition using a human nasal cavity cast 
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2.3. Materials and Methods 
2.3.1. Materials 
Dulbecco’s Modified Eagle Medium (MEM), Dulbecco’s Modified Medium: Nutrient Mixture 
F12 (DMEM-F12), Dulbecco’s Phosphate buffered saline (PBS), L-glutamine 200mM, non-
essential amino acids (NEAA), penicillin/streptomycin and trypsin-EDTA solution were 
obtained from PAA laboratories (Austria); foetal bovine serum (FBS) (Labtech, UK); 
polyethylene glycol 4000 (PEG4000), polyethylene glycol 12000 (PEG12000),  chitosan-
medium molecular weight (CS), sodium chloride, potassium chloride, magnesium sulphate, 
calcium chloride, acetonitrile, orthophosphoric acid, acetic acid, ethanol, sodium hydroxide, 
and sodium chloride were obtained from Fisher Scientific (Loughborough, UK); Acutase 
(Biolegend, UK) and unless otherwise indicated all other chemicals were obtained from Sigma 
(Dorset, UK), rat tail I collagen solution from First Link (Birmingham, UK) . 
2.3.2. Formulation development 
Formulations were prepared using a modified ‘Cold method’ approach as originally 
described by Schmolka (Schmolka, 1972b). Briefly, fixed quantities of excipients were utilised 
in all formulations and consisted of d-sorbitol (humectant) (0.5% w/w), sodium metabisulphate 
(antioxidant) (0.1% w/w) and benzalkonium chloride (surfactant) (0.1% w/w). Initially four 
mucoadhesive polymers were investigated (Na CMC (sodium carboxymethyl cellulose), CS, 
PEG4000 and PEG 12000) at concentrations of 0.5-1.5% w/w.  These components were 
combined with ultrapure water under constant stirring, followed by the addition of amantadine 
(AMT) (0.5-1.5% w/w).  The resulting solution was maintained for 2-hours in an ice bath prior 
to the slow addition of the thermoresponsive polymer pluronic-127 (P127) at concentrations of 
15-20% w/w followed by storage at 4°C for 12 hours prior to use.   
In the case of CS, the required quantity was first dissolved in 1% v/v acetic acid (Cho et 
al., 2011) for 24 hours before being combined with the remaining formulations (prepared in 
ultrapure water) and stored at 4°C for at least 24 hours prior to analysis.  
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2.3.3. Assessment of sol-gel transition (Tsol-gel)  
Visually: A modified method described by Zaki et al (Zaki et al., 2007b) was used to determine 
the sol-gel transition temperature (Tsol-gel). A sample of each formulation (1 g) was transferred 
into a glass vial and heated in a dry block (Techne Dri-Block ® DB-2D), initiated at 20°C and 
increased by 1°C after every 5 minutes of equilibra tion time. The Tsol-gel point was defined as 
the temperature whereby the upper meniscus of the gel did not move upon tilting the vial by 
90 ° and this was used to demark optimal formulatio ns. The optimal subset of formulations 
were then further characterised.  
Rheologically: To assess the rheological properties of the formulations, samples were 
transferred to a AR-G2 Rheometer (TA instruments, USA). Throughout the tests a parallel 
plate geometry with 40mm steel plates having a gap 1.0mm were used.  The approximate 
sample volume used was 1.26mL and the instrument was used in the oscillatory mode in the 
linear viscoelastic range. The rheological behaviour was characterised as a dynamic moduli 
G’ and G” as a function of frequency. Storage modulus (elastic) G’ is a measure of energy 
stored and recovered for solid like component or how well structured a material is, loss 
modulus (viscous) G” measures the energy lost for liquid like component of viscoelastic 
behaviour of the material, whereas loss tangent (tan δ) indicates overall viscoelasticity of the 
formulation measured (G”/G’) (Madsen et al., 1998). Tests conducted included: 
Time sweep test: performed in a linear viscoelastic regime to ascertain any changes in 
formulation rheology over time at a fixed constant temperature (20°C or 34°C), stress (1 Pa) 
and frequency (1 Hz).  
Temperature sweep test: performed to assess formulation behavior at a constant frequency 
and stress across a temperature range of 20-40°C, a t different heating rates but at constant 
frequency (1 Hz) and stress (1 Pa). A temperature ramp of 5°C min -1 was used in order to 
minimise dehydration or degradation of the formulation.  
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Steady shear viscosity: samples were subjected to shear rates ranging from 0.1 to 100 s-1 and 
tests were conducted at 20°C and 34°C to identify t he impact of temperature on viscosity. 
To quantify the rheological properties, the Ostwald-de Waele relationship (often called the 
power law) was applied to relate the sheer stress (σ) is related to a consistency coefficient (k), 
the sheer rate () and an index value (n) (Bonacucina et al., 2004):   
 =  
which is applicable to the formulations in light of the constant shear viscosity curves. In the 
context of rheology, the index value can be used to determine the type behavioural flow, with 
Newtonian behaviour when to n ≈ 1 (where n is identical to the viscosity).  When the magnitude 
of n is < 1, the underlying rheological process is shear-thinning (pseudoplastic flow) and then 
when n > 1 the fluid is shear-thickening. 
2.3.4. Assessment of formulation mucoadhesion 
2.3.4.1. Texture analysis 
To assess the mucoadhesive properties of formulations, a modified texture analysis method 
was utilized (Curran et al., 2009) (Bruschi et al., 2007) through the means of a Brookfield 
Texture Analyzer CT3 (Figure 2-1). Porcine mucin discs were prepared in a manual hydraulic 
press (SPECAC, UK) using 250mg mucin with the application of 10t force for 30s. The 
prepared mucin discs were then hydrated in 5% w/v mucin solution for 30s and excess mucin 
solution was carefully removed. Using double sided tape, the prepared discs were attached to 
a 13mm aluminum cylinder probe of the texture analyser and 1.5mL of formulations were 
placed on a 34°C heated surface of a dry block. The  texture analyzer was programed such 
that the probe of the texture analyzer was lowered at the speed of 0.10mm s-1 until the mucin 
disc contacted the gel surface. A trigger load of 2g was then applied for 2mins, and then the 
probe was lifted at the same speed. The adhesive force required to detach the mucin disc from 
the gel was measured in grams and used as measure of mucoadhesion. 
 57
 
 
Figure 2-1: Tensile strength apparatus 
(A) Schematic and (B) apparatus setup, to assess tensile strength using a dry block maintained at 34°C.  A wetted 
(5% w/v mucin) compressed mucin disc was adhered onto the bottom of the probe of a texture analyser and tensile 
strength recorded as the force required to detach the probe from the formulation. 
 
2.3.4.2. Displacement method  
To further assess the mucoadhesion of formulations, an adapted inclined plate displacement 
method (Nakamura et al., 1999) was developed.  Briefly, 100mL of a hot 1% w/v agar and 2% 
w/v mucin mixture in PBS (pH 6.0) was cast onto a glass plate and left to dry at 4°C for 4 hours.  
The gel plate was then equilibrated at 34°C for 1 h our before formulation mucoadhesion was 
assessed through the application of a 250µL sample of each formulation with the plate kept at 
a 45° angle and maintained at 34°C in a heated incu bator (Figure 2.2). The displacement (cm) 
of each formulation, measured for 1 minute, was used as a measure of the potential for 
adhesion. 
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Figure 2-2: Displacement measurement apparatus 
(A) Schematic and (B) apparatus setup, to measure displacement using a agar/mucin coated glass plate inclined 
at 45° and maintained in a 34°C environment.  
 
 
2.3.5. Pre-column derivatisation of AMT and HPLC detection  
To enable detection of AMT from formulations, a pre-column derivatisation method for 
memantine hydrochloride was modified in order to enable detection of AMT (Narola et al., 
2010). Amantadine lacks a chromophoric group to be detected by UV. 9-Fluorenylmethyl 
chloroformate (FMOC) is one of the derivatising agents which reacts with primary and 
secondary amines through ionic interactions (Bahrami and Mohammadi, 2007). Amantadine is 
a primary amine and its amino group can be trapped with FMOC to form amantadine-FMOC 
complex (Figure 2.3) which can be easily detected in the UV wavelength range. 
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Figure 2-3: FMOC reaction and complex formation with amines (Bahrami and Mohammadi, 2007). 
In comparison to other derivatization methods of memantine hydrochloride, this method was 
found to be more reliable, sensitive and reproducible (Xie et al., 2011).  Briefly, to 50µL of 
sample or standard solution of AMT, 40µL of 0.015 M FMOC and 50µL of 0.5 M ate buffer 
were mixed well and kept at room temperature for 20 minutes prior to the addition of 360µL of 
diluent (0.05M borate buffer:acetonitrile (50:50 v/v)). A Shimadzu HPLC system was used with 
a Phenomenex Luna C18 (150 × 4.6mm) 5µm column. The mobile phase consisted of 
premixed and degassed phosphate buffer:acetonitrile (20:80 v/v) which was filtered through 
0.45µm membrane filter. The column was maintained at 30°C and volume of injection was 
10µL.  The flow rate was maintained at 2mL/minute with run time 12 minutes. The software 
used for data collection and control of the system was LCsolution Version 1.24 SP1.  The UV 
detection of derivatised amantadine was measured at 265nm. The intra/inter-day precision 
was determined and the limit of detection (LOD) and limit of quantitation (LOQ) were calibrated 
according to ICH (QR (R1) recommendations (Guideline, 2005),(Group, 2005) . 
Stability of formulations 
Optimised formulations were stored in stability cabinets maintained at 4 ± 1°C (Sanyo 
Medicool, Loughborough, UK) and 25 ± 2°C (Firlabo, Paris, France) at a humidity of 60% ± 
5%. The stability of the formulation was assessed based on the gelation of a sample of the 
formulation at 34°C within 5 minutes, followed by a ssessment of the extent of drug release and 
drug content by HPLC as described in the section 2.3.5. 
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2.3.6. Membrane-less release kinetics 
The release of AMT from the formulations were assessed by a ‘membrane-less’ diffusion 
system (Varshosaz et al., 2006, Chen et al., 2013b, Chi and Jun, 1991).  A mass of formulation 
(0.25g) appropriate for the nasal cavity volume was transferred to a glass vial and allowed to 
equilibrate in a dry block at 34°C. Artificial nasa l electrolyte (ANE) (0.8g/L NaCl, 3g/L KCl, and 
0.45g/L CaCl2, pH 6.8) (Martinac et al., 2005) was used as a release medium. 100µL of ANE 
was carefully layered on top of the gelled formulation.  This volume was completely withdrawn 
and replaced with fresh ANE at each time point. Samples were analysed by a pre-column 
derivatisation method followed by HPLC analysis. 
Several kinetic drug release mathematical models were used to assess drug release from the 
formulations (Tamaddon et al., 2015).  The best-fit to the mathematical models described 
below confirmed the appropriate release kinetics: 
Higuchi model: 
	
= 
 ∙ 


 
where Mt/M∞ is the drug fraction released at time t and kH is the Higuchi constant. 
Zero order model: 
	
=  ∙ t 
where Mt/M∞ is the drug fraction released at time t and k0 is the zero-order release constant. 
First order model: 
	
= 1 −  
where Mt/M∞ is the drug fraction released at time t and k1 is the first-order release constant. 
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To assess the mechanism of drug release, the Korsmeyer-Peppas power law (Korsmeyer, 
1983) has been used in many pharmaceutical formulations (Siepmann and Peppas, 2001, Kim 
and Fassihi, 1997, Bettini et al., 1994, Peppas and Sahlin, 1989) and can be defined as: 
Power law: 
	
=  ∙  
where Mt/M∞ is the drug fraction released at time t, kKP is a kinetic constant which describes 
the structural and geometrical elements of the formulations and n is the release exponents 
which is used to indicate the mechanism of drug release.  The value of n is important in 
understanding the mechanism of release when it is unknown and often polymeric formulations 
can be categorised accordingly to this scale. When n ≤ 0.45 drug release is diffusion controlled 
and sometimes referred to as Fickian diffusion and when n > 0.89 the diffusion is indicative of 
erosion controlled drug release or class-II kinetics.  For situations where 0.45 < n ≤ 0.89 the 
diffusion is a complex mixture of both processes and often termed anomalous transport.  In all 
cases this is based on the assumption of release from a cylinder and applied to cumulative 
release rates < 60% (Korsmeyer, 1983). 
2.3.7. Human nasal epithelial cell culture: RPMI 2650 
The immortalised human nasal epithelial cell line RPMI 2650 (CLS, Germany) (Figure 
2-4), was used to assess the compatibility of the formulations with human nasal epithelia and 
to develop an in-vitro nasal epithelial cell culture model (Reichl and Becker, 2012a) to assess 
drug release/transport.  Cells were grown in MEM supplemented with 10% FBS, 1% L-
glutamine, 1% NEAA, 1% penicillin-G/streptomycin in a humidified 37°C incubator with 5 % 
CO2 (Reichl and Becker, 2012b). The media was changed every 2 days. Thereafter the cells 
were passaged 3-4 days post seeding (at 70-80% confluency) by washing with pre-warmed 
PBS followed by the addition of 1mL of trypsin-EDTA to the flask. The flask was then placed 
in an incubator for 5-10 min and observed under microscope to make sure cells were lifted 
before seeding in the new flask. 
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Figure 2-4: Morphology of RPMI 2650 cells 
Light microscopic image (20 X) confirming the rounded and polygonal structures of the human nasal epithelial cells. 
 
Cells were cryopreserved for further use by centrifugation at 1500 rpm for 10 min to obtain 
a cell pellet, followed by resuspension of the pellet in cryopreservation media (10% DMSO and 
90% RPMI 2650 media).  A 1mL volume of the cell suspension was aliquoted to the cryovials 
and stored overnight at -80˚C in cell cooling box (Mr. Frosty, Nalgene®, Thermo Fisher 
Scientific, UK). After 24 h, cryovials were transferred to liquid nitrogen for long-term storage. 
 
2.3.7.1. Human nasal epithelial airway cell culture model 
To develop an in-vitro human nasal cell culture model, 6-well permeable inserts 
(ThinCert®) were used as a support for cell growth, with the addition of a matrix coating of 
5µg/cm2 of rat-tail collagen. Inserts were left to dry for 3-4 h in a laminar airflow hood before 
excess collagen was aspirated and inserts washed twice with PBS. 
To assess the release and transport of AMT from formulations, an in-vitro nasal epithelial 
airway cell culture model was developed with RPMI-2650 cells seeded onto collagen-coated 
6-well 0.4µm permeable inserts (ThinCertsTM) at a seeding density of 4 x105 cells/cm2 (Bai et 
al., 2008) (Reichl and Becker, 2012a) and grown for 14-days, with media replacement                       
on alternative days.  On days 10-14 an air-liquid interface (ALI) was initiated with the removal 
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of the media from the apical compartment producing the ‘air-interface’.  The integrity of the 
monolayer was determined by measuring the trans-epithelial electrical resistance (TEER) 
using an EVOM epithelial voltohmmeter (World Precision Instruments Inc.). TEER values for 
filter without cells (blank) were subtracted and values were calculated as per the surface area.  
TEER values were calculated as follows (Du et al., 2016): 
	TEER	Ω. cm"# = $%&'((	)*+*(,-'. 	− 	%/(,+0	12(3'.4 × A        
where A = surface area of the permeable insert (cm2), Rcell monolayer = resistance across cell 
monolayer permeable inserts and Rblank filter = resistance across permeable insert without cells. 
Control measurements were made using filters without cells (blank filter).  
To confirm the formation of monolayer (Bai et al., 2008) hence to further assess the 
formation of a suitable monolayer, lucifer yellow (LY) was used as a passive diffusion marker. 
LY was prepared in RPMI 2650 maintenance media without serum (termed serum free media 
(SFM)) and added to the apical chamber of the inserts to achieve a final concentration of 
100µM with and LY-free SFM added to the basolateral chamber (1.5mL). The inserts were 
incubated at 37°C for 1 h. Thereafter, a sample of the basolateral media was then collected 
and quantified for LY permeation on a fluorescent plate reader at an excitation wavelength of 
428nm and emission wavelength of 536nm using dual-scanning microplate spectroflurometer 
(Spectra 70 Max Gemini XS, Molecular Devices, Sunnyvale, California). The percentage 
transport of LY across the permeable inserts were calculated as follows: 
%	89	:;<=>?: = 	100	 ×		
%ABCDEFGDHIDG
%ABDJKLDG
# 
where RFUbasolateral is the relative fluorescence units in the sample taken from basolateral 
compartment and RFUapical is the relative fluorescence unit in the sample taken from the apical 
compartment.  
The cut-off TEER values for an acceptable in-vitro model was set at 150 Ω.cm2 (Bai et al., 
2008) (Reichl and Becker, 2012a) and LY transport of less than 1% 
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2.3.8. Porcine olfactory bulb neuroblastoma cell culture: OBGF400 
To assess the compatibility between formulation and olfactory mucosa type cells, the 
porcine olfactory bulb neuroblastoma cell line OBGF400 was used as an in-vitro cell culture 
model of the olfactory neuronal pathway.  OBGF400 cells are bipolar to multipolar in nature 
with prominent cell bodies and a distinctive nucleus and extending axonal structures confirm 
as neuronal cells (Figure 2-5). Currently, these are the only available immortalised neuronal 
cell line (Uebing-Czipura et al., 2008). 
OBGF400 were a kind gift from Dr. Gail Scherba (University of Illinois, USA) and were grown 
in DMEM/F-12 (Dulbecco’s Modified Medium: Nutrient Mixture F12) supplemented with sodium 
bicarbonate, HEPES, Gentamicin (50µg/mL), Penicillin G/Streptomycin, Bovine calf serum in 
a humidified 37°C incubator with 5% CO 2. 25cm2 flasks were used to grow the cells with 5mL 
media, which was changed every 2 days.
 
At 80-90% confluency, the media was aspirated and 
cells were treated with Acutase® for 20-30 minutes for passaging.  
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Figure 2-5: Morphology of OBGF400 cells 
Light microscopic image (20 X) indicating neuronal structures such as bi or multi polar processes, prominent cell 
body with distinctive nucleus. 
 
To cryopreserve cells, 1mL maintenance media was added to the lifted cells and transferred 
to 15mL centrifuge tube. The cell suspension was then pelleted by centrifuging at 277 RCF 
(relative centrifugal force) for 7 minutes. After removal of the supernatant carefully the pellet 
was hand vortexed to disperse in the remaining fluid. Subsequently 0.5mL of cold (4°C) 
solution-I (1:1 maintenance media: calf serum) was added and gently hand vortexed. Finally, 
0.5mL of cold (4°C) solution-II (1:4 DMSO: calf ser um) was added in a drop wise fashion with 
hand vortexing after each addition.  
 A 1mL volume of the cell suspension was aliquoted to the cryovials and stored overnight at -
80˚C in cell cooling box (Mr. Frosty, Nalgene®, Thermo Fisher Scientific, UK). After 24 h, 
cryovials were transferred to liquid nitrogen for long-term storage. 
2.3.9. Formulation cellular viability: 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) assay 
 
To assess the cellular toxicity of formulations towards nasal cell lines, an MTT cell 
viability assay was conducted with RPMI-2650 and OBGF400 cells.  Cells were suspended in 
200µL medium and seeded at a density of 1 x104 and 6 x103 cells/well of a 96-well plate 
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respectively. After 24 hours the media was removed and replaced with 200µL of media 
containing either compound (AMT, curcumin or chysin) (0.01-50,000µM) or 
P127/mucoadhesive polymers (10-4000µg/mL) and incubated for 24 hours at 37°C in a 5% 
CO2 air humidified environment. Subsequently 100µL of 0.5mg/mL MTT dissolved in PBS was 
added to each well and incubated at 37°C in an air humidified environment for 4 hours. 
Thereafter, the media was removed and 100µL of DMSO was added and the plates left to 
incubate for 15 minutes in the dark. The UV-absorbance of the formazan product was 
determined at 595nm. Each concentration was assayed in eight wells and run in three 
independent experiments and results expressed as percentage cytotoxicity relative to a control 
(0.5% DMSO).   
2.3.10. AMT release and transport across an in-vitro human nasal epithelial cell culture 
model 
Immediately prior to the start of the transport study, RPMI 2650 cells grown on permeable 
inserts were washed and fresh transport media (HBSS with 25mM HEPES) added to the apical 
and basolateral compartment of the wells and the cells left to acclimatise for 30 minutes in a 
humidified 37°C incubator. Thereafter the transport  media was removed and 1mL of 
formulation were gently placed on top of the cell monolayer in the apical chamber and returned 
to the incubator for 5 minutes to allow the formulation to gel.  Once gelled, fresh transport 
media was placed into the basolateral chamber and the transport study initiated.  250µL of the 
basolateral media was withdrawn at 5, 15, 30, 60, 120, 150 and 180 minutes and replaced with 
fresh pre-warmed transport media.  Withdrawn samples were derivatised and AMT release 
quantified by HPLC analysis. 
2.3.11. Nasal spray systems: droplet size distribution 
To assess the potential in-vivo deposition characteristics of the proposed nasal formulation, a 
multi-dose pump spray delivery system was employed to characterise the formulation droplet 
size distribution using a laser diffraction technique.  The Helos/Sympatec system was used 
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with an R3 lens (0.5-175µm).  The nasal pump was vertically mounted 3cm away from the 
laser path and a vacuum source was mounted anterior to the pump system.  The pump 
systems were pre-actuated prior to mounting, and actuated three times to detect the particle 
size distribution.   Data was reported as volume diameters at 10%, 50% and 90% of the 
cumulative undersized volume distribution (Dv). Span was calculated as follows (Food and 
Administration, 2002):  
MN90 − MN10
MN50
 
2.3.12.  Nasal spray system: human nasal cast deposition  
To assess the potential in-vivo deposition characteristics of the proposed nasal formulation, a 
multi-dose pump spray delivery system was employed to assess the disposition of formulations 
into an anatomically correct transparent human nasal cast model (Koken Ltd, Japan).  The 
inner surface of each nostril was evenly coated in a water-indicated dye (Kolorkut®, USA).   
Formulation was loaded into a 5mL volume spray pump, which was pre-actuated 5 times prior 
to use. Thereafter a single spray (dose) was delivered into the nasal cast where the cast was 
fixed in an upright head position (Figure 2.6).  The impact of spray angle (60-80°) and nostril 
insertion depth (5mm) on nasal deposition was analysed and captured images were 
subsequently processed through pixel quantification software to quantify the deposition 
patterns (Kundoor and Dalby, 2010).  The depositions within the nasal cast was classified 
according to the predominate regions of deposition within the cast, i.e. lower nasal regions 
(nasal vestibule), the middle/upper nasal regions (turbinates) and the olfactory regions were 
assessed. 
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Figure 2-6: Assessment of nasal deposition in a human nasal cast model using a multidose nasal spray 
A transparent human nasal cast (A) model was used to asses formulation deposition within the nasal cavity under 
conditions of different angles (60-90 °) (B) and noz zle insertion depths and anterior tilting of the head (C). To 
visualise and quantify regional deposition a water-indicating dye (Kolorkut®) was coated on the interior of the cast. 
 
2.3.13. Statistical analysis 
Unless otherwise stated, three independent experiments were carried out for each study. 
Statistical significance was evaluated by one-way ANOVA or paired two-tail Students t-test 
using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California 
USA, www.graphpad.com). Unless otherwise states, data is reported as mean ± standard 
deviation (SD). A significance level (P-value) of < 0.05 was considered as statistically 
significant. 
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2.4. Results 
2.4.1. Formulation development and optimisation 
2.4.1.1. Optimisation of thermoresponsive polymer content 
Five preliminary formulations (F1-F5) containing 14-22% PF127 but without the addition of 
AMT or additives, were prepared in ultrapure water and assessed for the Tsol-gel through visual 
methods.  Formulations F2 and F3 (16 and 18% w/w PF127) demonstrated Tsol-gel of 28 ± 1.3 
and 25 ± 1.5°C , closest to that of the nasal cavity (34°C) and were considered for further 
investigation (Table 2-1). 
 
Table 2-1: Impact of PF127 on Tsol-gel, indicating the inverse relationship between concentration and Tsol-gel in 
Pluronic only formulations.   
Formulations 
PF127 Tsol-gel 
% w/w °C ± SD 
1 14 43 ± 1.1 
2 16 28 ± 1.3 
3 18 25 ± 1.5 
4 20 23 ± 1.2 
5 22 21 ± 1.3 
 
 
Using CMC as the primary mucoadhesive to optimise formations, six further formulations with 
18% PF127 and 2% CMC and AMT ranging from 0.5-1.5% were prepared (Table 2-2). 
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Table 2-2: Effect of addition of amantadine and excipients on gelation temperature 
Formulations 
CMC Amantadine BLK MTB Tsol-gel 
(% w/w) (% w/w) (% w/w) (% w/w) °C ± SD  
 
F1 - - - - NG 
F2 2 - - - 19 ± 1.6 
F3 2 0.5 - - 21 ± 1.5 
F4 2 1.0 - - 20.5 ± 1.0 
F5 2 1.5 - - 22 ± 0.4 
F6 2 0.5 0.2 0.1 20.5 ± 1 
 
All formulations contain 18% w/w PF127. CMC: Carboxymethyl cellulose, BLK: 
benzalkonium chloride; MTB: sodium metabisulfite; Tsol-gel: solution to gel transition 
temperature; NG: not gelled; SD: standard deviation.  n=5. 
 
 
However, formulations F2-F6 gelled at 21°C ± 1.5°C.   Thereafter the concentration of PF127 
was varied from 14-18% w/w and CMC concertation from 0.5-1.5% w/w.  The addition of CMC 
lowered the Tsol-gel with increasing CMC concentration (Table 2-3) with only F9-10 
demonstrating gelation from 25°C onwards and hence were selected for further optimisation. 
 
Table 2-3: Effect of addition of CMC on gelation temperature 
Formulation 
PF127 CMC Tsol-gel 
(% w/w) (% w/w) °C ± SD  
F7 14     0.5 >40 
F8 14     2.0 >40 
F9 
  16   0.5 27 ± 1.3 
F10 
  16   2.0 25 ± 1.2 
F11 
    18 0.5 23 ± 1.4 
F12 
    18 1.0 22 ± 1.1 
F13 
    18 1.5 21 ± 0.9 
 
PF127: pluronic F127; CMC: carboxymethyl cellulose; Tsol-gel: solution to gel transition 
temperature; SD: standard deviation.  n=5. 
 
 
 71
When PF127 concentrations were kept constant at 15% w/w with varying concentrations of 
CMC (0.5 to 1.5% w/w) and AMT (0.5 and 1.0% w/w), formulations with 1% w/w AMT did not 
demonstrate a gelation transition over the desired temperature range of 30-34°C (Table 2-4). 
Table 2-4: Effect of addition of amantadine on gelation temperature 
Formulation 
CMC AMT Tsol-gel 
(% w/w) (% w/w) °C ± SD  
F14 0.5 0.5 31 ±1.3 
F15 0.5 1.0 >40 
F16 1.0 0.5 32 ±1.5 
F17 1.0 1.0 >40 
F18 1.5 0.5 >40 
F19 1.5 1.0 >40 
F20 1.5 1.0 >40 
 
All formulations contain 15% w/w PF127. CMC: carboxymethyl cellulose; Tsol-gel: solution to gel transition 
temperature; SD: standard deviation.  n=5. 
 
Further formulations increased PF127 concentrations in order to allow AMT content of 1% w/w 
per formulation (Table 2-5) with F23 demonstrated gelation close to the required nasal 
temperature. 
Table 2-5: Effect of Increase in PF127 content on gelation temperature 
Formulations 
PF127 CMC Tsol-gel 
% (w/w) % (w/w) °C ± SD  
F21 16 1 >35 
F22 16 2 >35 
F23 18 1 26 ±1.2 
F24 18 2 26 ±1.6 
F25 20 1 RT 
F26 20 2 RT 
 
All formulations contain 1% w/w AMT. CMC: carboxymethyl cellulose, RT- room temperature; Tsol-gel: 
solution to gel transition temperature; SD: standard deviation.  n=5. 
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Increasing PF127 concentration from 16 to 17% w/w resulted in gelation at the target of 33°C 
± 1.5°C (Table 2-6). 
Table 2-6: Optimised formulation based on CMC as mucoadhesive 
PF127 CMC AMT BLK MTB D-sorb 
(%w/w) (% w/w) (% w/w) (% w/w) (% w/w) (% w/w) 
17 1 1 0.1 0.1 0.5 
 
PF127: pluronic F127; CMC: carboxymethyl cellulose; AMT: amantadine; BLK: benzalkonium 
chloride; MTB: sodium metabisulfite; D-sorb: D-sorbitol. 
 
 
 
2.4.2. The impact of mucoadhesive polymers on formulation Tsol-gel.  
In order to compare the effect of different mucoadhesives on the overall performance of 
the formulations PEG 4K, PEG 12K and chitosan were incorporated into the optimised 
formulation (Table 2-7).  
Table 2-7: Impact of mucoadhesive polymers on formulation gelation 
Formulation Composition   (% w/w) 
Tsol-gel          
(°C ± SD) pH 
FCMC 1.00% 30°C ± 2 6.13 ± 0.15 
FPEG 4K 1.00% 32°C ± 2 5.79 ± 0.21 
FPEG 12K 1.00% NG 5.86 ± 0.08 
FCS 1 0.10% 31°C ± 1 5.52 ± 0.15 
FCS 2 0.30% NG 5.81 ± 0.21 
 
All formulations included PF127 17%, amantadine 1%, BLK 0.1%, MTB 0.1%, D-Sorbitol 0.5%  
 
FPEG 12K and FCS 2 (0.3% w/w chitosan) did not demonstrate gelation and were rejected.  
However, FCMC (1% w/w CMC), FPEG4K (1% w/w PEG 4000) and FCS 1 (0.1% w/w 
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chitosan) gelled beyond 30°C. Furthermore, the pH o f these formulations was within 5.5-6.5 at 
preparation. 
2.4.3. Formulation characterisation 
2.4.3.1. Sol-gel transition (Tsol-gel) by rheology 
To identify the appropriate rheological temperature ramp for associated studies, two 
different heating rates of 1°C/min and 5°C/min were  utilised to optimise rheological studies 
using FCMC. Under these conditions the gelation phase commenced at 30°C ± 0.7°C and 
completed at 34°C ± 0.5°C at 1°C/min compared to 22 .5°C ± 0.5°C and completed at 27°C ± 
0.3°C when heated at the rate of 5°C/min (Figure 2- 7).   A temperature ramp of 1°C/min was 
selected to further characterise all formulations. 
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Figure 2-7: Impact of differing heating rates on FCMC temperature sweep properties 
Rheological characterisation was assessed using FCMC as a model formulation with a heating rate of (A) 5°C /min 
and (B) 1°C/min.  A sample volume of 1.26mL was used  and the instrument setup in oscillatory mode within the 
linear viscoelastic range using parallel plate geometry with 40mm steel plates having a gap 1.0mm.  Data represents 
mean ± SD. n=4  
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All formulations demonstrated a gelation phenomenon, which initiated at approximately 26-
28°C, and was preceded by the stable plateau region  (Figure 2-8). FCS (Figure 2-8A) and 
FCMC (Figure 2-8C) demonstrated a complete profile with three distinct phases culminating in 
a stable gel formulation, whereas FPEG (Figure 2-8B) did not form a stable gel at the 
termination of the study (34°C).  
The rate of gelation is also a key determinant of residency within the nasal cavity and this was 
assessed through a time-sweep analysis at a fixed temperature (34°C).  FCMC demonstrated 
the quickest gelation of 28 ± 2 seconds (Figure 2-9C) which was followed by FCS (37 ± 3 
seconds) (Figure 2-9A) and FPEG (> 60 seconds) (Figure 2-9B). 
At nasal cavity temperature, a significant sheer thinning behaviour was observed in all 
formulations, indicative of temperature-induced gel formation when compared to ambient 
temperatures (Figure 2.10), with viscosities for 34°C being statistically significantly different to 
those at 18°C (P < 0.0001).  Furthermore, at 34°C n o significant difference in viscosity was 
reported over the range of sheer rate studied (P=0.227), however FPEG did however 
demonstrate a statistically significant lower viscosity compared to FCS and FCMC (P < 0.01). 
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Figure 2-8: Temperature sweep of AMT containing formulations 
Rheological analysis of AMT containing thermoresponsive gels. Figures A-C represent temperature sweep analysis 
for FCS, FPEG and FCMC using parallel plate geometry with 40mm steel plates having a gap 1.0mm. The 
approximate sample volume used was 1.26mL and the instrument was used in the oscillatory mode in the linear 
viscoelastic range. Data represents mean ± SD. n=4  
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Figure 2-9: Time sweep of AMT containing formulations 
Rheological analysis of AMT containing thermoresponsive gels. Figures A-C represent time sweep analysis at 34°C 
for FCS, FPEG and FCMC using parallel plate geometry with 40mm steel plates having a gap 1.0mm. The 
approximate sample volume used was 1.26mL and the instrument was used in the oscillatory mode in the linear 
viscoelastic range. Data represents mean ± SD. n=4  
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Figure 2-10: Steady shear behaviour of AMT containing formulations 
Rheological shear viscosity analysis of the formulations (A) at ambient (18°C) and (B) at nasal cavity ( 34°C) 
temperature. Figures A-C represent steady sheer analysis at 34°C for FCS, FPEG and FCMC using parallel 
plate geometry with 40mm steel plates having a gap 1.0mm. The approximate sample volume used was 
1.26mL and the instrument was used in the oscillatory mode in the linear viscoelastic range. Data represents 
mean ± SD. n=4  
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As the sheer rate increased from 0.091 to 100 s-1, the viscosity of the formulations dropped by 
990-fold (FCMC), 409-fold (FCS) and 207-fold (FPEG) (Figure 2-10B).  However, all 
formulations demonstrated Newtonian behaviour at nasal temperature compared to non-
Newtonian (pseudoplastic) behaviour at ambient temperatures (Table 2-8), with significantly 
larger consistency coefficients (13-100 Pa.sn) compared to those at ambient temperatures 
(0.06-0.157 Pa.sn) (Table 2-8). 
Furthmore as the shear rate at 34°C increased (Figu re 2.10B), FCS viscosity started to 
decrease and it matched up with FCMC at the end of the test at shear rate 100. 
Table 2-8: Power law rheological analysis of AMT at ambient and nasal temperatures 
Formulation Temperature  (°C)  
K n 
Behaviour (Pa.sn) 
FCMC 18 0.157 0.972 Non-Newtonian 
FPEG 18 0.0545 0.9651 Non-Newtonian 
FCS 18 0.0656 0.997 Non-Newtonian 
     
FCMC 34 100.2 0.066 Newtonian 
FPEG 34 13.59 0.3043 Newtonian 
FCS 34 56.56 0.1762 Newtonian 
m: Power-law consistency coefficient; n: Power-law index value 
2.4.3.2. Assessment of formulation mucoadhesion: texture analysis 
The results demonstrate that the required force for detachment of the mucin disc from the 
formulation FCMC was the greatest (48.3g ± 36.1g) followed by FPEG (36.6g ± 27.54g) and 
FCS (31.6g ± 7.6g) (Figure 2-11).  However, a high degree of variability was noted in the 
experiment design and therefore no statistical significance between any of the formulations 
were identified.  
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Figure 2-11: Assessment of formulation mucoadhesion through tensile strength measurements 
Tensile strength of each optimised formulation was assessed through the interaction of the formulation with a mucin 
disc attached to a Brookfield’s Texture analyser CT3 at 34°C. The force of detachment was measured with  a 
detachment speed of 0.1mM/sec. FCMC: optimised caboxymethyl cellulose formulation; FPEG 4K: optimised PEG 
4000 formulation; FCS: optimised chitosan formulation. Data represents mean ± SD. n=3. 
 
2.4.3.3. Assessment of formulation mucoadhesion: displacement method  
Mucoadhesion of the optimised formulations was further assessed using an inclined-plate 
method in the presence and absence of mucin as described by (Nakamura et al., 1999).  In 
this test, mucoadhesion is assumed to have occurred if the displacement of the formulation in 
the absence of mucin is greater than in the presence of mucin (Nakamura et al., 1999). 
In the absence of mucin, statistically significant differences were observed in the displacement 
transfer between all optimised formulations (P ≤ 0.001). With the inclusion of mucin, similar 
statistically significant differences were observed in the displacement transfer between all 
optimised formulations (P ≤ 0.001) (Figure 2-12).  Furthermore, all formulations demonstrated 
significant differences in the displacement transfer when comparing absence to the presence 
of mucin, indicating formulation mucoadhesion.  The greatest displacement was observed with 
FPEG (absence of mucin: 9.5cm ± 0.05cm; presence of mucin: 5.7cm ± 0.19cm) with FCM 
demonstrating the least displacement (absence of mucin: 6.5cm ± 0.34cm; presence of mucin: 
4.24cm ± 0.34cm) (Figure 2-12).   
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Figure 2-12: Assessment of formulation mucoadhesion through displacement measurements 
Displacement transfer of optimised formulations in the absence and presence of mucin-containing agar gel plates. 
Mucoadhesion was assessed through application of a 250 µL sample of each formulation when the plate was kept 
at a 45° angle in VWR orbital shaker maintained at 34°C. The displacement (cm) was used as a measure o f the 
potential for adhesion. Data represents mean ± SD. ** ≤ P 0.01; *** ≤ P 0.001. n=3. 
 
2.4.3.4. Validation of a pre-column derivatisation method to detect AMT  
The lack of chromophoric group makes the UV-detection of AMT difficult. However an 
approach developed by (Narola et al., 2010) for detecting memantine hydrochloride was 
adapted to detect AMT through pre-column derivatisation followed by HPLC-UV analysis. 
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Figure 2-13: HPLC chromatogram of derivatised amantadine at retention time 4.911 min. 
A Shimadzu HPLC system was used with a Phenomenex Luna C18 (150 × 4.6mm) 5µm column. The mobile 
phase consisted of premixed and degassed phosphate buffer:acetonitrile (20:80 v/v) which was filtered through 
0.45µm membrane filter. The column was maintained at 30°C and volume of injection was 10µL.  The flow rate 
was maintained at 2mL/minute with run time 12 minutes. 
 
The pre-column derivatisation method developed was successfully used to detect AMT 
with a retention time of 4.9 minutes (Figure 2-13).  System precision and method precision 
demonstrated RSD within acceptable limits of 1% and 2% respectively, indicating an 
acceptable level of precision of the analytical system. 
System precision: six replicate injections of an identical standard AMT stock solution were 
injected into the HPLC and peak area calculated. The relative standard deviation (% RSD) for 
the six samples was not more than 1.0% indicating system precision is within acceptable limits 
as measured per individual run, each with its own identical standard AMT stock solution, with 
an overall RSD of 0.30% (Table 2-9). 
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Table 2-9: System precision assessment for AMT pre-column derivitisation method 
Injection no. Area counts (µV sec)   
  Run 1 Run 2 Run 3 Mean 
1 2702580 2698550 2694502 2698544 
2 2702812 2675784 2675811 2684802 
3 2699283 2674899 2677574 2683919 
4 2698179 2672313 2674985 2681826 
5 2694163 2667233 2663766 2675054 
6 2697227 2670255 2671056 2679513 
     
Mean 2699041 2676506 2676282 2683943 
SD 3306.0 11240.0 10193.3 7963.1 
     
RSD (%) 0.12 0.42 0.38 0.30 
 
System precision was assessed through 6 injection of the same AMT stock solution for each independent runs (3 
runs in total).  Mean and SD reported with percentage root-square deviation. 
 
Method precision: six preparations of the same batch of samples were analysed for method 
precision with a resultant% RSD of less than 2.0% (Table 2-10) for all samples demonstrating 
method precision is within acceptable limits.  Six replicate injections of the same batch sample 
of AMT solution were injected into the HPLC and peak area calculated and used to determine 
AMT content. The relative standard deviation (% RSD) for the six samples was not more than 
2.0% indicating method precision is within acceptable limits and with an overall mean RSD for 
three independent runs of 0.72%. 
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Table 2-10: Method precision assessment for AMT pre-column derivitisation method 
Injection no. Assay (% w/w)  
  Run 1 Run 2 Run 3 Mean 
1 101.10 99.90 101.25 100.75 
2 100.50 100.10 103.25 101.28 
3 100.30 98.99 100.78 100.02 
4 99.50 100.58 99.12 99.73 
5 98.90 101.10 98.25 99.42 
6 100.60 99.12 99.23 99.65 
     
Mean 100.15 99.97 100.31 100.14 
SD 0.80 0.82 1.82 0.72 
     
RSD (%) 0.80 0.82 1.81 0.72 
 
Linearity of response: the linearity of precision for derivitised AMT was determined over a 
concentration range of 62.5 -1000µg/mL.  A proportional response was evident versus the 
analytical concentration over the working concentration range with a r2 of 0.9987 and linear 
equation of Q = 1354 ± 9.07	 ∙ V (Figure 2-14). The LOD was 2.8µg/mL, LOQ was 8.7µg/mL, 
and the signal to noise ratio was >10.  
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Figure 2-14: Linearity plot for a AMT pre-column derivatisation method 
A RP-HPLC method was used with a Phenomenex Luna C18 (150 × 4.6mm) 5µm column. The mobile phase 
consisted of phosphate buffer:acetonitrile (20:80v/v). The column was maintained at 30°C and volume of  injection 
was10µL.  The flow rate was maintained at 2ml/minute with run time 7 minutes. Data represents mean (solid line) 
± SD (error bars). Dotted lines represent 95% confidence intervals for the best fit line. n=3.  
 
2.4.3.5. Human nasal epithelial cell culture model: MTT assay 
To investigate the toxicity of AMT and polymers used within the formulations, a cellular 
viability study was conducted using RPMI-2650.  Cell viability was generally maintained for 
AMT up to 1mM, with an IC50 of 4.6mM ± 0.05mM (Figure 2-15A) when exposed for 24 hours.  
For all polymers tested in RPMI 2650, no significant decrease in cellular viability was observed 
up to 4mg/mL (Figure 2-15B to E).   
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Figure 2-15: Cellular toxicity of amantadine (A), CMC (B), PEG4000 (C), F127 (D) and CS (E) on RPMI-2650 
cells. 
Cells were grown on a 96-well plate at a density of 20 x 103 cells per well and exposed to various concentrations of 
amantadine (0.0001 – 10000µM) or polymer (10-4000µg/mL). After 24 hour incubation 10 µL MTT in PBS 
(0.5mg/mL) added to each well & incubated for 4 hours. The MTT-formazan produced was solubilised in DMSO 
and quantified colorimetrically using spectrophotometer.  The control cell (without drug) corresponded to a cell 
viability of 100%. Data is reported as mean ±SD with up to 8 replicates per compound in at least 3 independent 
experiment.  
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2.4.3.6. Porcine olfactory bulb cell culture model: MTT assay 
To investigate the toxicity of amantadine and polymers used within the formulations with 
olfactory neurones, the OBGF400 cell line was used as a surrogate for the olfactory nasal 
mucosa and olfactory neural pathways to assess the cellular viability study of cells in the 
presence of the formulation components.  Cell viability was generally maintained for AMT and 
all polymers incorporated into the formulations across the concentration ranges studied with 
no significant decreases in cellular viability (Figure 2-16).   
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Figure 2-16: Cellular toxicity of amantadine (A), CMC (B), PEG4000 (C), F127 (D) and CS (E) on OBGF400. 
Cells were grown on a 96-well plate at a density of 10 x 103 cells per well and exposed to various concentrations of 
amantadine (0.0001 – 10000µM) or polymer (10-4000µg/mL). After 24 hour incubation 100µL MTT in PBS 
(0.5mg/mL) added to each well & incubated for 4 hours. The MTT-formazan produced was solubilised in DMSO 
and quantified colorimetrically using spectrophotometer.  The control cell (without drug) corresponded to a cell 
viability of 100%. Data is reported as mean ±SD with up to 8 replicates per compound in at least 3 independent 
experiment. 
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2.4.3.7. The development of a human nasal epithelial airway cell culture model  
RPMI 2650 cells were used to develop a permeable-insert based cell culture model of the 
human nasal epithelial using an ALI.  RPMI 2650 cells were grown for 22 days with an ALI 
initiated on the 6th day post-seeding. The TEER was used as a measure of monolayer 
formation and rose steadily during the first 10 days post-seeding and reaching peak TEER 
over days 12-20 (126-140 Ω.cm2) (Figure 2-17). 
 
Figure 2-17: Monolayer resistance of RPMI 2650 cells grown on permeable inserts. 
RPMI 2650 cells were seeded at a density of 4 x105 cells/cm2 onto collagen coated inserts and incubated at 37˚C 
with 5% CO2 in a humidified atmosphere. The media was replaced every other day and TEER values were 
measured with EVOM voltammeter up to 22 days. Statistical analysis compares TEER at day 2 to all other data 
points. *** P ≤ 0.001 and ****P≤0.001. N=3. 
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2.4.3.8. Human nasal epithelial airway cell culture model: AMT transport 
The in-vitro release of AMT alone and from formulations was further assessed in an in-vitro 
nasal epithelial airway cell culture model over 3-hours (Figure 2-18). 
 
 
Figure 2-18: Release and transport of AMT from formulations 
The transport of AMT was assessed across an in-vitro permeable insert cell culture model of the human nasal 
epithelia. N= 3, ** P ≤ 0.01 
 
In all formulations a statistically significant (P ≤ 0.01) mean release of 43-44% was 
observed over the duration of the transport study in comparison to that of AMT alone (79% ± 
3.58%) (Figure 2-18) when studied across RPMI 2650 monolayers.  No significant difference 
in release was observed within the 3 optimised formulations. 
 91
2.4.4. Stability and AMT release from optimised formulations  
To assess the stability of the optimised formulations, batches were prepared and stored in 
stability cabinets at 25°C/60 % RH and refrigerated (4°C) for 8 weeks, with sampli ng of drug at 
weekly intervals to assess gelation and release profiles. At preparation (week 0), all 
formulations demonstrated similar release profiles with Higuchi kinetics and Fickian-type 
diffusion (Table 2-11 and Figure 2-19).  During the first week of storage at 4°C, all formulations 
demonstrated similar release profiles to week 0 (Figure 2-20).  However, after 1-week storage 
at 25°C/60 % RH only FCS demonstrated a gelation transition and showed a similar release 
profile to week 0 (Figure 2-20), while FPEG and FCMC failed to gel at 34°C.   
FCMC and FCS continued to show gelation phenomena over the 8-week study period when 
stored at 4°C but FPEG did not gel after the first week of storage at 4°C (Figure 2-21). 
Statistically significant differences (P < 0.05) in the release profile of FCMC and FCS were 
observed after 8-weeks storage at 4°C, typically re sulting in slower release profiles (reduction 
in kH at week 8 compared to week 0) (Table 2-11). FCS continued to show gelation 
phenomena at 25°C/60 % RH at week 2 (Figure2-22), but failed thereafter to gel. 
In all cases, AMT release obeyed a Higuchi model, with a consistent release constant (kK: 
1.2-1.5), although this was significantly reduced at 8-weeks (FCMC: 1.440 ± 0.150 to 1.224 ± 
0.063; FCS: 1.319 ± 0.028 to 1.291 ± 0.043). Diffusion was modelled by the Korsmeyer-
Peppas power law and generally demonstrated Fickian-type diffusion early on (except for 
FCS).  By week 8 this had moved towards anomalous transport (Table 2-11), whereby drug 
diffusions and the polymer relaxation were contributing to the overall release kinetics. 
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Figure 2-19: Amantadine cumulative% release for optimised formulations at week 0 and stored at 4°C, (A) FCMC; (B) FCS and (C) FPEG  
Formulations were prepared and immediately assessed for drug release at a baseline (termed week 0).   The stability of the formulation was assessed based on the gelation of 
a 250 µL of sample of the formulation at 34°C withi n 5 minutes, followed by assessment of the extent of drug release in ANE in a membrane less diffusion study over three hours 
and drug content by HPLC. Data represents mean ± SD. n=3 independent batches. 
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Figure 2-20: Amantadine cumulative % release for optimised formulations at week 1 and stored at 4°C, (A) FCMC; (B) FCS and (C) FPEG 
Formulations were prepared and stored in a 4°C stability cabinet at preparation.  A sample was  withdrawn for assessment of drug release at 1 week post-formulating 
(termed week 1).   The stability of the formulation was assessed based on the gelation of a 250 µL of sample of the formulation at 34°C within 5 minutes, followed by asses sment 
of the extent of drug release in ANE in a membrane less diffusion study over three hours and drug content by HPLC. Data represents mean ± SD. n=3 independent batches. 
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Figure 2-21:  Amantadine cumulative % release for optimised formulations at week 8 and stored at 4°C, (A) 
FCMC; (B) FCS. 
Formulations were prepared and stored in a 4°C stab ility cabinet at preparation.  A sample was withdrawn for 
assessment of drug release at 8 weeks post-formulating (termed week 8) and compared to drug release at 
preparation (week 0).   The stability of the formulation was assessed based on the gelation of a 250 µL of sample 
of the formulation at 34°C within 5 minutes, follow ed by assessment of the extent of drug release in ANE in a 
membrane less diffusion study over three hours and drug content by HPLC. Data represents mean ± SD. n=3 
independent batches. 
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Figure 2-22: Amantadine cumulative % release for FCS at week 1 and 2 stored at 25°C.  
Formulations were prepared and stored in a 25°C/60 % RH stability cabinet at preparation.  A sample was withdrawn 
for assessment of drug release at 1 and 2 weeks post-formulating (termed week 1 and 2).   The stability of the 
formulation was assessed based on the gelation of a 250µL of sample of the formulation at 34°C within 5 minutes, 
followed by assessment of the extent of drug release in ANE in a membrane less diffusion study over three hours 
and drug content by HPLC. Data represents mean ± SD. n=3 independent batches. 
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Table 2-11: Drug release kinetics analysis of formulations stored at refrigerated (4°C) and ambient (25°C) temper ature for up to 8 weeks. 
 
Week Formulation Higuhci  Korsmeyer-Peppas  
4
°
C
 
0 
FCMC kH = 1.440 ± 0.150 kKP = 2.859 ± 0.899 ; n =0.391 ± 0.051 
FPEG kH = 1.372 ± 0.084 kKP = 2.931 ± 1.160 ; n =0.352 ± 0.076 
FCS kH = 1.319 ± 0.028 kKP = 2.888 ± 0.632 ; n =0.684 ± 0.039 
1 
FCMC kH = 1.480 ± 0.091 kKP = 2.004 ± 0.027 ; n =0.438 ± 0.024 
FPEG kH = 1.356 ± 0.087 kKP = 2.012 ± 0.032 ; n =0.423 ± 0.013 
FCS kH = 1.485 ± 0.119 kKP = 1.852 ± 0.135 ; n =0.433 ± 0.019 
8 FCMC kH = 1.224 ± 0.063 kKP = 1.034 ± 0.170 ; n =0.538 ± 0.024 FCS kH = 1.291 ± 0.043 kKP = 1.011 ± 0.092 ; n =0.553 ± 0.024 
2
5
°
C
 
    
1 FCS kH = 1.385 ± 0.097 kKP = 1.997 ± 0.659 ; n =0.433 ± 0.059 
2 FCS kH = 1.394 ± 0.108 kKP = 1.614 ± 0.351 ; n =0.474 ± 0.042 
 
kH: Higuchi constant; kKP: Korsmeyer-Peppas constant; n= release exponent. Mean ± SD. 
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2.4.5. Nasal spray systems: droplet size distribution 
Prevention of pulmonary deposition of nasally administered spray formulations is extremely 
important to ensure residency within the nasal cavity.  Droplet size distribution is key in 
determining the potential for pulmonary deposition (< 2µm) (Stuart, 1973, Hatch, 1961a), 
however the droplet size is often dictated by the design of the orifice of the actuator device 
used to deliver the spray plume. 
All our formulations demonstrated a diameter in excess of the traditional cut-off of 5µm. 
(Table 2-12) (Figure 2-23 to 2.25). FCS demonstrated a 10% fraction of 7.27µm ± 0.28µm 
(Figure 2.24 Table 2-12) closet to the cut-off for pulmonary deposition, whereas both FCMC 
and FPEG were well above this.  FCS also demonstrated the smallest diameter (VMD= 
92.41µm ± 1.72µm). However, when considering the span of particle sizes, FCS was the 
broadest (1.38 ± 0.) with both FCMC (Figure 2-25) and FPEG showing a smaller distribution 
spread (Table 2-12 Figure 2-23). 
Table 2-12: Laser diffraction particle size analysis 
 
Diameter (µm) 
  
Dv10 Dv50 Dv90 VMD Span 
FCS 7.27 ± 0.28 109.07 ± 3.42 157.77 ± 0.99 92.41 ± 1.72 1.38 ± 0.21 
FCMC 39.81 ± 1.02 129.86 ± 0.29 167.39 ± 0.09 120.87 ± 0.59 0.98 ± 0.30 
FPEG 43.93 ± 0.88 104.67 ± 1.88 150.95 ± 1.04 100.35 ± 1.53 1.02 ± 0.06 
 
Dv10, Dv50 and Dv90: particle diameter corresponding to 10, 50 and 90% cumulative undersize particle size 
distribution; VMD: volume mean diameter; data is represented of mean ±SD, n=6 replicate spray actuations per 
formulation 
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Figure 2-23: Nasal spray droplet size distribution graph for FPEG 
The Helos/Sympatec system was used with an R3 lens (0.5-175 µm). The nasal pump was vertically mounted 3cm away from the laser path and a vacuum source was mounted 
anterior to the pump system.  The pump systems were pre-actuated prior to mounting, and actuated three times to detect the particle size distribution.   Data was reported as 
volume diameters at 10%, 50% and 90% of the cumulative undersized volumes. 
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Figure 2-24: Nasal spray droplet size distribution graph for FCS. 
The Helos/Sympatec system was used with an R3 lens (0.5-175µm). The nasal pump was vertically mounted 3cm away from the laser path and a vacuum source was mounted 
anterior to the pump system.  The pump systems were pre-actuated prior to mounting, and actuated three times to detect the particle size distribution.   Data was reported as 
volume diameters at 10%, 50% and 90% of the cumulative undersized volumes. 
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Figure 2-25: Nasal spray droplet size distribution graph for FCMC. 
The Helos/Sympatec system was used with an R3 lens (0.5-175µm). The nasal pump was vertically mounted 3cm away from the laser path and a vacuum source was mounted 
anterior to the pump system.  The pump systems were pre-actuated prior to mounting, and actuated three times to detect the particle size distribution.   Data was reported as 
volume diameters at 10%, 50% and 90% of the cumulative undersized volumes. 
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2.4.5.1. Nasal spray system: human nasal cast deposition  
To assess the potential in-vivo application of formulations, the spray deposition within a 
human nasal cast model was assessed. The angle of spray administration was altered from 
60-80° and the impact on deposition patterns assed.   For all formulations the administration 
angle had a significant effect on deposition, with an increased angle (80°) having a significantly 
pronounced localisation in the nasal vestibules and lower regions of the nasal cavity.  In 
general, with an increasing angle of spray from 60° to 80°, the deposition for all formulations 
was more anterior in the nasal cavity.   
For FCS the greatest level of olfactory deposition was recorded at 60° (0.7cm 2) with spray 
at an angle of 80° leading to pronounced distributi on in the nasal vestibules and middle-upper 
turbinates (Figure 2-27).  Following insertion of the nozzle into the nasal orifice by 5mm, 
pronounced delivery on the olfactory region was noted at 60° (0.6cm 2), which diminished as 
the angle of spray increased to 80° (0.15cm 2) (Figure 2-27).  When the nasal cast was tilted 
by 15° posterior, the deposition across all spray a ngles was generally localised to the middle-
upper turbinates 4.0-4.6cm2 with limited olfactory deposition (0.2-0.4cm2) (Figure 2-27). 
For FCMC the greatest level of olfactory deposition was reported at 70° (0.25cm 2) with 
spray at an angle of 80° leading to pronounced dist ribution in the nasal vestibules and middle-
upper turbinates (Figure 2-28).  Following insertion of the nozzle into the nasal orifice by 5mm, 
pronounced delivery on the olfactory region was noted at 60° (0.91cm 2), which diminished as 
the angle of spray increased to 80° (0.09cm 2) (Figure 2-28). When the nasal cast was tilted by 
15° posterior, the deposition across all spray angl es was generally localised to the middle-
upper turbinates 4.3-4.6cm2 with no olfactory deposition (Figure 2-28). 
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Figure 2-26: Representative nasal deposition patterns of FCS. 
The inner surface of each nasal cavity was evenly coated in a water-indicated dye (Kolorkut®).  Formulation was 
loaded into the spray pump, pre-actuated, before one dose was delivered into the nasal cast where the cast was 
fixed in an upright head position. Angles refer to nasal spray position relative to the horizontal plane (60, 70 or 80°), 
insertion of the spray orifice into the nostril (5mm) or with the nasal cast angled 15° forward.  Gree n regions 
represent the deposition of the formulation. 
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Figure 2-27: Representative nasal deposition patterns of FCMC. 
The inner surface of each nasal cavity was evenly coated in a water-indicated dye (Kolorkut).  Formulation was 
loaded into the spray pump, pre-actuated, before one dose was delivered into the nasal cast where the cast was 
fixed in an upright head position. Angles refer to nasal spray position relative to the horizontal plane (60, 70 or 80°), 
insertion of the spray orifice into the nostril (5mm) or with the nasal cast angled 15° forward. Green  regions represent 
the deposition of the formulation.   
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2.5. Discussion 
Drug delivery to the CNS is a major challenge due to the presence of the BBB, which acts 
as a significant physical and metabolic barrier for the transport of therapeutic agents into the 
wider CNS. The endothelial cells forming the cerebral capillaries of the BBB act as a physical 
barrier which limits the transport of molecules in and out of the brain and wider CNS (Pardridge, 
2007b, Zlokovic, 2008).  Age related CNS dementia-type disorders, such as Parkinson’s 
disease (PD) and AD, are insidious progressive neurological disorders which affects over 1.5% 
of the population over 65-years of age (Foltynie et al., 2004), with age-adjusted prevalence 
rates thought to be around 150 per 100,000 with a suggested mean onset in the 70’s (Foltynie 
et al., 2004).  
One of the major complications of age associated CNS disorders is the emergence of 
dysphagia affecting the ability to ingest/swallow and is a thought to affect between 45-95% of 
PD patients (Foltynie et al., 2004, Leopold and Kagel, 1997) and has significant implications 
for orally dosed therapeutics such as leveodopa and other anti-Parkinsonian and anti-
Alzheimer’s disease therapeutics agents.   
For PD specifically the occurrence of bradykinesia and morning akinesia is often associated 
with delayed gastric emptying following the oral administration of anti-Parkinsonian 
therapeutics.  This is again confounded using dopaminergic and other concomitant medical 
interventions.  At least 24% of PD patients are thought to suffer from gastroparesis, the delay 
in empting of the stomach, which will inevitably impact upon clinical outcome of any orally 
administered medication.  
There has been a recent shift in the approaches to deliver APIs to the brain and wider CNS 
with a view to overcoming the BBB and other CNS-barriers, specifically the intranasal route 
has been targeted to obtain systemic deposition as a practical alternative to oral and parenteral 
routes (Leonard et al., 2007, Ikechukwu Ugwoke et al., 2000).   
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The nasal cavity is divided in to two symmetrical halves by a septum with each cavity sub-
dived into four areas namely vestibules, atrium, respiratory region and olfactory regions.  With 
a surface area of 150cm2, total volume of 15-20mL the nasal cavity provides an optimal 
absorption area for drugs into the systemic circulations which would inevitably enhance the 
bioavailability of the therapeutic agent, particularly those which demonstrate poor oral 
absorption (intestinal permeation) or significant first-pass metabolism (extra-hepatic and 
hepatic) (Bitter et al., 2011, Illum, 2012).   
Although originally exploited for the delivery of locally acting agents (allergic of infections 
rhinitis, nasal pluposos and sinusitis) the highly vascularised nature of the nasal cavity has 
provided a portal for systemic delivery of small molecules and biomolecules (Ozsoy et al., 
2009) (Zaki et al., 2007b). This non-invasive route not only provides rapid onset of action, but 
often increased bioavailability in low doses as it bypasses the first pass metabolism (Pires et 
al., 2009).  
The olfactory region covers the uppermost part of the cavity covering approximately 2.5cm² 
in each cavity in humans. Although this area is about 3% of the nasal surface area (Gizurarson, 
2012) since the olfactory neurons do not have the synapse between the receptive element and 
the afferent pathways, it presents itself as a direct route to the CNS (Wen, 2011) and is the 
only part of the CNS which is directly exposed to the outer environment (Illum, 2000). 
The primary aim of this chapter was to develop and characterise thermoresponsive and 
mucoadhesive nasal gel systems, which have the potential to deliver the model anti-
Parkinsonian drug amantadine (AMT) onto the nasal epithelia and at the olfactory mucosa.  
These studies consisted of screening a range of mucoadhesive polymers to identify the most 
potent mucoadhesive and characterise the rheological properties, mucoadhesive nature  
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and AMT release kinetics from optimised formulations.  Furthermore, cellular toxicity studies 
were conducted to assess the compatibility between formulations and nasal epithelial (RPMI 
2650) and olfactory bulb cells (OBGF400).  This was then followed by assessing the stability 
of optimised formulations and assessing the deposition patterns within a human nasal cast 
model when delivered from multi dose nasal spray. 
2.5.1. Development of thermosensitive mucoadhesive hydrogel formulations 
 
A key function of the developed formulations is to delay the clearance from the nasal cavity 
through  the formation of a mucoadhesive ‘gel’ at an ideal Tsol-gel of 32-34°C (Lindemann et al., 
2001). Although a formulation may undergo gelation at a lower temperature, it would be difficult 
to prepare at ambient temperature and difficult to administer (Majithiya et al., 2006). Hence our 
primary formulation selection criteria was based on a Tsol-gel of between 25-34°C through a 
visual gelation test using dry block.  
The initial formulation development considered only the thermoresponsive nature of the 
formulation and included only PF127.  An increasing PF127 concentrations (14-20% w/w) lead 
to a proportional decrease in the Tsol-gel, with F1 (Table 2-1) (14% w/w PF127) resulting in the 
highest Tsol-gel (43°C ± 1.1°C). The reason for this decrease in Tsol-gel with increasing PF127 
concentration has previously been reported and is related to the non-ionic PEO-PPO-PEO 
block copolymer composition and their interactions which form polymolecular aggregates 
(micelles) in solution (Nagarajan and Ganesh, 1996, Zhou and Chu, 1988, Wanka et al., 1990, 
Mortensen and Brown, 1993, Mortensen and Pedersen, 1993) (Prudhomme et al., 1996).  This 
transition occurs as a critical micellisation concentration (CMC) where below the CMC very 
small particle sizes are reported with little micellisation.  Above the CMC the micelle formation 
becomes appreciable and the micellar mass increase in a linear fashion with temperature 
(Pisal et al., 2004).  
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At low temperatures, typically 4-8°C, a significant  hydration layer surrounds the PF127 
molecules and as the temperature is raised, the hydrophilic chains of the copolymer begin to 
become desolvated due to the rupture of the hydrogen bonds established between the water 
molecules and these chains. During this process, the balance is shifted towards the 
hydrophobic interactions which predominate amongst the polyoxypropylene domains, and 
leads to gel formation (Attwood et al., 1985, Miller and Drabik, 1984).   
Previous studies have reported a concentration range between 14-20% w/w PF127 as 
demonstrating a gelation process close to nasal temperature (Zaki et al., 2007a, Shin et al., 
2013, Nie et al., 2011, Majithiya et al., 2006, Kumari et al., 2012, Jones et al., 2009, 
Bhandwalkar and Avachat, 2013). With the inclusion of additives (F1-F6) including CMC, AMT, 
BLK and MTB, the Tsol-gel was generally lower (21°C ± 1.5°C).  As a final op timised formulation 
would require mucoadhesive polymers as additional excipients, the impact of these additives 
on Tsol-gel is important to characterise.  
The results from F1-F6 resulted in the decision to reduce the PF127 range to 14-18% w/w to 
increase the Tsol-gel in combination with the existing additives however with a reduced 
concentration range of CMC (0.5-1.5% w/w) (F7-F13) (Table 2-3).   
The impact of increasing the mucoadhesive CMC on Tsol-gel was evident, resulting in a 
decrease in Tsol-gel across all formulations. Furthermore, at fixed CMC concentration, 
increasing PF127 resulted in decrease in Tsol-gel, although F9 and F10 demonstrated gelation 
close to the nasal cavity temperature with a PF127 concentrations of 16% w/w.  This was used 
as the basis to further develop the formulations with the addition of AMT but at lower PF127 
concentrations (15% w/w) (Figure 2-4).  The impact of increasing concentrations of AMT is 
again clearly evident in the way Tsol-gel increases (e.g. F14: 31°C ± 1.3°C and F15: > 40°C) .  
From this set of optimised formulations, it was decided to take F16 and F17 for further 
development but to adjust the PF127 concentration to allow a Tsol-gel at nasal cavity 
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temperature while also incorporating higher AMT doses into the formulation (1% w/w).  
Therefore, the final batch of formulations comprised of 16-20% w/w PF127 and 1 or 2% w/w 
CMC with the inclusion of 1% w/w AMT (Table 2.5).  From these studies it was noted that F22 
and F23 resulted in a Tsol-gel which was generally equally distributed around the nasal cavity 
temperature.  It was also noted that the key driver for changes in Tsol-gel was the PF127 
concentration rather than CMC. The final optimised formulation was therefore a derivative of 
F22 and F23 and contained 17% w/w PF127 (Table 2.6) and resulted in gelation at 33°C ± 
1.5°C. 
Whilst the trend in altering PF127 concentrations has been previously reported, the impact of 
additives on Tsol-gel is important to assess when developing and optimising thermoresponsive 
nasal gel formulations. (Vadnere et al., 1984) studied the effect of different additives on the 
gelation temperature of PF127 gels. They observed that NaCl, KCL, Na2SO4 lowered the Tsol-
gel whereas urea, alcohol and dodecyl sulphate increased it. They came to the conclusion that 
additives act by disrupting the hydration sphere surrounding the hydrophobic PF127 
molecules.  Furthermore, Schmaljohann (Schmaljohann, 2006) stated that all additives effect 
the solvent to some extent, for example addition of surfactants which are amphiphilic will 
adsorb to the polymer molecule and alter its hydrophilic/hydrophobic balance. This may result 
in shifting of Tsol-gel to a greater extent or even abolish the phase transition entirely.  
When considering the final optimised formulations, CMC, PEG4000 at 1% w/w and FCS at 
0.1% w/w were deemed appropriate and demonstrated Tsol-gel close to that of the nasal cavity 
with appropriate pH properties (5.5-6.5) (Sutto et al., 2004b). Chitosan at 0.3% w/w (FCS 2) 
did not gel and this may have been a result of the presence of acetic acid used to dissolve 
chitosan affecting the micelle formation by reducing hydrogen bonding formation (Cho et al., 
2011). PEFG 12,000 (FPEG 12K) also failed to gel.  According to (Pandit and McGowan, 1998) 
the greater the molecular weight of the PEG the lower the concertation of PEG is required to 
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prevent the phase transition of P127. We observed similar phenomenon as PEG 12K could 
not form a gel whereas PEG 4K did when both were used in the same concentration.  It has 
been proposed that the higher the molecular weight of PEG, the more they occupy a larger 
volume in the solution and therefore become more effective at disrupting the stability of F127 
micellar aggregates, even at very low concentration (Malmsten and Lindman, 1993) (Pandit 
and McGowan, 1998). 
The pH of our three optimised formulations was within the nasal pH range (Washington et al., 
2000) (Table 2.7). Although nasal pH ranges from 5.5 to 6.5, nasal mucosa has been shown 
to tolerate wide pH ranges from 3-10 (Pujara et al., 1995).  The prevention of mucocilliary 
clearance is one of the major hurdles in delivering drugs intranasally. Studies have 
demonstrated that decreasing the nasal pH below its normal pH range can also decrease the 
ciliary beat frequency (CBF).  This process it thought to be regulated by the intracellular 
changes in alkalinisation (increase CBF) or acidification (reduces CBF) (Sutto et al., 2004a, 
Seybold et al., 1990).  Thus formulations with lower pH’s may act to attenuate the CBF and 
mucocilliary clearance within the nasal cavity to increase its residence time.   
2.5.2. Rheological assessment of thermosensitive formulations 
An assessment of the rheological changes in the formulation during transitions across 
temperature is important to ascertain important molecular-level information about this phase 
transition, that would otherwise be unavailable.   However, it was also important that when 
assessing formulations using rheology that the three-dimensional gel structure was not 
damaged. Hence all rheological tests were performed in the linear visco-elastic region where 
the strain on the formulation is not destructive to the gel structure and the data will provide 
useful information on the intermolecular and interparticulate forces in the formulation 
(Korhonen et al., 2000). 
When assessing the properties of thermoresponsive gel-like systems, the storage/elasticity 
modulus (G′) and the loss modulus (G′′) are key metrics for describing the rheology of the 
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formulation.  The elasticity modulus is an important metric in this regard and measures the 
energy stored and which is subsequently recovered for each cycle of deformation (Almdal et 
al., 1993). It presents with lower values with reduced temperatures but significantly increases 
with an increase in temperature, and the point at which G′ overtakes G′′ indicates the initiation 
of the gelation phenomena (Chang et al., 2002). To assess this phase transition, the ratio of 
G′′ and G′ (the loss tangent, Tan δ) was used, and where a phase-transition occurs an abrupt 
change in Tan δ is observed with values of < 1 indicating a greater G′ compared to G′′, 
indicative of gel formation.  This phase transition is often associated with three distinct phases: 
(i) an initial stable liquid phase plateau at low temperatures; (ii) an abrupt transition phase 
during the gelation process; (iii) a late stage stable gel plateau. 
During the rheological study, it was observed that gelation temperature also depends on the 
rate of heating. A similar phenomenon was observed by (Gradinaru et al., 2012) when 
polyurethane based triblock copolymers were heated at 0.5°C/min and 1°C/min ,where at a 
1°C/min heating rate the gelation phase started at 30°C and the gelation was completed at 
34°C (Neuhaus et al., 2006).  
Temperature sweep results (Figure 2-7) show that formulations FCMC and FCS both 
demonstrated gelation at the end of the test at 34°C, whereas FPEG was still in the gelation 
phase. (Pisal et al., 2004) found that PEG increased the gelation temperature of PF127 gel. 
The study also showed that PEG narrows the gelation temperature, meaning formation and 
melting of the gel occurs over a short temperature range. FPEG demonstrated similar effects 
and on this basis FPEG was deemed as being an unsuitable candidate as its retention in the 
nasal cavity may be unsuitable. 
It is important that the formulation gels as soon as it is in the cavity so that it doesn’t get cleared 
by the mucociliary clearance mechanism. The results (Figure 2-8) show that FCMC and FCS 
were the quickest to start the gelation phase where as FPEG was twice slower than the other 
two.  
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From an interpretation of the Ostwald model, the gel structure can be changed as a result of 
any deformation induced changes in the gel particles, through changes in the alignment of the 
polymer chains and also any changes in the interactions between polymer chain segments 
and any side chains. Therefore, upon heating the values of n will be lower for stronger gels 
due to an increase in the noncovalent forces between neighbouring particles (Islam et al., 
2004).  
It was also apparent that the presence of different mucoadhesives can significantly alter the 
behaviour of the formulations.  For examples, the viscosity of FCMC was always higher than 
all other formulations and particularly at 34°C whe re there is an approximate 8-fold difference 
between FCMC and FPEG. Furthermore, the FCMC demonstrated a much lower n-value 
compared to FCS and FPEG (Table 2-8), suggesting a stronger gel formation at 34°C.  This 
phase represents the gradual conversion into a highly viscous/solid state.  During this phase 
the intricate hydrogen-binding network between the unimers of F127 and water molecules are 
disrupted and drives the formation of micelles, which further aggregate to form the physical 
gel-like structure (Kabanov et al., 2002). On the basis of 13C NMR studies (Pisal et al., 2004) 
suggested that at high temperature, conformational changes in the methyl group of the 
polyoxypropylene within the hydrophilic micellar region and in the motion of the hydrophilic end 
chains takes place. This results in dehydration and end chain friction, which causes the 
gelation.  
  
 112
2.5.3. Evaluation of in-vitro mucoadhesion 
Due to mucociliary clearance mechanisms in the nasal cavity, any material on the mucous 
layer without mucoadhesive properties will have a half-time no longer than 20 minutes (Illum, 
2000) and hence highlights the importance of imparting mucoadhesive properties into nasal 
gel-type formulations. 
Mucoadhesion is defined as “attractive interaction at the interface between a pharmaceutical 
dosage form and a mucosal membrane” (Khutoryanskiy, 2011b). The mechanism of 
mucoadhesion is not yet clearly understood, and there are several theories proposed by 
scientists. There is no particular technology developed specifically to measure mucoadhesion, 
most of the developed tests are a built up on previously available techniques, and two types 
of in-vitro mucoadhesion tests have been predominated.  The shear stress measurements 
were first applied to mucoadhesion in a Wilhelmy plate method as developed by Smart et al 
(Smart et al., 1984, Smart and Kellaway, 1982).  Tensile strength tests have also been 
developed (Ponchel et al., 1987) and are widely used. 
Our initial attempts at applying tensile strength measurements to assess mucoadhesion 
resulted in poorly differentiating and non-significant differences in tensile strength across 
formulations and the methods was deemed unreliable (Figure 2-11).  We then adapted a 
method that had previously been described by (Mikos and Peppas, 1990) and (Nakamura et 
al., 1999).   
Our results demonstrated that FPEG resulted in the greatest degree of displacement (absence 
of mucin: 9.5cm ± 0.05cm; presence of mucin: 5.7cm ± 0.19cm) with FCS demonstrating the 
least displacement (absence of mucin: 6.5cm ± 0.34cm; presence of mucin: 4.24cm ± 0.34cm), 
with all formulations showing a statistically significant difference in displacement (P < 0.001) 
when compared to the absence of mucin.  The results demonstrate the superiority of FCMC 
and FCS compared to FPEG and the fact that displacement is observed in the absence of 
mucin would indicate that the use of mucin is able to recover some of the mucoadhesive 
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properties of the mucoadhesive polymers included within the formations, and although known 
to show less biophysical properties as compared to native mucin, this purified mucin has less 
batch-to-batch variation and hence provides better reproducibility in measuring 
mucoadhesiveness (Khutoryanskiy, 2011a). 
Due to the nature of these tests it is often advised not to rely on single method to assess 
mucoadhesion (Hagerstrom and Edsman, 2003). Although both the tests show similar results 
the displacement transfer method was more reproducible, reliable and statistically significant.  
Furthermore Ivarsson and Wahlgren (Ivarsson and Wahlgren, 2012) demonstrated similar 
results with CMC-based formulations requiring a stronger detachment force than CS under 
tensile strength measurements, however they also noted that conflicting reports existing with 
different methods and support the previously reported by Hagerstrom and Edsman method 
(Hagerstrom and Edsman, 2003) for the need to avoid solely relying on a single method of 
mucoadhesion assessment. 
It is believed that mucoadhesion occurs at micro level interactions between mucus and the 
mucoadhesive, however tensile strength measurements occur at a macro level and therefore 
may not represent the micro-level changes taking place during mucoadhesion (Smart, 1999). 
The mucoadhesive properties of polymers can be influenced by the polymer structure and 
functional groups and the most commonly used mucoadhesive polymers are composed of 
polar chemical functional groups such as hydroxyl (—OH), carboxyl (—COOH), amide (—
NH2), and sulfate (—SO4H) groups which are able to interact with the mucin glycoproteins and 
capable of forming hydrogen bonds (Park and Robinson, 1987, Madsen et al., 1998).  
Furthermore the charge of the polymer is important in governing the mucoadhesion with non-
ionic polymers (such as PF127) demonstrated minimal mucoadhesion properties, with greater 
mucoadhesion often demonstrated with anionic polymers such as CMC (Peppas and Buri, 
1985) and superior mucoadhesion with cationic polymers (such as chitosan), particularly at 
neural pHs (Lehr et al., 1992). 
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2.5.4. Cellular toxicity associated with formulation exposure 
The compatibility and cellular toxicity of formulations components with the target tissue/cell 
type is an important process in determining the safety and efficacy of the formulations.  At a 
cellular level the viability of cells can be assessed through a range of cellular toxicity studies.  
To our knowledge, no studies have demonstrated the cellular toxicity of the polymers 
incorporated into thermoresponsive mucoadhesives nasal gel systems again either human 
nasal epithelial systems (RPMI 2650) or olfactory neuronal cells (OBGF400). Our studies 
demonstrated that with RPMI 2650 cells the IC50 for AMT was relatively high, 4.6mM ± 0.05mM 
(Figure 2-15) with no significant reduction in cellular viability with PF127, CS, CMC or FPEG.  
Similarly, no significant reduction in cellular viability was observed with AMT and all polymers 
investigated for OBG400 cells (Figure 2-16). 
PF127 is a relatively safe and widely used thermoresponsive and biocompatible polymers and 
hence would be expected to possess minimal toxicities towards human tissues.  A range of 
studies have also confirmed our results with Khattak et al reporting that a 0.1-5% w/w solution 
of PF127 demonstrated no cellular toxicity over a 5 day period in human liver carcinoma 
(HepG2) cells (Khattak et al., 2005). (Gong et al., 2009) demonstrated limited toxicity towards 
HEK293 cells from 0-1000µg/mL but with a reduction in cell viability at 2500µg/mL to 64 ± 9%.  
Zhang et al (Zhang et al., 2007) also demonstrated limited toxicity towards HEK293 cells at1% 
w/w (10,000µg/mL).  (Brunet-Maheu et al., 2009) demonstrated limited toxicity towards MG-63 
osteoblast cells which was time dependant and decreased to 85% on day 2 of incubation with 
20% w/w PF127. Yang et al (Yang et al., 2012) demonstrated no significant toxicity of 
PEG4000 in Hela cells across a concentration range of 0.5-9mg/mL.  Furthermore no cellular 
toxicity was reported in Caco-2 cells for concentration of PEG4000 of up to 4% w/w (Hodaei 
et al., 2015).   (Lin et al., 2006a) developed a novel PEGylated amphiphilic copolymer of poly(δ-
valerolactone) (PVL) with PEG4000 and reported no cellular toxicity over a PEG4000 
concentration range of 0.001-0.1mg/mL. 
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CMC is a commonly used tablet disintegrant and has been granted GRAS status by the FDA 
(SCOGS, 1979) and is therefore considered to be relatively non-toxic.  As a result, there are 
very few studies reporting the cellular viability data for CMC in the native polymer form (i.e. 
without formulation into a novel delivery system) with limited cytotoxicity associated with 
exposure to human corneal epithelial cells with cellular viability dropping to 80% ± 3% following 
24 hours of incubation (Lee et al., 2015). 
CS is a natural polysaccharide and is often used as a cellular scaffold in biomaterial and tissue 
engineering applications (Tchemtchoua et al., 2011, Sun et al., 2011, Martin-Lopez et al., 
2012, Lv et al., 2011) and is therefore generally considered to be relatively safe to use when 
exposed to cell cultures.   
Cellular toxicity studies have therefore confirmed that the formulation polymers studied do not 
adversely affect the viability of cell proliferation which concurs with their widespread use in 
pharmaceutical formulations and biomedical/tissue engineering systems.  Furthermore, limited 
cellular toxicity was observed with MTT with an IC50 in the low milli-molar concentration range 
and therefore its use within the developed formulation would pose little cellular toxicity 
concerns. 
2.5.5. AMT release and transport across a permeable insert model of the human nasal 
epithelia 
Whilst the assessment of AMT release in non-cell based systems may give an indication of the 
kinetics of release, the impact of a physiological/cellular barrier is important to assessing the 
eventual delivery into the systemic circulation or CNS via cellular barrier.   
We developed a permeable insert based model system of the human nasal epithelia using 
RPMI 2650 cells and assessed the transport of released AMT from formulations to better 
understand any potential changes in release patterns of AMT when interacting with a cellular 
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barrier. Furthermore, the lack of current immortalised olfactory mucosa cell lines makes it 
difficult to develop a viable model for the human olfactory epithelial mucosa barrier. 
The growth of RPMI 2650 cells on permeable inserts resulted in an increase in the monolayer 
integrity, as judged by the TEER (Figure 2-17), with a statistically significant (P ≤ 0.0001) 
difference in TEER values compared to day 2 post seeding observed during days 12-20, with 
a peak TEER value attained on day 12 (139 ± 14Ω.cm2) (Figure 2-17). These results are in 
agreement with (Bai et al., 2008) who validated these results in their findings of western blot 
which showed presence of four tight junction proteins ZO-1, occludin, claudin-1 and E-cadherin 
considerably higher when maintained under ALI conditions.  
The release of AMT from all formulations was delayed compared to the diffusion of AMT alone 
across the monolayer with release of 43-44% was observed over the duration of the transport 
study in comparison to that of AMT alone (79% ± 3.58%) (Figure 2-18).  The mechanism of 
drug release, as described by the Korsmeyer-Peppas power law, was modelled according to 
a super case-II effect (n > 0.89) where the sorption of solvent results in breaking of the polymer 
network (termed solvent crazing) (Alfrey et al., 1966) as a result of the swelling of the gel within 
the vitreous nucleus and can be a result of crosslinking density (Orienti, 1995), drug loading 
(Davidson, 1986) and copolymer composition (Franson and Peppas, 1983).  The super-case 
II diffusion of AMT from all gel systems was surprising, and therefore the release of AMT from 
the formulations is not clear as it is beyond the limits of the power law.  It suggests that a rapid 
release of AMT occurred later in the experiment resulting in rapid relaxation 
governing/controlled transport of AMT from the polymer network (Hopfenberg, 1974) (Peppas 
and Khare, 1993).  The ionic composition of the media, comprising a pH of 7.4, may have 
directly altered the state of ionization within the polymer gel network, compared with the pH of 
the ANE (pH 5.5) leading to an altered release profile, with the rapid release being a time-
dependant reflection of the shift in equilibrium as the solvent (media) penetrates the polymer 
network (Long and Richman, 1960, Klech and Simonelli, 1989). 
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However, our results demonstrate viable release and transport of AMT across the nasal 
epithelial and hence confirm that the optimised formulations may be potentially viable 
formulation systems for the local delivery of AMT (and other APIs) to the nasal cavity resulting 
in delivery across the nasal epithelia. 
2.5.6. Stability and release of AMT from optimised formulations  
Whilst the gelation, rheology and release of AMT from freshly prepared formulations provides 
vital information to characterise these formulations, their stability and the impact of formulation 
instability on AMT release is important in understanding their potential applications clinically.  
Optimised formulations were stored at both refrigerated (4°C) and room temperature (25°C) 
conditions within controlled humidity cabinets for a duration of 8 weeks.  At regular intervals of 
the stability study samples were withdrawn for assessment of AMT release kinetics. 
The analysis of stability of the optimised formulations during prolonged storage demonstrated 
that both FCMC and FCS were relatively stable (in terms of AMT release kinetics) during a 
period of 8 weeks when stored in refrigerated conditions but FPEG failed to gel after the first 
week of storage at 4°C.  Furthermore, the release k inetics for FCMC and FCS were associated 
with a slower release profile as a result of a reduction in kH at week 8 compared to week 0 
(Week 0: FCMC: 1.440 ± 0.150 and FCS: = 1.319 ± 0.028; Week 8: FCMC: 1.224 ± 0.063 and 
FCS: kH = 1.291 ± 0.043) (Table 2-11) (Figure 2-19 and 2-21).  
Formulations stored at 25°C generally failed to gel  after 8 weeks of storage with FCS 
demonstrating a gelation transition and similar AMT release profile to week 0 (Figure 2-19 B) 
after the first week of storage and which continued to show gelation phenomena at 25°C/60 % 
RH at week 2 (Figure 2-22), but failed to gel thereafter. 
The release kinetics generally followed Korsmeyer-Peppas power law kinetics and 
demonstrated Fickian-type diffusion early on (except for FCS).  At the end of the study period 
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this had moved towards anomalous transport (Table 2-11), whereby drug diffusions and the 
polymer relaxation were contributing to the overall release kinetics.   
The swellable nature of hydrogel systems involves a dissolution process which creates an 
erosion front within the polymer, the imbibing of water as a solvent, results in the relaxation of 
polymer chains and the dissolution of the drug particles and results in an almost tripartite 
phenome of diffusion, swelling and erosion.  In Fickian-type diffusion (Case-I), the rate of 
solvent diffusion (RD) is much slower compared to the rate at which polymer chains relax (RR).  
For non-Fickian diffusion (Case II, Anomalous and Super Case II) the main differences lies 
with the RD whereby for Case II RR >> RD, for anomalous-type kinetics RD ≈ RR and for Super 
Case II  RD >> RR (J, 1967, Lin et al., 2005, Khare and Peppas, 1995, Klech, 1989).  Initially, 
formulations demonstrated Fickian-type diffusion but the Korsmyer-Peppas exponent 
increased over the stability period to > 0.5 by week 8 moving towards anomalous transport.  
This would suggest that polymer relaxation (swelling/erosion) plays a critical role in the release 
of AMT at earlier stability time points.  The mathematical description and modelling of the 
casual factors for anomalous transport is challenging, and is beyond the scope of this study 
however a number of detailed reviews have been published discussing this issue (De Kee et 
al., 2005).  The mass transport of AMT into the polymer network can be assumed to be 
comprised of 3 processes (Vrentas and Vrentas, 1998, Aminabhavi et al., 1989), whereby the 
solvent (water) is absorbed onto the surface of the polymer.  The solvent molecules may then 
enter the lattice network of the polymer, which causes a ‘swelling’ of the network and 
elongation.  This elongation is then counter balanced by an elastic-restrictive force to oppose 
the swelling.  Eventually a state of equilibrium is reached when both forces are balanced, these 
process can significantly alter the kinetics of drug diffusion through the polymer network and 
are highly influenced by time-scale associated structural changes in the polymer (Wu and 
Peppas, 1993, Thomas and Windle, 1982, Thomas and Windle, 1981, Thomas and Windle, 
1980). 
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The move towards anomalous transport over 8 weeks may suggest at a polymer network time-
associated effect (Crank, 1968, HJ, 1966), which becomes more apparent over the longer 
stability study.  The equilibrium between swelling and elastic-restrictive force within the 
polymer may be associated with a time-dependent equilibrium, where equilibrium is not 
established immediately (Long and Richman, 1960).  
Although the formulations are in liquid-phase during the stability storage period, the 
interactions between both mucoadhesive polymers and thermoresponsive polymers may 
influence eventual formulations of the polymer networks, altering the equilibrium processes 
and hence contributing towards the anomalous transport.  
The lack of literature reports concerning of the stability of pluronic-based hydrogel was recently 
reported by (Grela et al., 2014) and they aimed to characterise the stability of PF127 over a 
range of temperatures during prolonged storage (up to 3 months).  They noted that a stronger 
degradation of the formulation structure, as noted from Tsol-gel, viscosity and rheology 
assessment, was evident at elevated storage temperatures.  However, storage of optimised 
formulations at refrigerated temperature would enhance the relative stability of the gelation 
phenomena and associated AMT release kinetics for prolonged periods of time. 
2.5.7. Nasal spray system 
The prevention of pulmonary deposition of any nasally administered formulations is key to 
ensuring the residency within the nasal cavity.  The droplet size distribution is important in 
identifying the potential for pulmonary deposition (< 2µm) (Stuart, 1973, Hatch, 1961a), 
however the droplet size is often dictated by the design of the orifice of the actuator device 
used to deliver the spray plume. For ensuring retention of drug within the nasal passages, 
droplet sizes of in-excess of 5µm are recommended and represented our target cut-off (Stuart, 
1973, Hatch, 1961b).   
Our formulations all demonstrated a diameter in excess of the traditional cut-off of 5µm. (Table 
2-12). FCS demonstrated a 10% fraction of 7.27µm ± 0.28µm (Table 2-12) closest to the cut-
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off for pulmonary deposition, whereas both FCMC and FPEG were above this.  FCS also 
demonstrated the smallest diameter (VMD= 92.41µm ± 1.72µm). However, when considering 
the span of particle sizes, FCS was the broadest (0.96 ± 0.30) with both FCMC and FPEG 
showing a smaller distribution spread (Table 2-12).  A one-way ANOVA confirmed droplets 
VMD were significantly different across all formulations (P < 0.0001), suggesting that the 
incorporation of different mucoadhesive polymers contributed to the differing polymer sizes 
with FCS demonstrating the small resulting droplets (92.41µm ± 1.72µm) and FCMC the 
largest (120.87µm ± 0.59µm).  When considering the viscosity of the polymers used in each 
formulation (Figure 2-10), CMC resulted in the most viscous formulations and this may have 
contributed to the larger particle sizes, with similar trends observed for CS and PEG. 
  
To assess the potential in-vivo application of formulations, FCS and FCMC were taken 
forward to assess spray deposition within a human nasal cast model. The angle of spray 
administration was altered from 60-80° and the impa ct on deposition patterns assed.  For both 
formulations the administration angle had a significant effect on deposition, with an increased 
angle (80°) having a significantly pronounced local isation in the nasal vestibules and lower 
regions of the nasal cavity.  For FCMC (Figure 2-28) this deposition area was significantly 
lower than that for FCS (Figure 2-27).  
 
Spray angles of 60° and 70° lead to deposition of t he formulation in the olfactory regions of the 
nasal cavity, highlighting the possibility for exploitation in nose-to-brain delivery of amantadine.  
FCS sprayed at an angle of 60° with insertion lead to olfactory deposition of 0.6-0.7cm2.  For 
FCMC a greater olfactory deposition of 0.91cm2 was observed at 60° with insertion. Although 
the higher deposition for FCS may be a result of the smaller particle sizes for FCS (92.41 ± 
1.72µm) compared to 120.87 ± 0.59µm, the impact of nozzle insertion for FCMC may enhance 
delivery onto the olfactory regions (Figure 2-28).  When considering the surface area of the 
human olfactory mucosa (2-10cm2) (Gross et al., 1982), FCMC may be a viable candidate for 
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further development targeting nose-to-brain drug delivery (Badhan et al., 2014).  In both 
formulations, the impact of head position (15° post eriorly) was important in governing nasal 
depositions, leading to significantly higher deposition within the middle-upper regions of the 
cast irrespective of the insertion angle 
 
The higher viscosity of FCMC compared to FCS resulted in significantly larger particle sizes 
(P < 0.001) for the optimal formulations and may have resulted in a more focussed (less 
disperse) spray plume resulting in more localised deposition patterns.  In contrast, the lower 
viscosity of FCS, leading to small particles would lead to a wider plume and greater deposition 
in the nasal cavity (Kundoor and Dalby, 2011, Guo et al., 2005).  
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2.6. Conclusion 
The treatment of age-associated degenerative CNS disorders such as Parkinson’s 
diseases (PD), poses particular difficulties in the design of appropriate drug delivery systems 
capable of overcoming the hindrances associated with dyskinesia and dystonia that are 
inherent in current pharmacological interventions for PD.  Although reformulation of existing 
orally dosed formulations may provide some benefit, there is an inherent need to provide an 
alternative delivery routes for a range of CNS disorders which can both provide ease of clinical 
use but also to improve the bioavailability of the therapeutic. 
The nasal mucosa fulfils this purpose in light of the large and vascularised route of access for 
drugs to the systemic circulation and can provide a relatively non-invasive approach to deliver 
drugs.  A key concern of any nasal administered formulation is the residency of the formulation 
within the nasal cavity. Existing formulations are often associated with a nasal drip or ‘run-off’ 
effect which potentially diminish the bioavailability of nasal formulation.  A novel development 
in this area has been the formulation of intelligent response based hydrogel nasal formulations 
which act to enhance residency within the nasal cavity (Schmolka, 1972b, Nazar et al., 2011, 
Wu et al., 2007, Alsarra et al., 2009, Li et al., 2010, Jeong et al., 2002, Agrawal et al., 2010, Li 
et al., 2014, Qian et al., 2014, Chen et al., 2013b, Nakamura et al., 1999, Ikechukwu Ugwoke 
et al., 1999, Zaki et al., 2007a, Hosny and Banjar, 2013, Basu and Maity, 2012). 
 
This study has investigated the potential to administer the antiviral/antiparkinsonian drug 
through the nasal route using mucoadhesive and thermoresponsive hydrogel formulation 
systems.  We have demonstrated that both CMC and CS can provide the requirements for 
mucoadhesion in these formulations, whilst also leading to a relatively stable formulation which 
can be targeted to deliver drug in specific regions of the nasal cavity dependant on 
administration angle and nozzle insertion depth.  Furthermore, our results have indicated the 
potential for nose-to-brain delivery of amantadine, yielding a potentially novel avenue 
therapeutics delivery route to avoid the blood-brain barrier. 
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3.1. Introduction 
The delivery of drugs and therapeutic agents to the CNS is hampered by the insidious 
nature of the BBB in restricting the entry of xenobiotics across into the brain and wider CNS 
(Abbott, 2005, Abbott et al., 2010b, Abbott and Romero, 1996, Pardridge, 2007b).  The BBB 
has evolved to essentially govern the permeability of drugs through its formation as a physical 
barrier formed by the endothelial and epithelial (Persidsky et al., 2006) and as a result of the 
expression of membrane transporters and transcytotic vesicles.  Furthermore, the 
physicochemical properties of compounds permeating across the BBB is a driving factor in its 
ability to distribute into the CNS.  
 Despite advances in neurosciences and drug delivery technologies, the targeting and 
delivery of therapeutics into the brain and CNS is still a limiting factor, with less than 1% of all 
CNS-targeted compounds showing activity against CNS disease states (Pardridge, 2005, 
Lipinski, 2000).  This is despite many of these compounds possessing physicochemical 
properties that world normally predispose them to good membrane permeability (e.g, 
molecular weight < 500 and highly lipid soluble) (Pardridge, 2007c, Pardridge, 1998). 
As an alternative to direct BBB penetration the olfactory mucosa has gained interest as a 
potential novel target site for CNS delivery. The olfactory region covers the uppermost part of 
the nasal cavity covering approximately 2.5-10cm² in humans  (Gizurarson, 2012), is 
comprised of approximately 12 million olfactory receptor cells (Purves, 2007) and is the only 
part of the CNS which is directly exposed to the external environment (Illum, 2000, Pires et al., 
2009). 
The olfactory nerve pathway provides a rapid and non-invasive route for CNS drug delivery. 
This is evident from studies carried out showing fluorescent traces associated with olfactory 
nerves as they traverse through cribriform plate, with highest drug concentrations observed in 
the olfactory bulb (OB), and the correlation between olfactory epithelium (OE) and OB 
(Lochhead and Thorne, 2012, Renner et al., 2012). 
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Previously we demonstrated the development of a novel mucoadhesive-thermoresponsive 
nasal gel formulation for the delivery of the water soluble drug amantadine.  However, with 
poorly soluble drugs, such formulation systems often requires mixed solvent systems with high 
solvent concentrations (Agrawal and Maheshwari, 2014).   
To enhance the solubility of poorly soluble drugs, nanotechnology based formulation 
systems are often employed and have been developed as a concept for solubility 
enhancement for over 30 years (Poste et al., 1976, Papahadjopoulos, 1988, Douglas et al., 
1987, Davis et al., 1987, Poste and Kirsh, 1983).  Considering that it has been estimated that 
approximately 40% of new active substrates are difficult to formulate due to poor water 
solubility (Lipinski, 2000, Lipinski, 2002),(Lee et al., 2014), the application of nanoparticle 
technologies to improve solubility is gaining interest.  Furthermore, the formulation of drug 
products into orally dosed tablet formulation can be problematic to the targeting the brain and 
CNS as a result of the limitations associated with the drug crossing the gastrointestinal barrier 
coupled with the BBB.  Despite approaches to enhance the solubility to improve dissolution, 
limitations associated with bypassing the BBB may still exist. 
 
A potentially novel class of compounds with widely cited biological activities, including 
cognitive effects, are flavonoids.  These are polyphenolic compounds that are abundantly 
found in fruits and vegetables and have attracted attention due to their antioxidant activities.  
Over 6000 flavonoids  have been reported to date and many have been reported to possess 
CNS indicating effects including the protection of neurons from neurotoxins and neuro-
inflammation in degenerative disease status such as Dementias (Williams and Spencer, 2012, 
Solanki et al., 2015, Shukitt-Hale, 2012, Mecocci et al., 2014, Macready et al., 2009, 
Cherniack, 2012, Blumberg et al., 2014).  Furthermore, an increasing body of clinical evidence 
is supporting the view that flavonoid impart a protective function towards dopamine neurons 
through prevention of oxidative damage and apoptosis (Mercer et al., 2005, Meng et al., 2009). 
Furthermore, a range of flavonoids have been reported to be capable of reducing the impact 
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of drug efflux transporter proteins, such as P-glycoprotein or BCRP, which are prominently 
expressed at BBB and significantly hinder CNS drug delivery and which have also been 
identified to be expressed at the olfactory mucosa (Kandimalla and Donovan, 2005).  The 
localisation and expression at the olfactory mucosa may therefore provide a limiting factor for 
the directly delivery of substrates of P-glycoprotein or BCRP, mimicking aspects of the barrier 
function of the BBB. 
 
Of the wide array of flavonoids/phytochemical based compounds reported, curcumin has 
been widely reported to impart a protective function from AD/PD in epidemiological studies in 
humans and in rodent models (Muthane et al., 1998, Ganguli et al., 2000, Alladi et al., 2009, 
Mythri et al., 2011). Curcumin, also known as diferuloylmethane or 1,7-bis (4-hydroxy-3-
methoxyphenyl) -1,6-hepatadiene-3,5-dione, is a natural yellow coloured and low molecular 
weight polyphenol compound purified from the rhizome of the plant Curcuma longa. It is 
insoluble in water and hence it’s therapeutic applications are limited due to its poor 
bioavailability when administered orally as a result of rapid glucuronidation in therapeutic and 
resultant poor tissue distribution (Ravindranath and Chandrasekhara, 1980, Pan et al., 1999).   
Phytochemical flavonoids are therefore a potently novel multi-faceted class of molecules 
which show potential for a range of CNS patho-physiologies (Katayama et al., 2007, Breedveld 
et al., 2006b, Allen et al., 2002b, Ashida et al., 2000, Pick et al., 2011, Fleisher et al., 2015, 
Zhang et al., 2004, van Zanden et al., 2007, Zhang et al., 2005, Robey et al., 2004, Ferrandiz 
and Alcaraz, 1991, Breedveld et al., 2006a, Allen et al., 2002a).  
Recently, the application of nanoparticle technology to improve the solubility of curcumin 
has been reported and resulted in an increase in the pharmacokinetics and bioavailability 
(Gupta et al., 2009, Gupta and Dixit, 2011b, Gupta and Dixit, 2011a, Krausz et al., 2015). 
Among various type of nanoparticle based carrier system, mesoporous silica nanoparticles 
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offer various advantages, such as large surface area, porous surface with pores ranging from 
2-50nm allows maximum drug loading, which can act as a drug reservoir and they are also 
biodegradable (Zhai et al., 2012) whilst also being relatively stable in many harsh organic 
solvents (Stein et al., 2000).  
The focus of this chapter was to develop mesoporous silica nanoparticles as carrier 
systems for poorly soluble compounds such as phytochemicals, to both enhance their inherent 
solubility but to also to assess their compatibility as drug delivery systems for intranasal and 
olfactory drug delivery. 
Another important member of the flavonoid family is chrysin, which also has shown 
neuroprotective activity (He et al., 2012). Due to its wide variety of actions such as 
antioxidant, anti-inflammatory, anti-tumour, antihemolytic and anti-hypertensive and its 
abundance in plants makes it an attractive compound.  
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3.2. Aims and objectives 
The aim of this chapter was to develop a mesoporous silica nanoparticle drug delivery 
system suitable for the loading of the water insoluble phytochemicals curcumin and chrysin. 
To achieve these aims the overall objective were: 
• To identify the appropriate nanoparticle size for olfactory uptake 
• To synthesize and characterize a mesoporous nanoparticle system (MSNPs) within a 
tuneable size range 
• To assess the cellular toxicity of MSNPs against olfactory derived cell culture models 
• To assess the cellular toxicity of curcumin and chrysin against olfactory cell culture 
models 
• To study the uptake of MSNPs into olfactory neurons 
• To assess the loading capacity of MSNP towards curcumin and chrysin 
• To assess the release of phytochemical-loaded MSNP  
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3.3. Materials and Methods 
Eagle’s Minimum Essential Medium (MEM), Dulbecco’s Modified Eagle Medium: Nutrient 
Mixture F12 (DMEM-F12), Dulbecco’s Phosphate buffered saline (PBS), L-glutamine 200mM, 
non-essential amino acids (NEAA), penicillin/streptomycin and trypsin-EDTA solution were 
obtained from PAA laboratories (Austria); foetal bovine serum (FBS) (Labtech, Essex, UK); 
potassium chloride, magnesium sulphate, calcium chloride, acetonitrile, orthophosphoric acid, 
acetic acid, ethanol, sodium hydroxide, and sodium chloride were obtained from Fisher 
Scientific (Loughborough, UK); acutase (Biolegend, UK); gentamycin, cetyl 
trimethylammonium bromide (CTAB), tetraethoxy orthosilicate (TEOS),  MTT (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl Tetrazolium bromide), trypan blue, dimethyl sulfoxide 
(DMSO),  potassium phosphate, ammonium hydroxide, rhodamine 6G, FITC (fluorescein 
isothiocynate),DAPI(4',6-diamidino-2-phenylindole),collagen, cell culture water, monobasic 
were obtained from Sigma-Aldrich (Dorset, UK). 
3.3.1. Fluorescent bead uptake in porcine olfactory bulb neuroblastoma (OBGF400) 
cells 
OBGF400 cells were cultured as described in section 2.3.9.  Coverslips were sterilised in 70% 
ethanol for 30 min, dried in a laminar air hood and coated with 6µg/cm2 of a collagen prepared 
in sterile water from a 0.1% w/v (0.1M acetic acid) stock solution, with coating taking place in 
12-well plates.  Plates were left to dry in the laminar air flow for 2 hours.  Excess collagen was 
then removed and coverslips washed with sterile water and left for drying. Thereafter cell 
suspensions of OBGF400 cells were seeded at a density of 1x105 cells/cm2 into wells of a 12 
well plate containing the coated coverslips and left to adhere and proliferate to a confluency of 
approximately 70% in a 5% CO2 humidified incubator.  Fluorescent latex beads (carboxylate 
modified) of 100nm (λex ~491nm; λem ~521nm) and 500nm (λex 487nm; λem 530nm) were 
dispersed into HEPES (25mM) buffered HBSS at a concentration of 0.1% v/v and sonicated 
for 10 minutes in a water-bath sonicator prior to the addition into wells.Coverslips were 
incubated for 2 hours in a 5% CO2 humidified incubator before being washed with ice cold 
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HEPES (25mM) buffered HBSS and fixed with 4% w/v paraformaldehyde for 30 minutes in the 
dark.  The coverslips were then mounted onto glass slides with mounting media containing 
DAPI. The localisation of the latex beads was analysed using an upright confocal microscope 
(Leica SP5 TCS II MP) and visualised with a 40x oil immersion objective. All images were 
acquired using an argon laser at 494nm to visualise FITC and a helium laser to visualise DAPI 
at 461nm. 
3.3.2. Preparation of mesoporous nanoparticles (MSNP) 
A desirable mesoporous nanoparticle system is the one which offers large surface area, 
high pore volume, and tuneable size. However the dispersity of the MSNPs is highly dependent 
on the methods employed for template removal and particle collection (Wu et al., 2013). To 
therefore identify an appropriate method to develop size controlled MSNPs three published 
methods were considered and formed MSNP were characterised by size and morphology 
before selecting a suitable method for subsequent studies. 
3.3.2.1. Synthesis of MSNPs: template removal by calcination (Gul-MSNP) 
This method is based upon a published study by Gulfam and Chung and is termed the 
‘Gul- method’ (Gul-MSNP) (Gulfam and Chung, 2014).  To a reaction volume, 10mL ethanol, 
20mL diethyl ether and 0.8mL ammonium hydroxide were dissolved in 70mL distilled water. 
500mg CTAB was introduced in this emulsion system and the mixture was vigorously stirred 
at 600rpm. After 30 min, 2.5mL TEOS was rapidly added into the system and the mixture was 
vigorously stirred at 600rpm for 4h. The white precipitate was collected by filtration and 
subsequently washed with distilled water before being dried at 60°C for 24h. The CTAB 
template was removed by vigorously stirring the particles in a mixture containing 15mL HCl 
and 120mL ethyl alcohol at 70°C for 24h.  The forme d nanoparticles were further calcinated at 
600°C for 12h. Thereafter the bare mesoporous silic a nanoparticles were washed several 
times with distilled water and ethyl alcohol before being air dried at dried in air at 80°C. These 
were termed ‘Gul-MSNP’. 
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3.3.2.2. Synthesis of MSNPs: charged template approach (Pro-2-MSNPs) 
This method is based upon a published study by (Nooney et al., 2002) and is termed the 
‘Pro-2 method’ forming ‘Pro-2-MSNP’. This method involves the homogeneous synthesis using 
a charged template and is associated with a water/ethanol solvent washing approach. Briefly, 
138g of ethanol and 162g of deionized water were combined and the resultant pH adjusted to 
11.7 with the addition of 11.6mL of ammonium hydroxide (29wt % NH3 in water). 0.274g of 
CTAB was then added with rapid stirring at room temperature. Subsequently after 5 min, 
1.39mL of TEOS was added with the solution turning slightly turbid indicating hydrolysis. After 
2 hours the suspension was filtered.  
3.3.2.3. Synthesis of MSNPs: template removal by refluxing (Fan-MSNPs) 
This method is based upon a published study by (Fan et al., 2011) and is termed the ‘Fan 
method’ formulating ‘Fan-MSNP’.  In this method 1.0g of CTAB (2.74mmol) was dissolved in 
480mL distilled water. Thereafter 3.5mL of aqueous sodium hydroxide solution (2M) was 
added and the temperature of the mixture was raised to 80°C. 5mL TEOS (22.4mmol) was 
then introduced drop wise into the reaction mixture whilst stirring vigorously for two hours until 
a white precipitate was formed. The precipitate was then filtered and washed with distilled 
water and methanol and dried under vacuum. The surfactant template (CTAB) was removed 
by refluxing 1.5g of the synthesized silica particles with 1.5mL of HCL (37.2% w/v) and 150mL 
methanol for 6 hours. The product was washed extensively with distilled water and methanol. 
The surfactant free silica particles were placed under high vacuum with heating at 60°C to 
remove the remaining solvent from the mesopores.  
3.3.3. Assessment of MSNP particle size distribution and zeta-potential (ζ)  
The size and zeta potential (ζ) of MSNPs were determined using dynamic light scattering 
techniques through the use of a NanoBrook 90 Plus Zeta (Brookaven Instruments 
Corporation).  100µL of 1mg/mL sonicated MSNPs suspension was added to 3mL ultrapure 
water, vortexed and used to measure the particles size. The mean diameter was obtained  
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from 3 runs of 3 minutes. The polydispersity index (PDI) was used to indicate the particle size 
distribution in within the sample.  The zeta potential is an indicator for charge present on the 
surface of nanoparticles, which is responsible for the stability of formulation and interaction 
with cellular membranes. The zeta potential of nanoparticles is measured using the principle 
of electrophoretic mobility under an electric field. The average of 3 readings (each reading = 
30 runs) was reported. The temperature was maintained at 25°C during the measurements. 
3.3.4. Scanning electron microscopy (SEM) based assessment of the morphology of 
MSNP  
Samples of MSNP were mounted on 12mm aluminium pin stubs with 12mm carbon tabs 
and coated with 15nm of gold. The powders were imaged at 5 kV with a 150pA beam in high 
vacuum due to beam damage to the samples at higher kV’s. The nanoparticles were imaged 
at 10kV with a 100pA beam also in high vacuum. The SEM used was Carl Zeiss EVO LS 15. 
The gold coater used was a Quorum QR105S. 
3.3.5. Porosity assessments using nitrogen adsorption/desorption isotherm analysis 
The specific surface areas of the blank MSNPs was analyzed using the Brunauer–Emmet–
Teller (BET) method (Brunauer et al., 1938) using a Quantchrome NOVA (Quantchrom, 
Finland). The analysis was based on the amount of Nitrogen (N2) gas adsorbed at various 
partial pressures (P/P0) between 0.05 and 0.3. Before N2 adsorption, samples were under 
vacuum at a temperature of 100°C. The nitrogen mole cular cross sectional area (0.162nm2) 
was used to determine the surface area. The pore size distribution and total pore volume was 
determined by using density functional theory (DFT) method.  All calculations were software 
automated (Quantchrome NOVAWIN, Quantchrom, Finland). 
3.3.6. Thermogravimetric analysis (TGA) of MSNP 
Thermal stability analysis of the functionalized silica was performed by thermogravimetric 
analysis (TGA) using a Pyris 1 TGA (Perkin Elmer) instrument. 3mg of MSNP materials were 
analyzed under nitrogen purge with a starting temperature of 35°C and 10°C/min ramp rate to 
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800°C. The corresponding carbon, hydrogen and nitro gen elemental analysis was performed 
using LECO CHN-2000 elemental analyzer under flowing oxygen.  
 
3.3.7. Loading of fluorescein isothiocynate (FITC) and targeted to OBGF400 
FITC loaded MSNP (FITC-MSNP) were prepared using a slightly modified method 
proposed by (Fan et al., 2011).  100mg of MSNP were refluxed with 8mL toluene and 100µL 
of 3-aminopropyltriethoxysilane for 20 hours to form amine-functionalised MSNPs. 150mg of 
these functionalised MSNPs were reacted under an argon atmosphere with 1.75mg of FITC 
(0.009mmol) 5µL of triethylamine (TEA) and 10mL of anhydrous dimethylformamide (DMF). 
The mixture was stirred at room temperature for 24h followed by centrifuging and washing 
twice at 8000rpm for 8 mins with DMF, diethyl ether and methanol. Finally, to remove the 
remaining solvent from the FITC-MSN particles were subjected to high vacuum at 60°C. 
To assess the release of FITC from FITC-MSNP, 1mg/mL FITC-MSNP was dispersed in 
PBS (154mM PBS pH 7.4), briefly sonicated and placed in a shaking incubator maintained at 
37˚C and 100rpm. Samples were withdrawn at set time intervals and the volume replaced with 
an equal volume of pre-warmed release medium. The release of FITC was assessed through 
fluorescence measurements using a dual-scanning microplate spectroflurometer (Spectra Max 
Gemini XS, molecular devices, Sunnyvale, California) at an excitation wavelength of 470nm 
and emission wavelength of 520nm. 
For intracellular tracking in OBGF400 cells, FITC-MSNP were dispersed into HEPES 
(25mM) buffered HBSS at a concentration of 50µg/mL prior to the addition into wells of a 12 
well plate containing collagen coated coverslips and incubated for 2 hours in a 5% CO2 
humidified incubator.  Thereafter the coverslips were washed with ice cold HEPES (25mM) 
buffered HBSS and fixed with 4% w/v paraformaldehyde for 30 minutes in the dark.  The 
coverslips were then mounted onto glass slides with mounting media containing DAPI. The 
localisation of the latex beads was analysed using an upright confocal microscope (Leica SP5 
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TCS II MP) and visualised with a 40x oil immersion objective. All images were acquired using 
an argon laser at 494nm to visualise FITC and a helium laser to visualise DAPI at 461nm.  
3.3.8. Differential scanning calorimetry (DSC) 
Heating curves of curcumin, chrysin, blank MSNPs and loaded MSNPs were obtained 
using differential scanning calorimeter (DSC Q200, TA instruments, Delware). Samples were 
weighed and 2-5mg were loaded into a non-hermetically crimped aluminium pan and heated 
under a nitrogen purge at the rate 50mL/min. Samples were heated from 30 to 350°C at the 
heating rate 10°C/min under nitrogen. The data was analysed using Universal Analysis 2000 
software V4.5A TA instruments. 
3.3.9. Fourier transform infrared (FT-IR)  
The loading of phytochemicals was additionally confirmed by using FT-IR techniques for 
the bare MSNPs, and drug Loaded MSNPs. FT-IR absorbance was collected using a FT-IR 
spectrophotometer (Thermo Scientific,USA) over the spectral range of 550-4000cm-1.  
3.3.10. HPLC analytical detection of curcumin  
The detection of curcumin was based on an adapted method previously reported by (Li et 
al., 2009).  An Agilent 1200 Series (Waldbronn, Germany) equipped with a multiple wavelength 
detector (MWD) and a Phenomenex Luna C18 (150 × 4.6mm) 5µm column was used for RP-
HPLC. The mobile phase was prepared using ACN:5% acetic acid in a ratio of 45: 55 (v/v). 
Mobile phases were filtered through 0.45µm filter and sonicated before use. The flow rate was 
maintained at 0.8mL/min with a 15 minutes run time and injection volume of 20µL, while column 
temperature was mainlined at ambient temperature. Calibration curves were constructed using 
standard solutions of known concentrations from 5 to 50µg/mL. The software used for data 
collection, analysis and control of the system was ChemStation Version 1.24 SP1.   The UV 
detection of curcumin was measured at 420nm.  
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3.3.11. HPLC method for chrysin 
An RP-HPLC method was used to quantify chrysin (Zaveri et al., 2008). The same HPLC 
system described above was used to analyse chrysin samples.  The mobile phase comprised 
of water:methanol:acetonitrile:phosphoric acid in a ratio of 60:30:38:1 (v/v). Mobile phases 
were filtered through 0.45µm filter and sonicated before use. The flow rate was maintained at 
1.0mL/min with 17 minutes run time and the injection volume was 10µL while column 
temperature was kept at ambient temperatures. Calibration curves were constructed using 
standard solutions of known concentrations from 0.78 to 10000µg/mL. The UV detection of 
chrysin was measured at 262nm. 
3.3.12. Toxicity of MSNP towards olfactory cells 
To assess the cellular toxicity of MSNP towards olfactory cells, the OBGF400 cell line was 
used as model systems for the olfactory mucosa.  Cells were seeded into 96-well plates at a 
density of 1x104 cells per well (see section 2.3.10). Cells were subsequently exposed to 10-
1000µg/mL Fan-MSNPs for 24 hours at 37°C in a 5 % CO2 air humidified environment and 
cellular toxicity was assessed using a MTT cytotoxicity assay (see section 2.3.11). The UV-
absorbance of the formazan product was measured on a multi-plate reader (Bio-Rad 
laboratories, Hercules, CA) using 570nm as a test wavelength and 600nm as a reference 
wavelength.  The mean of the blank UV-absorbance was subtracted from the UV-absorbance 
of each controls and samples and percentage viability was calculated. The percentage of 
cellular viability was calculated as follows (Zhang et al., 2010): 
%	cell	viability =
absorbance	of	sample
absorbance	of	control	
∗ 100 
 
The IC50 was subsequently calculated using a sigmoidal dose response function within the 
Graphpad Prism version 5.0 (GraphPad Software, Inc. USA). Each concentration was assayed 
in eight wells and run in three independent experiments and results expressed as percentage 
cytotoxicity relative to a control (0.5% DMSO).   
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3.3.13. Cellular toxicity of phytochemicals 
The cellular toxicity of curcumin and chrysin were also assessed using OBGF400 cells at 
a concentration range of 0.01-50,000µM, as described above. Each concentration was 
assayed in eight wells and run in three independent experiments and results expressed as 
percentage cytotoxicity relative to a control (0.5% DMSO).  The cell viability was calculated by 
comparing the absorbance of phytochemical or drug treated well to that of control well. 
3.3.14.  Phytochemical loading of MSNP Drug loading 
 
Loading of chrysin: 20mg/mL chrysin was dissolved in the DMF and in a separate vial 
20mg/mL of MSNPs were dispersed in DMF and bath sonicated for 15 minutes. A volume of 
1mL from each vial was combined and resulting in a final concentration of 10mg/mL of both 
chrysin and MSNP. The glass vial was sealed and covered with foil, sonicated for 15 minutes 
in water sonicating bath and left for stirring at 100rpm at room temperature. After 24 hours the 
vial contents was filtered through a 0.22µm cellulosic white membrane filter (MSI Micron 
Separations Inc., USA). The filtrate was collected to determine loading and this approach was 
termed the ‘wet’ approach. 
The loaded nanoparticles collected on the filter paper were dried under high vacuum for 2 
days, washed with PBS to remove superficially adsorbed chrysin on the surface and loading 
was assessed through TGA.  This approach was termed the ‘dry’ approach.  Chrysin loaded 
Fan-MSNP were termed ‘Chry-MSNP’. 
Loading of Curcumin: 20mg/mL curcumin was dissolved in a 30:70 mixture 
acetone:ethanol and processed as described above.  Curcumin loaded Fan-MSNP were 
termed ‘Curc-MSNP’. 
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The confirmation of phytochemical loading was determined using HPLC-UV, DSC and TGA 
analysis.  For the ‘wet’ method, an entrapment efficiency (EE) was calculated based on the 
following formula (Mohseni et al., 2015): 
EE	%# =
Drug	added − Free	"unentrapped	drug"
Drug	added
		× 	100								 
For the ‘dry’ method, a loading content (LC) was calculated from the difference between 
the final weight loss for Fan-MSNP and Phytochemical-MSNP at the end of the heating cycle 
and derived from data obtain from TGA analysis. 
3.3.15. Live cell imaging: Cell-IQ®  
 
To assess the morphological alterations in cellular structures when exposed to Fan-MSNP, 
curcumin loaded MSNP (Curc-MSNP) and chrysin loaded MSNP (Chry-MSNP), live cell 
imaging of OBGF400 was conducted over a 40-hour period in an oxygen, CO2 and humidity 
controlled phase contrast imaging systems (CellIQ®, Chip-Man Technologies, Tampere, 
Finland).  OBGF400 cells were seeded into wells of a 6-well plate at a density of 5x105 
cells/well and allowed to adhere and proliferate to 70% confluence.  Subsequently wells were 
washed with warm HEPES (25mM) buffered HBSS, followed by the addition of 50-150µg/mL 
of Fan-MSNP, Curc-MSNP and Chry-MSNP dispersed in maintenance media for 40 hours with 
images captured within a defined window within each well every 15 minutes using live-cell 
imaging and presented as images. 
3.3.16. In-vitro drug release studies 
To assess the in-vitro release of curcumin and chrysin from MSNPs, studies were 
performed in PBS (154mM pH 7.4) containing 0.1% Tween 80.  Phytochemical loaded MSNP, 
2mg, were dispersed into 2mL of release medium, briefly sonicated and placed in a shaking 
incubator maintained at 37˚C and 100rpm. Samples were withdrawn at set time intervals and 
the volume replaced with an equal volume of pre-warmed release medium. The release of 
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phytochemicals was assessed through HPLC-UV methods. Throughout the release studies 
Tween 80 was used to maintain sink conditions and also to dissolve curcumin in the release 
medium (Yallapu et al., 2010). The results were calculated in terms of cumulative release 
(%w/w) relative to actual entrapped weight of curcumin or chrysin in the MSNPs.  To assess 
the impact of pH on drug release, release studies were also conducted at pH 5.5 (average 
nasal pH). 
3.3.17. Incorporation of Fan-MSNP into thermoresponsive nasal gel systems 
In an attempt to ascertain whether the thermoresponsive nasal gel systems can act as 
viable bulk carriers for MSNP, final optimised formulations: FCMC, FCS and FPEG (Chapter 
2), were formulated with the replacement of AMT with Fan-MSNP at concentrations of 0.2, 0.4 
and 1% w/v.  Rheological assessments of the gelation trend and temperature stability were 
conducted as described in section 2.3.3. 
3.3.18. Statistical analysis 
Unless otherwise stated, three independent experiments were carried out for each study. 
Statistical significance was evaluated by one-way ANOVA or paired two-tail Students t-test 
using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California 
USA, www.graphpad.com). Unless otherwise stated, data is reported as mean ± standard 
deviation (SD). A significance level (P-value) of < 0.05 was considered as statistically 
significant. 
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3.4. Results 
3.4.1. Fluorescent bead uptake 
The cellular uptake of nano-sized fluorescent latex beads (100nm and 500nm) was 
assessed using confocal microscopy to determine the optimal cut-off for MSNP size. For 
100nm sized latex beads the cellular localisation of the beads is evident, particularly in the 
membrane regions and cytoplasm (Figure 3-1). For the 500nm sized latex beads a x63 
magnification was used to enlarge isolated OBGF400 cells with membrane localisation and 
partial cytoplasmic trapping observed (Figure 3-1). 
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Figure 3-1: Cellular uptake of fluorescent latex beads in OBGF400 
A concentration of 0.1% v/v of latex beads (100nm and 500nm) were dispersed into HEPES (25mM) buffered HBSS prior to the addition into wells containing OBGF400 cells 
grown on collagen coated coverslips.  Beads were incubated for 2 hours before the coverslip were washed, fixed and mounted onto coverslips with mounting media.  Confocal 
microscopy was used to visualize the cellular localisation of beads with a 40x (100nm) or 63x (500nm) oil immersion objective. All images were acquired using an argon laser at 
494 nm to visualise the beads and a helium laser to visualise DAPI at 461nm. 
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3.4.2. Synthesis and characterisation of MSNP 
To develop MSNP, three reported methods were utilised to identify an appropriate method 
leading to optimal nanoparticles of less than 500nm. The three approaches differed primarily 
in the method of template removal. The assessment of final MSNP size for each method 
employed identified the ‘Fan-method’ as resulting the smallest nanoparticle size with a narrow 
PDI and stable negative zeta potential (Table 3-1).   
Table 3-1: Particle size and zeta-potential of different MSNPs 
Method 
Particle size 
(nm) 
Zeta potential (ζ) 
(mV) 
PDI 
 
Gul-MSNP 275 ± 8.1 -20 ± 0.98 0.23 ± 0.08 
 
Pro-2-MSNP 
 
465 ± 10 -18.25 ± 1.18 0.25 ± 0.1 
 
Fan-MSNP 
 
216.5 ± 2.1 
 
-23.9 ± 0.4 
 
0.13 ± 0.02 
 
Data is presented as mean ± SD; n=3 and from 3 separate batches. 
 
3.4.2.1.  Scanning electron microscopy based assessment of the morphology of 
MSNP  
To confirm the particle size and polydispersity of the formulated MSNP, SEM imaging was 
used to assess the morphological structure of MSNP produced from each method. 
Gul-MSNP: the nanoparticles developed from the ‘Gul-method’ demonstrate some uniform 
spherical porous morphologies (Figure 3-2A), however the irregularity in spherical structures 
was evident (Figure 3-2B).  Furthermore, the application of sonication to enhance dispersion 
and reduce PDI, resulted in the disruption/damage of the mesoporous nature of the silica 
spheres (Figure 3-21C and D). 
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Figure 3-2: Scanning electron micrograph of Gul-MSNP 
 (A) Base magnification of 25000x with yellow box highlighting region of interest (ROI); (B) 150000x magnification 
of ROI from (A); (C) Region of interest at magnification of 80000x with ruptured MSNP indicated by the yellow arrow 
and individual MSNP ROI highlighted; (D) 150000x magnification of ROI from (C). Samples were mounted on 12mm 
aluminium pin stubs with 12mm carbon tabs and coated with 15nm of gold. The powders were imaged at 5kV with 
a 150pA beam in high vacuum due to beam damage to the samples at higher kV’s. The nano-particles were imaged 
at 10kV with a 100pA beam also in high vacuum. The SEM used was Carl Zeiss EVO LS 15. The gold coater used 
was a Quorum QR105S. 
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Pro-2-MSNP: the nanoparticles developed from the ‘Pro-2-method’ demonstrated relatively 
uniform smooth particles with ordered mesoporous morphologies (Figure 3-3), however the 
irregularity in spherical structures was evident (Figure 3-3B).  The starburst nature of the 
morphology is also evident, extending from the centre of the nanoparticle to the surface.  
 
Figure 3-3: Scanning electron micrograph of Pro 2 MSNP 
 (A) Base magnification of 15000x with yellow box highlighting region of interest (ROI); (B) 50000x magnification of 
ROI from (A) with a further ROI highlighted; (C) 80000x magnification of ROI from (C) with new region of interested 
highlighted by the yellow square; (D) 200000x magnification of ROI highlighted from (C)..The samples were 
mounted on 12mm aluminium pin stubs with 12mm carbon tabs and coated with 15nm of gold. The powders were 
imaged at 5kV with a 150pA beam in high vacuum due to beam damage to the samples at higher kV’s. The nano-
particles were imaged at 10kV with a 100pA beam also in high vacuum. The SEM used was Carl Zeiss EVO LS 15. 
The gold coater used was a Quorum QR105S. 
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Fan-MSNPs: the nanoparticles developed from the ‘Fan-method’ demonstrated significantly 
more uniform particle distribution of similar sizes and relatively uniform smooth particles with 
(Figure 3-4) and particle sizes of approximately 200nm. (Figure 3-4C), confirming the suitability 
of the ‘Fan-method’ to develop MSNP. 
 
 
Figure 3-4: Scanning electron micrograph of Fan-MSNP 
 (A) Region of interest (ROI); (B) Magnification of ROI from (A); (C) 60000x magnification of ROI from (B); (D) 5000x 
magnification of detection grid. The samples were mounted on 12mm aluminium pin stubs with 12mm carbon tabs 
and coated with 15nm of gold. The powders were imaged at 5kV with a 150pA beam in high vacuum due to beam 
damage to the samples at higher kV’s. The nano-particles were imaged at 10kV with a 100pA beam also in high 
vacuum. The SEM used was Carl Zeiss EVO LS 15. The gold coater used was a Quorum QR105S. 
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3.4.2.2. Surface porosity of MSNP using nitrogen adsorption-desorption studies 
To determine the porosity of the Fan-MSNP and ascertain the pore volume and density, 
nitrogen adsorption/desorption isotherms were generated.  The isotherm generated contains 
a distinct hysteresis phenomenon which occurs due to capillary condensation at a relative 
pressure (P/P0) in the range of 0.2-0.4 and confirms the mesoporous nature of the particles 
(Table 3-2 and Figure 3-5).  
Furthermore, this data confirms the honey comb structure of Fan-MSNP with a large surface 
area 987.67 ± 3.38 m2/g and the DFT method confirms that the average pore size of 1.93 ± 
0.01nm (Figure 3-6 and 3-7) with total pore volume 0.95 ± 0.004 cc/g (Table 3-2). 
 
Table 3-2: Nitrogen adsorption desorption data for Fan-MSNP 
Batch 1 2 3 Mean (± SD) 
     
Specific surface 
area (m2/g) 988.76 990.38 983.88 987.67 ± 3.38 
Average pore size 
(nm) 1.93 1.94 1.93 1.93 ± 0.01 
Total pore volume 
(cc/g) 0.95 0.96 0.95 0.95 ± 0.004 
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Figure 3-5: Nitrogen adsorption/desorption isotherms of Fan-MSNP. 
STP: standard temperature and pressure. 
 
Figure 3-6: BJH pore radius distribution of Fan-MSNP.      
The Barrett Joyner-Halenda pore sizes (Å: Ang) were calculated based on assessment of the cumulative pore 
volume (y-axis) (red line) with the region corresponding to a pore diameter of 1-4nm indicated by the shaded box. 
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Figure 3-7: BJH pore width distribution of Fan-MSNP. 
The pore width (nm) were calculated based on assessment of the cumulative pore volume.  
 
3.4.2.3.  FTIR assessment of MSNP 
The mesoporous nature of the particles can also be confirmed by characteristic vibrational 
bands in the FTIR spectra (Wanyika et al., 2011). In Fan-MSNPs (Figure 3-8) bands at 795, 
960 and 1633cm-1 were due to SiO-H symmetrical stretching, Si-OH bending and SiO-H 
bending respectively. The strong band at 1057cm-1 is attributed to Si-O-Si stretching vibrations, 
whereas the broad band at 3421cm-1 is due to stretching vibration of the Si-OH group. 
 
 148
 
Figure 3-8: FT-IR spectra of Fan-MSNP. 
A samples (2mg) of dried Fan-MSNP was loaded onto the diamond detection grid the FT-IR spectrophotometer 
and the IR spectra determined over the spectral range of 550-4000cm-1 and reported as percentage transmittance 
(%T). 
 
 
 
 
 
Template removal from the mesoporous nanoparticles can be confirmed from the FTIR 
data (Figure 3-9) four peaks can be observed in 550, 1500, 2900 and 3000cm -1 before CTAB 
removal. These peaks were eliminated after refluxing with EtOH–HCl. 
 
57
9.
86
79
5.
09
96
0.
88
10
57
.
47
16
33
.
76
33
82
.
49
Fan_2_blank
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
%
T
 1000   1500   2000   2500   3000   3500   4000  
Wavenumbers (cm-1)
 149
 
Figure 3-9: FT-IR spectra of Fan-MSNP prior to CTAB removal (green) and immediately after CTAB removal 
(red). 
 
The spectra indicate that due to presence of CH, CH2 and CH3 groups in CTAB molecule 
structure, four peaks can be observed in 550, 1500, 2900 and 3000cm -1 before CTAB removal.  
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3.4.3. FITC loading of MSNPs for cellular uptake studies 
The loading of MSNP with FITC was confirmed through FT-IR approaches.  FITC was 
loaded passively into functionalised MSNPs by reacting amino group and isothiocynate (Fan 
et al., 2011). Loading of FITC dye can be confirmed by FT-IR, where a band the absorbed 
amide group was observed at 1550 and 1640cm -1 and a band at 1583cm-1 corresponding to 
benzene ring of FITC (Figure 3-10).  
 
Figure 3-10: FT-IR spectra of FITC-MSNP 
A sample (2mg) of dried FITC-MSNP was loaded onto the diamond detection grid the FT-IR spectrophotometer 
and the IR spectra determined over the spectral range of 550-4000cm-1 and reported as percentage transmittance 
(%T). 
 
3.4.4. FITC release from Fan-MSNP 
The loading of FITC into Fan-MSNP resulted in a % EE of 48 ± 2.3%.  The release of FITC 
was subsequently assessed in PBS (pH 7.4). Following a 2-hour incubation 4.8 ± 0.19% was 
released from FITC-Fan-MSNP (Figure 3-11). 
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Figure 3-11: Release of FITC from FITC-MSNP. 
150mg of MSNPs were reacted under an argon atmosphere with 1.75mg of FITC (0.009mmol) 5µl of triethylamine 
(TEA) and 10ml of anhydrous dimethylformamide (DMF). The mixture was stirred at room temperature for 24h 
followed by centrifuging and washing twice at 8000RPM for 8 mins with DMF, diethyl ether and methanol. To remove 
the remaining solvent from the FITC-MSN particles were subjected to heating at 60°C under vacuum.  The release 
was assessed in PBS (pH 7.4) and quantified using a SpectraMax fluorescent microplate reader at an λex: 490nm 
and λem: 517nm. N=3. 
3.4.5. Cellular uptake of FITC-Fan-MSNP 
FITC-Fan-MSNP were subsequently incubated for 2-hours with OBGF400 cells seeded onto 
collagen-coated coverslips and the cellular localisation of FITC-Fan-MSNP was determined 
using confocal microscopy and z-stack image processing.  Single stage confocal imaging 
demonstrated generalised cellular location, with the presence of FITC-Fan-MSNP within the 
cellular membrane and cytoplasm (Figure 3-12).  However, to further discern the exact 
localisation within the cell, a z-stack multistage image capture was initiated to capture FITC-
Fan-MSNP fluorescence through the z-dimension of the cell.
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Figure 3-12: Cellular localisation of FITC-MSNP 
50µg/mL FITC-MSNP were resuspended in HEPES (25mM) buffered HBSS prior to the addition into wells of a 12 well plate containing collagen coated OBGF400 coverslips.  
FITC-MSNP were incubated with coverslips for 2 hours before being thoroughly washed, and fixed with 4%w/v paraformaldehyde for 30 minutes in the dark.  The coverslips were 
then mounted onto glass slides with mounting media containing 4',6-diamidino-2-phenylindole (DAPI). The localisation of the latex beads was analysed using an upright confocal 
microscope (Leica SP5 TCS II MP) and visualised with a 40x oil immersion objective. All images were acquired using an argon laser at 494nm to visualise FITC and a helium 
laser to visualise DAPI at 461nm.  
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Figure 3-13: z-dimension cellular localisation of FITC-MSNP (stage 1) 
FITC-MSNP previously incubated with OBGF400 cells for 2 hours were further subjected to a z-stack analysis with 
the lens (CON) positioned above the cell layer (10763µm) and lowered through the cells to the bottom of the cell 
layer (10758.4µm).  Images were captured of FITC (green) and DAPI (blue) through the z-dimension. 
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Figure 3-14: z-dimension cellular localisation of FITC-MSNP (stage 2) 
FITC-MSNP previously incubated with OBGF400 cells for 2 hours were further subjected to a z-stack analysis with 
the lens positioned above the cell layer (10763µm) and lowered through the cells to the bottom of the cell layer 
(10758.4µm).  Images were captured of FITC (green) and DAPI (blue) through the z-dimension. 
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The confocal stage was set at the upper-most boundary of the OBGF400 cells and the stage 
moved down towards the coverslip with images captured over a z-dimension of approximately 
5µm. At the onset of the z-stack analysis, FITC-Fan-MSNP is localised on the exterior of the 
cell boundary and potentially on the surface of the cells (10763µm).  As the stage progresses, 
the localisation of FITC-Fan-MSNP increases with clear demarked zones of cytoplasmic 
localisation near the ‘mid-to-bottom’ regions of the cells (Figure 3-13 and 3-14). 
3.4.6. Phytochemical loading of Fan-MSNP 
The loading of curcumin into MSNP was confirmed through FT-IR analysis. The 
characteristic IR absorption frequencies in the spectral range of 550-4000cm-1 were measured 
for free curcumin and Curc-MSNPs. The interaction between MSNPs and curcumin after being 
loading was also analysed using FTIR. 
Curcumin spectra shows a sharp peak at 3507 and 3293cm-1 corresponding to –OH group 
vibrations without and with intermolecular hydrogen bonding respectively. However, in case of 
Curc-MSNPs instead of these two peaks only one new broad peak at 3430cm-1 was observed 
which confirms the intermolecular hydrogen bonding isolated silanol and enolic hydroxyl group. 
The peak at 1620cm−1 was observed due to stretching vibrations of C=O bond (Figure 3-15). 
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Figure 3-15: FTIR spectra of (A) Fan-MSNP; (B) and (C) Curc-MSNP 
10mg of curcumin or MSNP were placed on the diamond probe of a Thermo Scientific FT-IR spectrophotometer 
and the IR spectrum analysed over the spectral range of 550-4000cm-1 and reported as the percentage 
transmittance (%T). 
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To further characterise the loading of curcumin into Fan-MSNP, DSC thermographs were 
analysed for blank and loaded MSNP.  The thermograms of pure curcumin show characteristic 
single melting endothermic peak at 176°C (Figure 3- 16).  However, the DSC thermograms for 
Curc-MSNPs show no characteristic melting point for curcumin at 176°C.  
 
 
Figure 3-16: DSC thermograms of curcumin, Fan-MSNP and Curc-MSNP 
2-5mg of samples were weighed and placed on the sample pan with quantified determined over a heating range of 
30-250°C, at the rate of 10°C/min and under nitroge n purge of 50mL/min. 
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The TGA results show that the total weight loss of the Fan-MSNP at the end of the run was 
22.16 ± 1.12% compared to the blank MSNPs, 7.21 ± 0.45% with a calculated LC of 14.95 ± 
0.67% and which corresponds to the calculated EE of 12.34 ± 1.28% for the ‘wet method’ 
(Figure 3.17). 
 
Figure 3-17: TGA thermograms of curcumin, Fan-MSNP and Curc-MSNP. 
2-5mg of samples were weighed and placed on the sample pan with weight loss quantified determined over a 
heating range of 50-700°C, at the rate of 10°C/min and under nitrogen and air purge. 
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Curc-MSNP were further characterise for changes in particle size and zeta potential 
compared to blank MSNP.  The hydrodynamic mean diameter of Fan-MSNPs size increased 
from 216.8 ± 2.1nm to 263.51 ± 8.3nm after loading with curcumin (P ≤ 0.01) with a statistically 
significant increase in the PDI from 0.13 ± 0.02 to 0.26 ± 0.05 (P ≤ 0.05) (Figure 3-18).  
 
 
Figure 3-18: Fan-MSNP size and PDI before and after loading with curcumin 
100µL of 1mg/mL sonicated Fan-MSNP or Curc-MSNP suspensions were diluted in 3mL ultrapure water, vortexed 
and analysed through dynamic light scattering techniques using NanoBrook 90 Plus Zeta (Brookhaven Instruments 
Corporation) to assess the particles size (mean diameter) and polydispersity index (PDI). Statistical significance 
tested between unloaded and loaded MSNP. * P≤ 0.05, ** P≤ 0.01. 
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Following loaded with curcumin, the zeta potential of the Curc-MSNP decreased from -23.9 ± 
0.4mV to -16.9 ± 0.9mV (P ≤ 0.01) (Figure 3-19). 
 
Figure 3-19: Fan-MSNP zeta potential before and after loading of flavonoid curcumin 
100µL of 1mg/mL sonicated Fan-MSNP or Curc-MSNP suspensions were diluted in 3ml ultrapure water, vortexed 
and analysed through dynamic light scattering techniques using NanoBrook 90 Plus Zeta (Brookhaven Instruments 
Corporation) to assess the sample zeta potential. * P≤ 0.05, ** P≤ 0.01. 
 
 
The loading of chrysin into Fan-MSNP was confirmed using FT-IR analysis. The 
characteristic IR absorption frequencies in the spectral range of 550-4000cm-1 were measured 
for free chrysin and Chry-MSNP. the FT-IR spectrum of chrysin, shows the carbonyl group 
vibrations coupled with the double band in the γ-benzopyrone ring at 1655cm-1 and absorption 
bands at 1612, 1577 and 1450cm-1 related to carbon vibration in benzene and γ-pyrone rings 
(valance vibrations C=C) can be observed in Figure 3-20.  
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Figure 3-20: FTIR spectra of chrysin, blank MSNPs and Chry-MSNPs 
Samples were analysed using Thermo Scientific FT-IR spectrophotometer in the spectral range of: (A) 1800-
4000cm-1 and (B) 550-1850nm for chryin (blue), Fan-MSNP (red) and Curc-MSNP (purple). 
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To further characterise the loading of chrysin into Fan-MSNP, DSC thermographs were 
analysed for blank and loaded MSNP.  The thermograms of pure chrysin show characteristic 
melting point depression at 286°C (Figure 3-21). Ho wever, the DSC thermograms for Curc-
MSNP show no characteristic melting point for chrysin at 286°C. 
 
 
Figure 3-21: DSC thermograms of chrysin, Fan-MSNP and Chry-MSNP 
2-5mg of samples were weighed and placed on the sample pan with the weight loss quantified determined over a 
heating range of 30-250°C, at the rate of 10°C/min and under nitrogen purge of 50mL/min. 
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The TGA results show that the total weight loss of the Fan-MSNP at the end of the run was 
21.07 ± 0.75% compared to the blank MSNPs, 9.58 ± 1.94% with a calculated LC of 11.49 ± 
1.19% and which corresponds to the calculated EE of 12.34 ± 1.28% for the ‘wet method’ 
(Figure 3-22). 
 
Figure 3-22: TGA thermograms of chrysin, Fan-MSNP and Chry-MSNP. 
2-5 mg of samples were weighed and placed on the sample pan with weight loss quantified determined over a 
heating range of 50-700°C, at the rate of 10°C/min and under nitrogen and air purge. 
 
Chry-MSNP were further characterised for changes in particle size and zeta potential 
compared to blank MSNP.  The hydrodynamic mean diameter of Fan-MSNPs size increased 
from 216.8 ± 2.1nm to 283.5 ± 8.3nm after loading with chrysin (P ≤ 0.01) with a statistically 
significant increase in the PDI from 0.13 ± 0.02 to 0.31 ± 0.11 (P ≤ 0.05) (Figure 3-23).  
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Figure 3-23: Fan-MSNP size and PDI before and after loading with chrysin 
100µL of 1mg/mL sonicated Fan-MSNP or Chry-MSNP suspensions were diluted in 3ml ultrapure water, vortexed 
and analysed through dynamic light scattering techniques using NanoBrook 90 Plus Zeta (Brookhaven Instruments 
Corporation) to assess the particles size (mean diameter) and polydispersity index (PDI). Statistical significance 
tested between unloaded and loaded MSNP. * P≤ 0.05, ** P≤ 0.01. 
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Furthermore, the zeta potential of the Chry-MSNP decreased -23.9 ± 0.4mV to -30.8 ± 
0.3mV (P ≤ 0.01) (Figure 3-24). 
 
 
Figure 3-24: Zeta potential before and after loading of flavonoid chrysin 
100µL of 1mg/ml sonicated MSNPs suspension was diluted in 1.5ml ultrapure water, vortexed and used to measure 
the zeta potential. The mean diameter and PDI was obtained from 3 runs of 3 minutes by dynamic light scattering 
technique using NanoBrook 90 Plus Zeta (Brookhaven Instruments Corporation). ** P ≤ 0.01. 
 
3.4.7. HPLC-UV detection of curcumin  
The HPLC-UV method was developed and successfully validated to detect curcumin with 
a retention time of 13.3 minutes for the majority constituent peak with minor peaks at 11.09 
and 12.15 minutes for the minor constituents of curcumin (Figure 3-25).  System precision and 
method precision demonstrated RSD within acceptable limits of 1% and 2% respectively, 
indicating an acceptable level of precision of the analytical system. 
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Figure 3-25: HPLC chromatogram of curcumin 
Curcumin was detected using an Agilent 1200 Series (Waldbronn, Germany) equipped with a multiple wavelength 
detector (VWD) and a Phenomenex Luna C18 (150 × 4.6mm) 5µm column was used for RP-HPLC. Mobile phase 
was made up of ACN:5% acetic acid in a ratio of 45:55 (v/v). Mobile phases were filtered through 0.45µm filter and 
sonicated before use. The flow rate was maintained at 0.8ml/min with 15 minutes run time and the injection volume 
was 20µL while column temperature was kept at ambient with a UV-detection wavelength of 420nm. 
 
System precision: six replicate injections of an identical standard curcumin stock solution 
were injected into the HPLC and peak area calculated. The relative standard deviation (%RSD) 
for the six samples was not more than 1.0% indicating system precision is within acceptable 
limits as measured per individual run, each with its own identical standard curcumin stock 
solution, with an overall RSD of 0.54% (Table 3-3). The LOD was 2.1µg/mL, LOQ was 
7.1µg/mL and the signal to noise ratio was >10. 
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Table 3-3: System precision assessment for curcumin HPLC-UV detection 
Injection no. Area counts (µV sec)   
  Run 1 Run 2 Run 3 Mean 
1 2546 2495 2415  
2 2562 2518 2447  
3 2542 2491 2451  
4 2532 2481 2454  
5 2544 2493 2465  
6 2545 2494 2467  
     
Mean 2545.17 2495.47 2449.83 2496.82 
SD 9.68 12.11 18.79 13.52 
     
RSD (%) 0.38 0.49 0.77 0.54 
 
System precision was assessed through 6 injection of the same curcumin stock solution for each independent runs 
(3 runs in total).  Mean and SD reported with percentage root-square deviation. 
 
 
Method precision: six preparations of the same batch of samples were analysed for method 
precision with a resultant %RSD of less than 2.0% (Table 3-4) for all samples demonstrating 
method precision is within acceptable limits with an overall %RSD of 1.08%. 
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Table 3-4: Method precision assessment for curcumin 
Injection no. Assay (% w/w) 
  
  Run 1 Run 2 Run 3  
1 99.08 98.09 101.81  
2 98.49 99.75 101.20  
3 99.23 100.49 101.00  
4 97.51 101.47 100.20  
5 99.24 97.69 99.59  
6 99.87 97.60 101.30  
     
Mean 98.90 99.18 100.85 99.64 
SD 0.81206281 1.62413 0.80999 1.08 
     
RSD (%) 0.82106994 1.63754 0.80316 1.08 
 
Linearity of response: the linearity of precision for curcumin was determined over a 
concentration range of 78 -10000µg/mL.  A proportional response was evident versus the 
analytical concentration over the working concentration range with a r2 of 0.998 and linear 
equation of Q = 700.3 ± 0.82	 ∙ V (Figure 3-26). 
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Figure 3-26: Linearity plot for curcumin 
A HPLC-UV method was developed to assess the linearity of detection over a concentration range of 78 -
10000µg/mL. Data represents mean (solid line) ± SD (error bars). n=3.  
 
3.4.8. HPLC-UV detection of chrysin  
The HPLC-UV method was developed and validated used to detect chrysin with a retention 
time of 11.78 minutes (Figure 3-27).  System precision and method precision demonstrated 
RSD within acceptable limits of 1% and 2% respectively, indicating an acceptable level of 
precision of the analytical system. 
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Figure 3-27: Chrysin HPLC chromatogram 
Chrysin was detected using a Phenomenex Luna C18 (150 × 4.6mm) 5µm column through RP-HPLC. The mobile 
phase consisted of water:methanol:acetonitrile:phosphoric acid in a ratio of 60:30:38:1(v/v). Mobile phases were 
filtered through 0.45µM filter and sonicated prior to use. The flow rate was maintained at 1.0mlmin−1 with an injection 
volume of 10µL. The UV detection of chrysin was measured at 262nm. 
 
System precision: six replicate injections of an identical standard chrysin stock solution were 
injected into the HPLC and peak area calculated. The relative standard deviation (%RSD) for 
the six samples was not more than 1.0% indicating system precision is within acceptable limits 
as measured per individual run, each with its own identical standard chrysin stock solution, 
with an overall RSD of 0.27% (Table 3-5). 
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Table 3-5: System precision assessment for chrysin HPLC-UV detection 
Injection no. Area counts (µV sec) 
  Run 1 Run 2 Run 3 Mean 
1 843 854 849  
2 842 855 851  
3 841 851 848  
4 843 850 852  
5 844 857 850  
6 842 855 843  
     
Mean 842.50 853.67 848.83 848.33 
SD 1.05 2.66 3.19 2.29 
     
RSD (%) 0.12 0.31 0.38 0.27 
 
System precision was assessed through 6 injections of the same chrysin stock solution for each independent runs 
(3 runs in total).  Mean and SD reported with percentage root-square deviation 
 
Method precision: six preparations of the same batch of samples were analysed for method 
precision with a %RSD of less than 2.0% (Table 3-6) for all samples demonstrating method 
precision is within acceptable limits with an overall %RSD of 1.79%. 
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Table 3-6: Method precision assessment for chrysin 
Injection 
no. 
Assay (% w/w) 
  
  Run 1 Run 2 Run 3 Mean 
1 102.12 98.19 102.12  
2 99.87 99.65 101.48  
3 98.99 102.36 100.56  
4 98.17 97.25 99.65  
5 97.69 98.11 98.57  
6 101.23 98.67 97.25  
     
Mean 99.67833333 99.0383 99.9383 99.55 
SD 1.738302812 1.80681 1.82787 1.79 
     
RSD (%) 1.743912397 1.82436 1.82899 1.79 
 
Linearity of response: the linearity of precision for chrysin was determined over a 
concentration range of 78 -10000µg/mL.  A proportional response was evident versus the 
analytical concentration over the working concentration range with a r2 of 0.998 and linear 
equation of  Q = 3220.3 ± 1.35	 ∙ V (Figure 3-28). 
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Figure 3-28: Linearity plot for chrysin 
A HPLC-UV method was developed to assess the linearity of detection over a concentration range of 78 -
25000µg/mL. Data represents mean (solid line) ± SD (error bars). n=3.  
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3.4.9. Cytotoxicity study 
To investigate the toxicity of MSNP, curcumin and chrysin towards OBGF400 cells a cell 
viability assay was conducted with phytochemicals/MSNP exposed to OBGF400 for 24 hours.  
For Fan-MSNP, cell viability was generally maintained across the concentration range of 10-
100µg/mL (Figure 3-29), with a statistically significant (P≤ 0.01) decrease in viability from 
100µg/mL onwards. 
 
Figure 3-29: Cellular toxicity of Fan-MSNPs on OBGF400 cells. 
Cells were grown on a 96-well plate at a density of 10 x103 cells per well and exposed to various concentrations of 
Fan-MSNP (10 – 1000µg/mL). After 24 hour incubation 100 µL MTT in PBS (0.5mg/mL) added to each well & 
incubated for 4 hours. The MTT-formazan produced was solubilised in DMSO and quantified colorimetrically using 
a UV-spectrophotometer at 570nm.  The control cell (without drug) corresponded to a cell viability of 100%. Data is 
reported as mean ±SD with up to 8 replicates per compound in at least 3 independent experiment. ** P ≤ 0.01. 
 
For curcumin (Figure 3-30) and chrysin (Figure 3-31), cell viability was maintained across the 
concentration range of 0.001-10µM and an IC50 of 33 ± 0.18µM was determined for curcumin.  
For chrysin at 100µM, a statistically significant (P ≤ 0.01) decrease in cell viability was observed 
(58.2 ± 8.5%) 
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Figure 3-30: Cellular toxicity of curcumin on OBGF400 cells 
Cells were grown on a 96-well plate at a density of 10 x103 cells per well and exposed to various concentrations of 
curcumin (10 – 1000µg/mL). After 24 hour incubation 100µL MTT in PBS (0.5mg/mL) added to each well & 
incubated for 4 hours. The MTT-formazan produced was solubilised in DMSO and quantified colorimetrically using 
a UV-spectrophotometer at 570nm.  The control cell (without drug) corresponded to a cell viability of 100%. Data is 
reported as mean ±SD with up to 8 replicates per compound in at least 3 independent experiment. 
 
Figure 3-31: Cellular toxicity of chrysin on OBGF400 cells. 
Cells were grown on a 96-well plate at a density of 5 x103 cells per well and exposed to various concentrations of 
chrysin (10 – 1000µg/mL). After 24 hour incubation 100 µL MTT in PBS (0.5mg/mL) added to each well & incubated 
for 4 hours. The MTT-formazan produced was solubilised in DMSO and quantified colorimetrically using a UV-
spectrophotometer at 570nm.  The control cell (without drug) corresponded to a cell viability of 100%. Data is 
reported as mean ±SD with up to 8 replicates per compound in at least 3 independent experiment. ** P ≤ 0.01. 
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3.4.10. Cellular toxicity of MSNP: live-cell time-lapse phase-contrast microscopy 
To assess the morphological alteration of cellular structures when exposed to Fan-
MSNP, Curc-MSNP and Chry-MSNP, a gas and humidity controlled phase contrast imaging 
study was conducted using the CellIQ® imaging system.  OBGF400 cells, grown in wells of a 
6-well plates, were exposed to 50-150µg/mL of Fan-MSNP, Curc-MSNP and Chry-MSNP for 
40 hours with images captures within a defined window within each well every 15 minutes 
using live-cell imaging. 
The impact of Fan-MSNP on cell viability/proliferation at 150µL/mL demonstrate a clear impact 
on the viability and proliferation of OBGF400 over 40 hours resulting in a reduction in the cell 
morphological volume and cell death. This effect was diminished at a concentration of 
50µg/mL, where cell morphology was maintained throughout the incubation period (Figure 3-
32) 
With Chry-MSNP, a similar impact on cell viability was noted at 150µg/mL. However, at 
50µg/mL cell morphology was seen to change associated with the apoptosis of some cells 
(Figure 3-33). For Curc-MSNP, cell morphology was noted to alter at 150µg/mL leading to an 
increase in cell death over time, however at 50µg/mL cell viability was not affected and 
proliferation of cells was noted (Figure 3-34). 
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Figure 3-32: Cell-IQ live cell imaging of OBGF400 cells (top) and Fan-MSNP at 150µg/mL (middle) and 50µg/mL (bottom). 
OBGF400 cells were seeded at a density of 5x104 cells/well in a 6-well plates.  Following the addition of Fan-MSNP or flavonoids loaded MSNP, the lens was positioned within 
fixed regions of interest within each well and images taken every 15 minutes over 40 hours, with the plate maintained in a 5% CO2 and 37°C controlled environment. Regions of 
interests depicted changes in cell morphology are illustrated by the yellow boxes. 
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Figure 3-33: Cell-IQ live cell imaging of OBGF400 cells (top) and Chry-MSNP at 150µg/mL (middle) and 50µg/mL (bottom). 
OBGF400 cells were seeded at a density of 5x104 cells/well in a 6-well plates.  Following the addition of Fan-MSNP or flavonoids loaded MSNP, the lens was positioned within 
fixed regions of interest within each well and images taken every 15 minutes over 40 hours, with the plate maintained in a 5% CO2 and 37°C controlled environment. Regions of 
interests depicted changes in cell morphology are illustrated by the yellow boxes. 
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Figure 3-34: Cell-IQ live cell imaging of OBGF400 cells (top), Curc-MSNP at 150µg/mL (middle) and 50µg/mL (bottom). 
OBGF400 cells were seeded at a density of 5x104 cells/well in a 6-well plates.  Following the addition of Fan-MSNP or flavonoids loaded MSNP, the lens was positioned within 
fixed regions of interest within each well and images taken every 15 minutes over 40 hours, with the plate maintained in a 5% CO2 and 37°C controlled environment. Regions of 
interests depicted changes in cell morphology are illustrated by the yellow boxes. 
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3.4.11. Drug release study from the mesoporous silica nanoparticles 
The release of curcumin from Curc-MSNP was assessed over 24 hours and demonstrated 
a pH sensitive release phenomena. A burst effect was also evident after 1 hour with 12% and 
16.6% released at pH 7.4 and pH 5.5 respectively (Figure 3-35).   Release at pH 7.4 was 
slower than that at pH 5.5, with 16.1 ± 1.6% released at 24 hours (P ≤ 0.001).  At pH 5.5 
release increased over 24 hours to 53.2% ± 2.2% (P ≤ 0.001).  However, no significant 
increase in curcumin release was observed from 1 hour to 24 hours. 
 
Figure 3-35: Cumulative percentage release of curcumin from Curc-MSNP. 
The in vitro release of curcumin was performed in 154mM PBS pH 7.4 and pH 5.5 containing 0.1% Tween 80. 
1mg/mL of Curc-MSNP were dispersed into 2ml of release medium, briefly sonicated and placed in a shaking 
incubator maintained at 37˚C and 100 rpm. Samples were withdrawn at set time intervals and the volume replaced 
with an equal volume of pre-warmed release medium. Release was assessed through HPLC-UV methods. N=3.  # 
# # indicates statistical comparison between the final time point (24 hours) and the first time point for (1 hour) for 
pH 5.5 with a P ≤ 0.001. *** indicates statistical comparison between the final time point (24 hours) between pH 5.5 
and 7.4 with a P ≤ 0.001 
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The release of chrysin from Chry-MSNP was assessed over 24 hours and also 
demonstrated a pH sensitive release phenomena. A burst effect was evident after 1 hour with 
3.2 ± 1.2% and 7.1 ± 1.6% released at pH 7.4 and pH 5.5 respectively (Figure 3-36).   Release 
at pH 5.5 was slower than that for pH 7.4 (P ≤ 0.001), with 9.4 ± 0.6% and 16.8 ± 0.8% at 24 
hours respectively. However statistically significant differences (P ≤ 0.001) were also observed 
between 1 hour and 24 hours release at each pH studied. 
 
Figure 3-36: Cumulative percentage release of chrysin from Chry-MSNP 
The in vitro release of chrysin was performed in 154mM PBS pH 7.4 and pH 5.5 containing 0.1% Tween 80. 1mg/mL 
of Chry-MSNP were dispersed into 2ml of release medium, briefly sonicated and placed in a shaking incubator 
maintained at 37˚C and 100 rpm. Samples were withdrawn at set time intervals and the volume replaced with an 
equal volume of pre-warmed release medium. Release was assessed through HPLC-UV methods. N=3.  # # # 
indicates statistical comparison between the final time point (24 hours) and the first time point for (1 hour) for pH 
5.5 and pH 7.4 with a P ≤ 0.001. *** indicates statistical comparison between the final time point (24 hours) between 
pH 5.5 and 7.4 with a P ≤ 0.001 
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3.4.12. Incorporation of Fan-MSNP into thermoresponsive nasal gel 
In order to deliver Fan-MSNP, a carrier systems was required to contain Fan-MSNP and 
to allow delivery at the olfactory mucosa.  Thermoresponsive nasal gels described in Chapter 
2 were adapted by the direct replacement of AMT with 0.2%, 0.4% and 1% w/w Fan-MSNP.   
All formulations demonstrated a tri-region gelation phenomenon, preceded by a stable plateau 
region and culminating in a stable gel formulation (Figure 3-37 to 3-39).  Furthermore, a general 
trend of a decrease in the initiation temperature of gelation with increasing Fan-MSP (0.2%, 
0.4% and 1% w/w) was noted: MSNP-FCMS: 25.8 ± 0.05°C, 22.1 ± 0 .08°C and 21.7 ± 0.03°C; 
MSNP-FCS: 25.4 ± 0.07°C, 25.1 ± 0.08°C and 20.1 ± 0 .09°C); MSNP-FPEG: 25.4 ± 0.07°C, 
25.1 ± 0.08°C and 20.1 ± 0.09°C.   
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Figure 3-37: Temperature sweep of FCMC following incorporation of Fan-MSNP 
Rheological analysis of FCMC following the incorporate of Fan-MSNP at a concentration of (A) 0.2% w/w; (B) 0.4% 
w/w and (C) 1% w/w.  Fan-MSNP were used in place of AMT.  Temperature sweep analysis was conducted using 
parallel plate geometry with 40mM steel plates having a gap 1.0mM. The approximate sample volume used was 
1.26ml and the instrument was used in the oscillatory mode in the linear viscoelastic range. Data represents mean 
± SD. N=3 
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Figure 3-38: Temperature sweep of FCS following Incorporation of Fan-MSNP. 
Rheological analysis of FCS  following the incorporate of Fan-MSNP at a concentration of (A) 0.2% w/w; (B) 0.4% 
w/w and (C) 1% w/w.  Fan-MSNP were used in place of AMT.  Temperature sweep analysis was conducted using 
parallel plate geometry with 40mM steel plates having a gap 1.0mM. The approximate sample volume used was 
1.26ml and the instrument was used in the oscillatory mode in the linear viscoelastic range. Data represents mean 
± SD. N=3 
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Figure 3-39: Temperature sweep of FPEG following Incorporation of Fan-MSNP  
Rheological analysis of FPEG following the incorporate of Fan-MSNP at a concentration of (A) 0.2% w/w; (B) 0.4% 
w/w and (C) 1% w/w.  Fan-MSNP were used in place of AMT.  Temperature sweep analysis was conducted using 
parallel plate geometry with 40mM steel plates having a gap 1.0mM. The approximate sample volume used was 
1.26ml and the instrument was used in the oscillatory mode in the linear viscoelastic range. Data represents mean 
± SD. N=3 
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To confirm gelation, the sheer thinning behavior of the gel was assessed at ambient and 
nasal cavity temperatures.  Sheer thinning behavior for all Fan-MSNP gel systems was noted 
with significant differences (P < 0.0001) when comparing ambient temperatures to 34°C across 
all Fan-MSNP loaded.  A significant difference (P < 0.05) in sheer thinning behavior was noted 
at 1% w/w at ambient and 34°C compared to 0.2 and 0.4 % w/w Fan-MSNP. (Figure 3-40). 
For Fan-MSNP incorporated into FCS (Figure 3-41) and FPEG (Figure 3-42), similar 
observations were noted as for FCMS, however at 34°C no significant differences were noted 
between the Fan-MSNP concentrations.  
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Figure 3-40: Steady shear behaviour of FCMC incorporating Fan-MSNP. 
Rheological shear viscosity analysis of the FCMC at: (A) ambient (18°C) and (B) nasal cavity (34°C) temp eratures 
was assessed using parallel plate geometry with 40mM steel plates having a gap 1.0mM. Concentration of 0.2, 0.4 
and 1% w/w was used in formulations. The approximate sample volume used was 1.26ml and the instrument was 
used in the oscillatory mode in the linear viscoelastic range. Data represents mean ± SD. n=4  
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Figure 3-41: Steady shear behaviour of FCS incorporating Fan-MSNP. 
Rheological shear viscosity analysis of the FCS at: (A) ambient (18°C) and (B) nasal cavity (34°C) temper atures 
was assessed using parallel plate geometry with 40mM steel plates having a gap 1.0mM. Concentration of 0.2, 0.4 
and 1% w/w was used in formulations. The approximate sample volume used was 1.26ml and the instrument was 
used in the oscillatory mode in the linear viscoelastic range. Data represents mean ± SD. n=4  
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Figure 3-42: Steady shear behaviour of FPEG incorporating of Fan-MSNP. 
Rheological shear viscosity analysis of the FPEG at: (A) ambient (18°C) and (B) nasal cavity (34°C) temper atures 
was assessed using parallel plate geometry with 40mM steel plates having a gap 1.0mM. Concentration of 0.2, 0.4 
and 1% w/w was used in formulations. The approximate sample volume used was 1.26ml and the instrument was 
used in the oscillatory mode in the linear viscoelastic range. Data represents mean ± SD. n=4  
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3.5. Discussion 
Age related neurological disorders such as Parkinson’s disease (PD) and Alzheimer’s 
disease (AD), are insidious progressive neurological disorders which affects over 1.5% of the 
population over 65-years of age (Foltynie et al., 2004).  Current approaches to CNS drug 
delivery are often hampered by poor targeting and drug delivery to the BBB.  Furthermore, the 
solubility of the drug may limit its formulation scope and impact upon the systemic 
bioavailability which drives CNS concentrations. 
An alternative approach to the delivery of drugs to the brain and wider CNS often focus on 
solubility improvements and enhancements in targeted delivery. For drugs that are 
systemically administered, nanoparticles are widely employed as carrier delivery systems to 
improve the solubility and, following surface modification, targeting vehicles which are capable 
of targeting the CNS.  Of the wide variety of NP systems that have been employed for CNS 
targeting, a recently developed mesoporous material based on silica has gained interested 
due to its tuneable particle radius and porosity.   
In Chapter 2 we discussed approaches to the formulation of a water-soluble drug.  Chapter 
3 moves forwards to address the approaches required to formulate and deliver poorly soluble 
compounds through the development and use of mesoporous silica nanoparticles.                    
For the purposes of selection of an appropriate compound, the phytochemicals chrysin and 
curcumin were selected based on their ability to modulate a range of CNS pharmacological 
targets and reported beneficial effects to CNS development/repair in part, due to their anti-
oxidant properties.  Furthermore, both are relatively poorly soluble and present as model 
candidates for poorly soluble APIs with the potential for significant clinical benefits if targeted 
and delivered to the CNS. 
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MSNP were utilised as a delivery vehicle within which chrysin and curcumin were entrapped, 
characterised and finally assessed for minimal cytotoxicity effects and intracellular uptake in 
the porcine olfactory bulb cell line OBGF400. MSNP are ideal drug delivery candidates and 
contain pore sizes ranging from 2-50nm and was first identified as MCM-41 superfamily or 
orders mesoporous silica materials(Kresge et al., 1992a). Furthermore, MSN are synthesised 
through a temple-directed approach in the presence of a supramolecular surfactant that acts 
as a template to direct the structure the mesoporous nature of the material (Kresge et al., 
1992a, Cai et al., 1999). The advantages of MSN are that they offer a large surface area/pore 
volume for drug loading within pore channels (Hu et al., 2011, Vallet-Regi et al., 2001) 
alongside the opportunity to adjust the pore size (Sun et al., 2013, Hu et al., 2012). Furthermore 
they possess limited toxicity profiles (Zhang et al., 2012, Hudson et al., 2008) and offer the 
opportunity to be used in bioimaging processes (Kim et al., 2008, Wu et al., 2011). 
3.5.1. Target MSNP size range for olfactory uptake 
A target goal for our studies are to demonstrate uptake of MSNP into olfactory bulb 
neuronal cells.  To assess this process fluorescent latex beads of 100nm and 500nm size 
ranges were selected to allow cellular imaging of the intracellular localisation of beads, 
providing some insight into appropriate size ranges for viable cellular uptake.   
100nm latex beads provided a broader and more uniform uptake into OBGF400 cells (Figure 
3-1) when compared to 500nm latex beads.  However, cellular uptake of both sizes of beads 
were detected using confocal microscopy and suggest MNSP formulation over this size range 
would be appropriate for olfactory uptake.   
Although the use of fluorescent latex beads as retrograde transport markers for neuronal 
pathways is not new (Katz et al., 1984, Persson and Gatzinsky, 1993, Katz and Iarovici, 1990), 
the application to olfactory bulb neuronal cells is novel and indicates the potential for nano-
sized material to penetrate into this class of cells. 
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3.5.2. Formulation of MSNP  
Having determined the optimal size range for olfactory neuronal cell uptake (100-500nm), 
MSNP were formulated according to the methods described by Fan et al (Fan et al., 2011), 
(Gulfam and Chung, 2014) and by (Nooney et al., 2002).  With all of these approaches, MSNP 
are formulated use templating methods (hard templating and soft templating). The template 
removal determines the hollow interior of the MSNP.  During the formation it is the CTAB that 
is responsible for the formation of the shell and TEOS determines the hollow interior of the 
MSNPs (Hao et al., 2015).  The three approaches we selected were part of a hard templating 
method but differed in the methods utilised to remove the template, Gul-MSNP were prepared 
using a calcination step with, exposure of the formed solid nanomaterial in an air-fired furnace 
at high temperatures to remove template, whereas Fan-MSNP were prepared with a solvent 
refluxing approach to remove template. 
The smallest sized MSP were formulated using the ‘Fan method’ (Fan et al., 2011), resulting 
in particles of 216.5 ± 2.1nm with a narrow PDI of 0.13 ± 0.02 with the ‘Pro-2 method’ resulting 
in the largest sized particles of 465 ± 10nm with a larger PDI of 0.25 ± 0.1. 
Gul-MSNP were of a similar size to that reported by (Gulfam and Chung, 2014), 225 ± 7.2nm. 
On the other hand Fan et al reported particle sizes slight smaller than ours, approximately 180-
185nm. Nevertheless, the outcome for both Gul-MSNP and Fan-MSNP resulted in a particle 
size similar to that reported by the original researchers and with a target particles size (100-
500nm) with a narrow PDI.  For the Pro-2-MSNP, our particle sizes were larger than those 
reported by Nooney et al (2002), 190nm.  Because of the poorer sizes of the Pro-2-MSNP 
method, this method was discarded in favour of Gul-MSNP or Fan-MSNP. 
 
To confirm the morphology of the formed MSNP, samples were analysed using SEM in 
order to assess the formation of spherical-shaped nanoparticles with hierarchical pores on the 
surface.  Gul-MSNP demonstrated a less uniform spread of nanoparticle structures (Figure 3-
2A and B). However, the presence of mesopores are visible in the overall pore structure (Figure 
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3-2C) however a broader size distribution of particles is evident (Figure 3-2D) along with 
presence of ruptured/poorly formed pores (Figure 3-2D).  The formation of mesoporous 
nanoparticles resulted in the particles being packed closely and the process of drying directly 
from the liquid environment results in significant shrinkage due to Si-O-Si bond formation 
between adjacent nanoparticles. This irreversible shrinkage may result in the loss of the 
characteristic mesoporous nature (Liong et al., 2008). This is clearly reflected in the SEM 
images (Figure 3-2) where Gul-MSNPs shows agglomerates and do not appear as uniform. 
Furthermore, the broader size range and PDI supports the notion of poorer consistency within 
and across batch formations of Gul-MSNP. 
The ‘Pro-2 method’ also resulted in spheroidal type mesoporous morphology, but the pore 
formation on the formed nanoparticles were too small to detect and the overall spread of 
particle sizes would suggest they are formed with a diameter of greater than 400nm, confirming 
the observations from DLS analysis. 
Fan-MSNP resulted in a more uniform distribution of formed MSNP with a consistent spherical 
morphology and particle size of ~ 200nm, corresponding with the results from the DLS 
approaches.  In case of the Fan method, MSNP were formed by hydrolysis and condensation 
of teraethoxysilane in a dilute aqueous environment using a cationic template (CTAB) and a 
catalyst NaOH (Fan et al., 2011) through extraction in boiling solvents. This method would 
prevent the agglomeration of MSNP seen using the Gul-method and hence is preferred over 
calcination as template removal method.  
3.5.3. Surface porosity and pore size determination 
Unlike non-porous nanoparticles, porous nanoparticles required further characterisation to 
assess pore density, pore diameters and surface area properties.  Surface area is routinely 
assessed through nitrogen adsorption-desorption isotherms and calculated with Brunauer-
Emmett-Teller (BET) theory (Barrett et al., 1951) using isotherm adsorption data at P/P0. 
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The total surface area, 987.67 ± 3.38 m2/g, was larger than that reported by Fan et al (803.2 
m2/g.  Furthermore, Fan-MSNP demonstrated a micro/meso sized pore diameter of 1.93 ± 
0.01nm, smaller than that reported by Fan et al (3.7nm).  However the features of Fan-MSNP 
would clarify it as a high surface area narrow pore diameter nanoparticle, similar to other 
reported values for similar MSNP (He et al., 2010, Wu et al., 2016).  Although we were unable 
to utilise TEM to assess the exact structural morphology, MCM-41 type mesoporous 
nanomaterial is hexagonal in shape and possess similarly high surface area and narrow pore 
diameters and Fan-MSNP may possibly be categorised under this type of mesoporous 
nanomaterial (Slowing et al., 2006). 
Furthermore, the nitrogen absorption-desorption isotherms identify the characterise 
hysteresis-type loop associated with capillary (pore) condensation at P/P0 > ≈ 0.2.  The 
hysteresis loop can be classified as a H1 loop, which is often associated with porous materials 
exhibiting a narrow distribution of relatively uniform (cylindrical-like) pores. 
The overall distribution of the pore radius was confirmed through BJH analysis and 
demonstrated a narrow pore radius relative to the cumulative pore volume with the majority of 
the radius distribution, dV(r), located <20-30 Ang (< 10nm).  Furthermore, the pore width 
distribution confirmed a pore with distribution of < 4nm. Similarly, (Fan et al., 2011) 
demonstrated a H1 loop profile with a similar pore diameter distribution.  Pore size is important 
for controlling the release kinetics of drug from the pore, with larger pore sizes often resulting 
in a higher rate of drug release (He and Shi, 2011).   
3.5.4. FT-IR assessment of Fan-MSNP 
Having confirmed the formation of mesoporous nanoparticles, FT-IR spectroscopy was 
utilised to confirm the removal of the template from the silica material, key in the formation of 
the porous structure.  CTAB surfactant is identified by the presence of bands at approximately 
2924, 2855, and 1478cm-1 which correspond to C-H vibrations of the surfactant molecules.   
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These are highlighted in Figure 3-9 and, following template removal, are absent from the 
MSNP demonstrating complete removal of the template surfactant. Furthermore, the band 
at 1068cm-1 and a band at 795cm-1, can be assigned to internal and external asymmetric 
Si-O stretching modes, and at 965cm-1 to the stretching vibrations of the surface Si-
O− groups (Huo et al., 2014),(Zhao et al., 1997),(Salonen et al., 1997). 
Having confirmed the formation of surfactant free Fan-MSNP, we next passively loaded 
FITC into Fan-MSNP with a view to develop a cellular imaging tracer to assess cellular 
uptake of Fan-MSNP.  Loaded FITC-MSNP demonstrated a distinct band at 1654cm-1 which 
is thought to be related to the amide group (Kotsuchibashi et al., 2013), and the benzene 
ring of FITC at 1583cm-1 (Zhang et al., 2015).  
3.5.5. FITC loading and release in Fan-MSNP 
Passive loading resulted in an EE of 48 ± 2.3% and the release of FITC was assessed in 
PBS (pH 7.4) media.  The duration of the release study was set at 2 hours, primarily as a result 
of the short exposure-time expected with nasally delivered formulation coupled with the limited 
duration with which cell cultures can proliferate in the absence of growth media.  Minimal FITC 
was identified as having been released from FITC-MSNP, 4.8 ± 0.19%, over a 2-hour period 
suggesting the relative stability of the FITC molecule within the MSNP structure. 
3.5.6. FITC-MSNP cellular uptake  
Having confirmed the minimal leakage of FITC, FITC-MSNP were incubated with 
OBGF400 to assess the cellular uptake of dye-doped FITC-MSNP.  Following a 2-hour 
incubation with the cells, FITC-MSNPs were identified using confocal microscopy with 
cytoplasmic accumulation of FITC-MSNP, confirming the successful uptake into OBGF400.  A 
similar report of interaction after 2-hours (i.e. acute exposure) was reported by Huang et al 
(Huang et al., 2010) using A375 human melanoma cells to study the effect of shape of the 
MSNPs on the cell internalisation.  
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To further ascertain the cellular localisation, a z-dimension confocal imaging sweep was 
conducted from the upper limit of the cell layer to the lower limit of the cell layer, a distance of 
4.6µm, with multiple images taken as the objective transferred along the z-scale.  The z-stack 
confirmed the strong localisation within the cytoplasm of OBGF400 cells.  The fluorescent latex 
beads study identified the optimal size range for cellular uptake of nanoparticles into OBGF400 
cells and the size of Fan-MSNP was located within this range, and the cellular localisation 
concurred with the confocal imaging identified with both 100nm and 500nm latex beads.  
Furthermore, Fan-MSNP were prepared without calcination and it has been demonstrated that 
the calcination process yields more hydrophobic MSNP which can hinder cellular uptake (He 
et al., 2009), further confirming the rationale to not consider Gul-MSNP. 
This highly unspecific but efficient internalisation of MSNPs is believed to be partially 
because of their strong affinity for clathrin-coated vesicles due to their siliceous composition, 
and unique hexagonal exterior and internal hexagonal mesopores (Huang et al., 2005). It has 
been also observed that MSNPs enter the cytoplasm by escaping the endolysosomal 
entrapment. This endosome escaping is also known as “proton sponge” effect (Boussif et al., 
1995).  
 
3.5.7. Phytochemical loading into Fan-MSNP 
Having successfully developed Fan-MSNP and confirmed both its mesoporous nature, but 
also its ability to undergo cellular uptake with a fluorescent cargo molecule, the phytochemicals 
curcumin and chrysin were used as candidate poorly soluble compounds and potential viable 
payloads of CNS pharmacological target sites (Chearwae et al., 2006, Choudhury et al., 2013, 
Gupta et al., 2009, Monroy et al., 2013, Mythri et al., 2011, Zbarsky et al., 2005) (Yao et al., 
2014, Xiao et al., 2014, Souza et al., 2015, Santos et al., 2015, Nabavi et al., 2015, Jia et al., 
2015). 
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For Curc-MSNP using FTIR we were able to identify a broad peak at 3420cm-1 confirming 
the intermolecular hydrogen bonding in isolated silanol and enolic hydroxyl groups and a peak 
at 1620cm−1  due to stretching vibrations of C=O bond (Jambhrunkar et al., 2014),(Khan et al., 
2015).  Having detected the IR spectra of curcumin within the Curc-MSNP, the thermal 
behaviour of Curc-MSNP was determined using differential scanning calorimetry. For curcumin 
a single characteristic single melting endothermic peak at 176°C was observed which was 
absent in Curc-MSNP confirming the washing step in the ‘dry method’ has removed residual 
curcumin adsorbed onto the surface of the MSNPs and secondly that the loaded curcumin is 
in the amorphous form. 
Thereafter TGA was utilised to assess the weight loss associated with Curc-MSNP as 
direct methods for measuring loading content (LC) (TGA detection), 14.95 ± 0.67%, which 
corresponded to a calculated EE of 12.34 ± 1.28% for the ‘wet method’ (HPLC-UV detection).  
Finally, confirmation of loading was confirmed through the change in particle size, 216.8 ± 
2.1nm to 263.51 ± 8.3nm after loading with curcumin (P ≤ 0.01), with a statistically significant 
increase in the PDI from 0.13 ± 0.02 to 0.26 ± 0.05 (P ≤ 0.05).  This increase in particle size 
and PDI has been previously reported after loading curcumin in their mesoporous 
nanoparticles (Kim et al., 2015),(Jambhrunkar et al., 2014).  Furthermore the decrease in zeta 
potential following loading, from -23.9  ± 0. mV to -16.9 ± 0.9mV (P ≤ 0.01), has previously 
been reported, however the polarity of the resultant charge is a function of the pH of the media 
that the zeta potential is measured in, with reports that a lower pH media often leads to more 
positive zeta potential with loading (Lee et al., 2008, Chung et al., 2007, DeMuth et al., 2011, 
Farghali et al., 2016). 
For Chry-MSNP we were able to identify the γ-benzopyrone ring at 1655cm-1 and 
absorption bands at 1612, 1577 and 1450cm-1 related to carbon vibration in benzene and γ-
pyrone rings (valance vibrations C=C) (Group, 2005).  Having detected the IR spectra of 
chrysin within the Chry-MSNP, the thermal behaviour of Chry-MSNP was determined using 
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differential scanning calorimetry. As with curcumin, a single melting endothermic peak at 
286°C was observed which was absent in Chry-MSNP, a gain confirming the washing step in 
the ‘dry method’ has removed residual chrysin adsorbed onto the surface of the MSNPs and 
secondly that the loaded chrysin is in the amorphous form.  Thereafter TGA was utilised to 
assess the weight loss associated with Chry-MSNP as direct methods to measuring loading 
content (LC) (TGA detection), 11.49 ± 1.19%, which corresponded to a calculated EE of 12.34 
± 1.28% for the ‘wet method’ (HPLC-UV detection).  
Finally, loading was confirmed through the change in particle size, 216.8 ± 2.1nm to 283.5 ± 
8.3nm after loading with chrysin (P ≤ 0.01), with a statistically significant increase in the PDI 
from 0.13 ± 0.02 to 0.31 ± 0.05 (P ≤ 0.05).  Following loading a decrease in zeta potential, from 
-23.9 ± 0.4mV to -30.8 ± 0.3mV (P ≤ 0.01) was noted.  
However reports from other chrysin loaded nanoparticle systems indicate a negative zeta 
potential in the range we detected (Wang et al., 2015, Sathishkumar et al., 2015) .  Traditionally 
the zeta potential has been considered an important element for cellular interaction, with 
positively charged NP being favoured over negatively charges NP due to the negative charge 
of a cell membrane (Cooper, 2000). That said, a number of reports have identified that the zeta 
potential is less of an issue for MSNP due to their highly mesoporous nature (Taebnia et al., 
2015) (Huang et al., 2014).  Furthermore the endosome escaping,  “proton sponge” effect 
(Boussif et al., 1995), may explain the ability of Fan-MSNP to undergo internalisation, 
considering negative charge, without any specific ligands for receptor mediated endocytosis. 
The application of DSC is important in giving an insight into the physical state of the drug 
molecule in the carrier system and its interaction with the carrier itself.  It is also important to 
identify if the loaded drug is present in a crystalline or amorphous form, which will directly 
determine its solubility. With mesoporous materials, the localisation of drug into the pores of 
the MSNP will exist as either a crystalline form, showing characteristic melting point depression 
of the drug, or in the amorphous for where no characteristic melting point will be seen in the 
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thermogram (Salonen et al., 2005b).   The thermographs for both curcumin and chrysin 
confirmed the amorphous form was present and has been reported elsewhere (Yallapu et al., 
2010) (Chen et al., 2013a). 
With TGA analysis some weight loss at low temperature may have been attributed to 
adsorbed water whereas the weight loss at higher temperatures can be attributed to loss of 
surface silanol groups. However, no significant weight loss was evident during the study and 
this implies Fan-MSNP were thermally stable (Wanyika et al., 2011). In the case of both chrysin 
and curcumin, the loaded nanoparticles demonstrated no characteristic melting point 
depression confirming the amorphous nature of the loaded phytochemical and confirming 
negligible drug adsorbed (Salonen et al., 2005a).  
The relatively low loading of phytochemicals into MSNP may be relative to the zeta potential 
charge of the nanoparticle, with studies reporting increased drug loading by altering the surface 
charge of the MSNP to increase drug loaded (Yoncheva et al., 2016, Ma'mani et al., 2014). 
3.5.8. HPLC-UV detection of phytochemicals 
HPLC-UV approaches for the detection of curcumin and chrysin were based on previously 
published methods and resulted in successful detection of both phytochemicals, with both 
methods demonstrating system precision and method precision across the range of 
concentration studied. 
The chromatogram for curcumin (Figure 3-25) demonstrated the three consistent 
curcuminoids peaks associated with commercially available curcumin with the greatest peak,  
namely curcumin (~80%), being used for analytical purposes rather than the smaller  
demethoxycurcumin (~ 17%) and bisdemethoxycurcumin (~ 3%) peaks (Govindarajan, 1980) 
(Figure 3-43).  
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Figure 3-43: Chemical structures of (A) curcumin, (B) demethoxycurcumin and (C) and bisdemethoxycurcumin. 
3.5.9. Cellular toxicity of MSNP  
The target cell of Fan-MSNP are the cells of the olfactory system.  In order to assess the 
compatibility between Fan-MSNP, curcumin and chrysin with olfactory cells a cellular toxicity 
assay was conducted using OBGF400 cells. Fan-MSN demonstrated cellular viability over 10-
100µg/mL for 24 hours but concentration in excess of this results in a statistically significant 
(P≤ 0.01) decrease in viability. Reports of toxicity of MSNP with olfactory cells have not been 
reported by others but contradictory reports comment on relationships between the particle 
size and cellular toxicity, which appears to be cell line specific.  For example, smaller-sized 
silica nanoparticles induced severe cellular damage in lung cancer cells, myocardial cells, and 
human endothelial cells (Napierska et al., 2009, Ye et al., 2010, Lin et al., 2006b) and this was 
thought to be related to the fact that smaller nanoparticles have larger ratio of surface area to 
weight and therefore potentially more contact with the cells to induce damage (Oberdörster et 
al., 2005, Kipen and Laskin, 2005, Nel et al., 2006).  However others have reported that larger 
silica nanoparticles are more cytotoxic than smaller particles on human hepatoma cells (Lu et 
al., 2011).   
All MTT assays were conducted in cell culture media containing serum.  A possible 
explanation for the conflicting reports in cellular toxicity associated with MSNP (and NP more 
generally) may be associated with a protein corona that is formed on the surface of silica 
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nanoparticles that may alter the cytotoxic potential of the nanoparticles when in contact with 
serum proteins from tissue culture media (Barrett et al., 1999, Cedervall et al., 2007) . 
For curcumin we reported an IC50 of 33 ± 0.18µM and a statistically significant (P ≤ 0.01) 
decrease in cell viability (to 58.2 ± 8.5%) for chrysin at 100µM (Figure 3-33 and 3-31). No other 
reports are available of the cellular toxicity of curcumin or chysin with OBGF400 cells, however 
others have reported similar IC50 in CNS related cell lines (porcine brain microvascular 
endothelial cells PBMEC/C1-2: 63 ± 1.2µM) (Kaur, 2016). Similar IC50 values have been 
reported for curcumin, 15.2µM and 16.4µM against A2780CP and MDA-MB-231 cells 
respectively (Yallapu et al., 2010).   Mukerjee and Vishwanatha (Boddupalli et al., 2010) found 
the IC50 of curcumin loaded PLGA nanoparticle was 31µM for PWR 1E cells as compared to 
37µM of free curcumin 
Any foreign particle to be taken up by the cell is dependent upon many factors such as 
size, charge, affinity etc. It has been reported that nanoparticles smaller than 100nm could 
cause unspecific cellular uptake and cytotoxicity (Yu et al., 2009). Silica nanoparticles in the 
size range of 50-300nm are capable of inducing endocytosis (Mayor and Pagano, 2007) 
without causing any cytotoxicity and they have been reported to possess high affinity to many 
phospholipids present on the surface of the cell, which may even induce pinocytosis (Slowing 
et al., 2008b). 
To evaluate the impact of long-term exposure of MSNP on OBGF400 cells, live cell imaging 
over 40 hours was conducted using the CellIQ® imaging system.  This system captures phase 
contrast images of cells or regions of wells at pre-defined time-periods during a study.  Cells 
were exposed to increasing concentrations of Fan-MSNP, Curc-MSNP and Chry-MSNP. 
The impact of higher concentration of Fan-MSNP was clearly evident, resulting in alteration 
in the morphology of cells and a reduction/halting of proliferation over the 40-hour period with 
observable changes in cell viability over the first 16 hours.  However, at lower concentrations, 
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this effect was minimal and cells were generally viable after 40 hours of incubation, and 
concurring with the concentration dependant trends results reported by the MTT cytotoxicity 
assay.  (Chen et al., 2014) compared the toxicity of MSNPs and gold nanoparticle capped  
MSNPs on HeLa cells by MTT assay. Both the types showed no toxicity up to 100µg/mL 
when exposed up to 48 hours. MTT assay involving Saos-2 cells showed no toxicity up to  
0.6mg/mL of mesoporous nanoparticles (Alvarez et al., 2015). In another study Huang et al  
(Huang et al., 2010) performed an MTT assay on A375 human melanoma cells using spherical, 
short rod and long rod shaped bare MSNPs with a length 100, 240 & 450nm respectively. None 
of the MSNPs in the concentration range 0.0625mg/mL to 1mg/mL showed any statistically 
significant toxicity. 
Chry-MSNP and Curc-MSNP also demonstrated a similar concentration dependant trend 
in changes in cellular morphology, interestingly cell viability decreased during the study time 
for the 50µg/mL Chry-MSNP whereas proliferation of cells was noted with 50µg/mL Curc-
MSNP. The CellIQ® imaging technology has allowed the visual analysis of changes in cellular 
morphology and support the observations obtained from the MTT cellular toxicity studies. 
3.5.10.  Phytochemical release from MSNP 
3.5.10.1.  Curcumin 
The release of curcumin from mesoporous nanoparticles followed a pH dependence, with 
greater release after 24 hours at pH 5.5, 53.2% ± 2.2%, compared to pH 7.4, 16.1 ± 1.6% (P 
≤ 0.001).  This significant differences in release rates at different pH is important as the release 
in the nasal cavity (pH 5.5) is likely to be more rapid.  Furthermore, it has been reported that 
curcumin is relatively unstable at pH 7.4 compared to more acidic pH, which may explain the 
lack of increase in cumulative release from 1 hour to 24 hours (~1.8%) compared to the ~36% 
increase in cumulative release at pH 5.5 at 24 hours (Wang et al., 1997, Tonnesen and 
Karlsen, 1985, Kunnumakkara et al., 2008).  The degradation has been reported to be complex 
 203
but at a pH < 1, curcumin exists in the protonated form (H4A+), with increasing pH the neutral 
form (H3A) predominates.  Furthermore stability in acidic conditions is likely due to its 
conjugated diene structure which becomes gradually destroyed as the proton is removed 
during the dissociation of the phenolic groups within the structure of curcumin (H2A−, HA2− and 
A3−) which occurs at higher pHs and is likely the cause of curcumin being significantly more 
prone to degradation (Figure 3-44) (Lee et al., 2013),(Tonnesen and Karlsen, 1985).   
 
 
Figure 3-44: Curcumin degradation products 
Degradation forms of curcumin at different pH (Lee et al., 2013). 
 
An analysis of the HPLC chromatograms for curcumin at 1 hour and 24 hour also confirms 
differences in peak ratios suggesting degradation of curcumin at pH 7.4 rather than pH 5.5 
(see Figure 3.45 and 3.46).   
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Figure 3-45: HPLC-UV chromatogram of curcumin at pH 7.4. 
HPLC chromatograms illustrate peak separation/identification for 1 hour (A) and 24 hour (B) release samples.  Retention time is indicated above peaks. 
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Figure 3-46: HPLC-UV chromatogram of curcumin at pH 5.5. 
HPLC chromatograms illustrate peak separation/identification for 1 hour (A) and 24 hour (B) release samples.  Retention time is indicated above peaks.
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3.5.10.2. Chrysin 
Chrysin demonstrated the opposite trend with increased release at pH 7.4 compared with 
5.5, 16.8 ± 0.8% and 9.4 ± 0.6% respectively, after 24 hours.  In both cases the cumulative 
release over the study period increases significantly (P ≤ 0.001 for 1 hour versus 24 hours).  
Furthermore, the release profile for both phytochemicals demonstrated a burst effect at early 
time points and this pattern has also been reported elsewhere (Anitha et al., 2011, Zou et al., 
2013, Yin et al., 2013).  This may be a result of the rapid dissolution of the loaded 
phytochemicals closer to the exterior of the pores with slower penetration of solvent into the 
pores as a result of the micro/meso size pores of < 2nm (Horcajada et al., 2004).  
Therefore at nasal pH (~5.5) both curcumin and chrysin loaded MSNP would be expected to 
be relatively stable at physiological pHs and undergo release from the MSNP.   
3.5.11.  Incorporation of Fan-MSNP into the thermoresponsive nasal gel 
The delivery of poorly soluble compounds often requires the intervention of formulation 
scientists to enhance solubility.  A novel approach for this can be found in the application of 
NP technologies are carrier entities for such compounds.  Phytochemicals are inherently poorly 
soluble and have been the focus on many approaches to enhance solubility through 
incorporation into NP.  However, to ensure residency of the NP within the olfactory region of 
the nasal cavity required its ‘forced retention’ at the olfactory mucosa.  In Chapter 2 we 
explored the formulation and development of a potently novel drug delivery system for AMT.  
To assess the compatibly between MSNP and thermoresponsive nasal gel, Fan-MSNP were 
incorporated into FCMC, FCS and FPEG and the gelation phenomena analysed using 
rheological processes. In this approach we replaced AMT with 0.2%, 0.4% and 1% w/w Fan-
MSNP.   
All formulations demonstrated a tri-region gelation phenomenon, preceded by a stable 
plateau region and culminating in a stable gel formulation and generally demonstrated a 
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decrease in the initiation temperature of gelation with increasing Fan-MSNP concentrations 
(Figure 3-37 to 3-39). 
A recent study by Dorraj and Moghimi (2015) demonstrated that the direct incorporation of 
SLN into thermoresponsive gels increased the gelation temperature.  In our studies the 1%w/w 
concentration corresponded to the AMT content within gels and our results contradict this 
observation.  The fact that all formulations mainlined the general tri-phasic trend suggests that 
there were no gross changes in the gel structure, however the resultant alteration in the 
initiation of the gelation phase may be a result of a disturbance in the micellar packing and 
entanglements of PF127 (Kim et al., 2002, Nie et al., 2011).  
Furthermore, sheer-thinning behaviour at 34°C compa red to ambient conditions confirmed that 
gelation had occurred, as a virtue of the significantly higher viscosity reading at 34°C compared 
to ambient conditions (Figure 3-40).  Interestingly, for FCMC the incorporation of 1% w/w Fan-
MSNP resulted in a significantly different, more viscous gel structure as noted by the increased 
viscosity compared to the lower concentrations. 
Therefore, the inclusion of MSNP into carrier systems such as thermoresponsive gel 
systems may pose as viable and single delivery approach to deliver the poorly soluble drug to 
the olfactory mucosa, giving the benefit of targeted delivery onto the olfactory mucosa through 
physical manipulation of spray deposition angles 
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3.6. Conclusion 
Phytochemicals possess a range of beneficial pharmacological properties that act directly 
on neurodegenerative pathways alongside negating the action of drug efflux transporters 
expressed at the BBB and other CNS barrier sites.  However, their clinical use is often limited 
by poor solubility.   
In this chapter, we have demonstrated the successful development of mesoporous silica 
nanoparticles, which are capable of acting as a viable delivery system to encapsulate 
phytochemicals.  Furthermore, we demonstrated the successful cellular uptake of MSNP with 
limited cellular toxifi6y, making MSNP a viable candidate for olfactory targeting of loaded 
drugs.  
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Chapter 4  
Adaptation of a pMDI spray 
device for targeted delivery onto 
the olfactory mucosa: a feasibility 
study 
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4.1.  Introduction 
 
In previous chapters we have explored the application of thermoresponsive nasal gels 
(Chapter 2) and nanoparticles (Chapter 3) as potential formulation systems which could be 
used to deliver a drug to the olfactory mucosa.  However, the feasibility of adapting current 
existing technologies for olfactory mucosa delivery of drugs may provide an alternative route 
of delivery which may benefit certain compounds. 
This chapter focuses on a feasibility design study to explore whether existing pressurised 
metered dose inhaler (pMDI) technologies can be adapted to delivery an API onto the olfactory 
mucosa and forms the partial basis for work conducted through collaboration with 3M®. 
 
The application of pMDI formulation technologies for aerosol delivery to the lungs, allows 
for the selective delivery of drugs to the target tissue with minimal side effects.  Furthermore, 
as delivery is targeted, lower doses are often employed to achieve optimal therapeutics 
outcome (Dalby and Suman, 2003, Hess, 2005).  The era of pMDI devices began in the mid-
1950s with the development of the Medihaler-Epi by 3M-Riker (Grossman, 1994, Anderson, 
2005) with the market for pDMI devices having developed extensively for inhaler drug 
formulations. 
The pMDI system comprises of the API dissolved directly into a propellant (HFA 134a or 
224 or, if solubility limitations exist, formulation with a co-solvent (e.g. ethanol) (Figure 4-1).  
The high vapour pressure of the propellant coupled with the reduced particle sizes of the API 
(often pre-processed through particle size reduction techniques) often leads to an eventual 
spray size distribution which is small (Polli et al., 1969, Newman, 2005).  The formulation is 
housed, under pressure, within the canister and the metering value determines the overall 
spray volume (~60-100µL/actuation). Furthermore, the final particle size if often determined by 
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the nozzle orifice, with narrow nozzles resulting in a spray cone angled spray mist deposition 
larger quantities on the mouthpiece (Polli et al., 1969, Newman, 2005). 
 
Figure 4-1: A pressured metered dose inhaler (Lavorini, 2013). 
The application of pMDI technologies to the area of nasal drug delivery has been limited 
primarily to the local treatment allergic rhinitis conditions (Djupesland, 2013).  Furthermore, for 
nose-to-brain delivery, technologies have recently been developed, e.g. ArhcerFIsh® N2B 
(www.mysticpharmaceuticals.com), ViaNase® (www.kurvetech.com), POD 
(http://impelnp.com/), although there are not current marketed products based on these inhaler 
technologies.  The direct delivery of an API targeting CNS delivery through a pMDI system 
would benefit medical emergencies such as status epilepticus, where repetitive or recurrent 
seizures can be fatal due to the long duration of seizures (Wolfe and Macfarlane, 2006). 
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Benzodiazepines such as diazepam, lorazepam, midazolam and clonazepam are first choice 
pharmacological treatment options in these conditions (Manno, 2011). The critical point in 
treating such conditions is the speed with which the medications can be delivered to the 
systemic circulation and then to the brain to control the seizures and protect the CNS. Outside 
of the hospital setting, the transmucosal route of delivery is the fastest alternative to 
intravenous injection. However intranasal delivery of benzodiazepines can be a faster way to 
control the seizures in the pre-hospital setting (Wermeling, 2009). Similar concerns have been 
raised by (Wolfe and Macfarlane, 2006) regarding paediatric status epilepticus where rectal 
diazepam is commonly used route of delivery which is not only expensive but also ineffective. 
They suggested that intranasal delivery of midazolam is much better alternative because of its 
rapid availability into blood and CSF.  
4.2. Aims and objectives 
The aim of this study was to assess the feasibility of developing a diazepam pMDI 
formulation using a custom fabricated intranasal actuator device, and to assess stability, 
administration orientations and air flow rates on the localisation of spray droplets onto the 
olfactory region of a human silicon nasal cast model. 
 
The objectives were to: 
• Determine solubility of diazepam in ethanol alone and ethanol HFA134a-mixture 
• Assess the stability of these mixtures at elevated temperature and humidity 
• Assess the spray pattern and required angle of spray using brilliant blue dye. 
• Assess the deposition of diazepam onto the olfactory mucosa region 
• Assess the cellular toxicity of diazepam in the olfactory bulb cell line OBGF400 
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4.3. Materials and Methods 
4.3.1. Materials 
Dulbecco’s Modified Medium: Nutrient Mixture F12 (DMEM-F12), Dulbecco’s Phosphate 
buffered saline (PBS), L-glutamine 200mM, penicillin/streptomycin and trypsin-EDTA solution 
were obtained from PAA laboratories (Austria); foetal bovine serum (FBS) (Labtech, Essex, 
UK); brilliant blue dye, acetonitrile, orthophosphoric acid, ethanol, methanol, brilliant blue dye 
(BB), potassium hydrogen phosphate were obtained from Fisher Scientific (Loughborough, 
UK); acutase (Biolegend, UK); gentamycin,  (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
Tetrazolium bromide) MTT, trypan blue and dimethyl sulfoxide (DMSO)  were obtained from 
Sigma-Aldrich (Dorset, UK). Diazepam RS was obtained from F.I.S. (Vicenza, Italy) 
4.3.2. Assessment of diazepam solubility in ethanol 
To assess the maximum solubility of diazepam in ethanol, 2mg of diazepam was weighted 
in a clear glass vial followed by the addition of 1mL ethanol.  The vial was sonicated and 
visually assessed for the complete dissolution of particles.  The quantity of diazepam was 
increased by the further addition of 2mg followed by sonication and repeated until a precipitate 
remained. 
4.3.3. Assessment of diazepam solubility in propellant 
To assess the solubility of diazepam in the propellant HFA134a, diazepam was solubilised 
first in ethanol 5% w/w and 10% w/w (of total final canister volume) in clear PET vials and 
subsequently filled with propellant using a semi-automatic aerosol filler (Pamasol, Switzerland) 
(Table 4-1). 
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Table 4-1: pMDI canister composition 
Ethanol Mass (g) Concentration 
% w/w (g) (mg/mL) 
 
Empty Filled HFA134a Diazepam 
5 18.4 ± 0.16 8.71 ± 0.03 8.15 ± 0.14 2.45 ± 0.04 
10 18.80 ± 0.16 8.71 ± 0.007 8.73 ± 0.14 2.29 ± 0.038 
Mean ± SD; n=12 
 
Solution quality was visually assessed immediately after manufacture and frequently thereafter 
for 3 weeks for crystal growth, precipitation or immiscible layers (phase separation). 
4.3.4. HPLC-UV detection of diazepam 
A modified reverse phase HPLC-UV method was used to quantify diazepam (Rouini et al., 
2008). An Agilent 1200 Series (Waldbronn, Germany) equipped with a variable wavelength 
detector (VWD) and a Phenomenex Luna C18 (150 × 4.6mm) 5µm column was used for RP-
HPLC. The mobile phase consisted of 10mM phosphate buffer (pH 2.5):methanol:acetonitrile 
(63:10:27 v/v) and was filtered through a 0.45µM filter and sonicated prior to use. The flow rate 
was maintained at 2.0mL/min with 20 minutes run time and an injection volume of 10µL. 
Calibration curves were constructed using standard solutions of known concentrations from 
7.8 to 1000µg/mL. The software used for data collection, analysis and control of the system 
was ChemStation Version 1.24 SP1. The UV detection of diazepam was measured at 230nm.  
4.3.5. Canister stability studies 
Pre-coated 16mL pMDI canisters were provided by 3M with matching 63µL valves.  
Canisters were filled with the optimal diazepam formulation and stored valve up, in a humidity 
cabinet (Firlabo, Finland) at 40°C/75% relative hum idity.  The stability of the formulations within 
the canisters was assayed based through spray content analysis assay following 3 months of 
storage. Briefly, a dosage unit sampling apparatus (DUSA) (Copley Scientic, USA), was 
assembled and attached to a flow-through air-flow system set at 10 L/min. To actuate the 
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canisters, a custom designed 3M prototype nasal pMDI actuator, termed the ‘Aardvark’ 
system, was provided by 3M and consisted of a 60µm nozzle orifice (Figure 4-2). 
 
 
 
Figure 4-2: The 3M fabricated nasal pMDI actuator (termed the ‘Aardvark’ system). 
At the end of the third month of storage, diazepam canisters were combined with the pMDI 
actuator and a single spray actuated into the DUSA.  5mL of ethanol was subsequently added 
and the unit shaken for 1 minute before 1mL of the ethanol sample was analysed by HPLC-
UV to quantify diazepam content. 
4.3.6. Nasal pMDI spray: droplet size distribution 
To assess the potential in-vivo deposition characteristics of the proposed nasal pMDI 
formulation, the spray droplet size was characterised using a laser diffraction technique.  The 
Helos/Sympatec system was used with an R3 lens (0.5-175µm).  The nasal spray was 
vertically mounted 3cm away from the laser path and a vacuum source was mounted anterior 
to the pump system.  The spray systems were pre-actuated prior to mounting, and actuated 
three times to detect the particle size distribution.  
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Data was reported as volume diameters at 10%, 50% and 90% of the cumulative undersized 
volume distribution (Dv). Span was calculated as:  
MN90 − MN10
MN50
 
 
4.3.7. Nasal pMDI spray deposition within a nasal cast model: brilliant blue 
visualisation 
To visually assess the deposition of spray patterns within a human nasal cast, brilliant blue 
dye was hand milled in a mortice and pestle for 30 minutes with circular motions, prior to being 
passed through a 20µm sieve. 3.6mg of this reduced particle size was weighed and dissolved 
in 360mg of ethanol. 50mg of this solution was weighed and transferred into an aluminium 
canister before being filled with propellant and sonicated prior to use. The final concentration 
of the dye was maintained at 0.07mg/g. The nasal cast was coated with an opaque acrylic 
nitrocellulose layer and allowed to dry.  The pMDI nozzle was angled at 30, 40 and 50° to the 
plane (Figure 4-3) and one spray actuated into the nasal cast. 
 
 
 
Figure 4-3: Spray angle used within the nasal pMDI actuators. 
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Furthermore, the impact of nozzle dimensions on depositions was assessed with a ‘short’ 
and ‘long’ nozzle attachment (Table 4-2 and Figure 4-4) 
 
Table 4-2: Dimensions of nozzle attachments 
  
Dimensions (mm) 
 
Length Width  Orifice  
Short 30 5.6 2.23 
Long 36 3.7 1.21 
 
Width refers to the largest width at the attachment point to the actuator 
 
 
 
Figure 4-4: Nozzle attachments 
Two attachments different in length and aperture were used to study the deposition pattern in the nasal cast. 
 
Deposition patterns were assessed under the application of an airflow to mimic gentle 
inhalation (10L/min) and rapid inhalation (30L/min) (Foo et al., 2007) following attachment of 
the nasal cast to a flow controller unit (Copley Scientific, UK). 
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4.3.8. Nasal pMDI spray deposition within a nasal cast model: diazepam localisation 
To evaluate this adopted spray device for olfactory drug delivery of diazepam, the nasal 
pMDI system was actuated 3 times prior to spraying 1 dose into the uncoated nasal cast model 
with optimal spray angle and air-flow as determined from the BB deposition studies.  The upper 
flat region of the nasal cast representing the approximate olfactory region in the human nasal 
cavity was washed twice with 100µL ethanol, collected and the deposition of diazepam on the 
olfactory region quantified by HPLC-UV approaches.  
4.3.9. Cellular toxicity of diazepam 
To assess the cellular toxicity of diazepam towards nasal cell lines, an MTT cell viability 
assay was conducted with OBGF400 cells.  Cells were suspended in 200µL medium and 
seeded at a density of 6 x103 per well of a 96-well plate. After 24 hours the media was removed 
and replaced with 200µL of media containing DZP (0.001-10,000µM) and incubated for 24 
hours at 37°C in a 5 % CO2 air humidified environment. Subsequently 20µL of 5mg/mL MTT 
dissolved in PBS was added to each well and incubated at 37°C in an air humidified 
environment for 4 hours. Thereafter, the media was removed and 100µL of DMSO was added 
and the plates left to incubate for 15 minutes in the dark. The UV-absorbance of the formazan 
product was determined at 595nm in a microplate reader (BIO-RAD). Each concentration was 
assayed in eight wells and run in three independent experiments and results expressed as 
percentage cytotoxicity relative to a control (0.5% DMSO).   
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4.4. Results 
4.4.1. Assessment of diazepam solubility in ethanol 
The solubility of diazepam in ethanol was confirmed as 36mg/mL (45.6mg/g of ethanol 
assuming a density of 0.789 g/ml). 
4.4.2. Assessment of diazepam solubility in propellant 
To assess the solubility and stability of diazepam when dispersed in HFA134a, diazepam 
was dissolved in 5% w/w and 10% w/w ethanol followed by filling with propellant and storage 
in stability cabinets at 40°C/75% RH for three week s.  During the three-week test period, no 
visual crystal growth, precipitation or immiscible layers were observed for 5% w/w or 10% w/w 
in either formulation (Figure 4-5) 
 
 
 
Figure 4-5: Stability of diazepam formulated in 5% or 10% w/w ethanol and HF134a following 3-week storage 
Glass vials were prepared with diazepam dissolved in 5% or 10% w/w ethanol.  Vials were stored at 40°C/75% RH 
for three weeks.   
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4.4.3. HPLC-UV detection of diazepam  
The HPLC-UV method was developed and successfully used to detect diazepam with a 
retention time of 13.95 minutes (Figure 4-6).  System precision and method precision 
demonstrated RSD within acceptable limits of 1% and 2% respectively, indicating an 
acceptable level of precision of the analytical system. 
 
 
 
 
Figure 4-6: Diazepam HPLC chromatogram. 
Diazepam was detected using an Agilent 1200 Series (Waldbronn, Germany) equipped with a variable wavelength 
detector (VWD) and a Phenomenex Luna C18 (150 × 4.6mM) 5µm column was used for RP-HPLC. Mobile phase 
was made up of 10mM phosphate buffer (pH 2.5):methanol:acetonitrile (63:10:27, v/v). Mobile phase was filtered 
through 0.45µM filter and sonicated before use. The flow rate was maintained at 2.0ml/min with 20 minutes run time 
and the injection volume was 10µL while column temperature was ambient with a UV-detection wavelength of 
230nm. 
 
System precision: six replicate injections of an identical standard diazepam stock solution 
were injected into the HPLC and peak area calculated. The relative standard deviation (%RSD) 
for the six samples was not more than 1.0% indicating system precision is within acceptable 
limits as measured per individual run, each with its own identical standard diazepam stock 
solution, with an overall RSD of 0.45% (Table 4-3). 
 
 221
Table 4-3: System precision assessment for diazepam 
Injection no. Area counts (µV sec) 
  
Run 
1 
Run 
2 Run 3 Mean 
1 3000 3045 3000  
2 3025 3041 3012  
3 3012 3025 3013  
4 3008 3018 3027  
5 3015 3009 3036  
6 3018 3012 3045  
     
Mean 3013 3025 3022.17 3020.06 
SD 8.58 15.03 16.82 13.48 
    
 
RSD (%) 0.28 0.50 0.56 0.45 
 
System precision was assessed through 6 injections of the same diazepam stock solution for each independent 
runs (3 runs in total).  Mean and SD reported with percentage root-square deviation 
 
Method precision: six preparations of the same batch of samples were analysed for method 
precision with a resultant %RSD of less than 2.0% (Table 4-4) for all samples demonstrating 
method precision is within acceptable limits with an overall %RSD of 1.09%. 
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Table 4-4: Method precision assessment for diazepam 
Injection 
no. 
Assay (% w/w)  
  Run 1 Run 2 Run 3   
1 101.25 100.12 97.56  
2 99.58 99.78 102.17  
3 100.08 99.05 103.36  
4 101.23 98.98 100.98  
5 99.87 102.12 103.12  
6 98.67 101.89 101.11  
     
Mean 100.11 100.32 101.38 100.61 
SD 1.00 1.37 2.12 1.50 
    
 
RSD (%) 0.82 1.64 0.80 1.09 
 
Linearity of response: the linearity of precision for diazepam was determined over a 
concentration range of 78 -10000µg/mL.  A proportional response was evident versus the 
analytical concentration over the working concentration range with a r2 of 0.999 and linear 
equation of  Q = 2288.7 ± 1.1	 ∙ V (Figure 4-7). 
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Figure 4-7: Linearity plot for diazepam. 
A HPLC-UV method was developed to assess the linearity of detection over a concentration range of 78 -
10000µg/mL. Data represents mean (solid line) ± SD (error bars). n=3.  
 
4.4.4. Canister stability studies 
Canisters were prepared and stored in stability cabinet at 40°C/75% RH for three months.  At 
the end of the 3-month period, the canisters were removed from the cabinet, shaken and 
actuated 10 times into waste prior to a single unit sprayed into a DUSA.  At preparation the 
content assay for 5% and 10% w/w ethanol canisters were determined to be 0.187 ± 
0.005mg/mL and 0.178 ± 0.025mg/mL respectively.  At the end of the storage period the assay 
content was 0.169 ± 0.008 and 0.159 ± 0.01mg/mL for the 5% and 10% w/w ethanol canisters, 
and were not significantly different to the starting canister content assay (Figure 4-8). The LOD 
was 1.1µg/mL, LOQ was 4.3µg/mL and the signal to noise ratio was >10. 
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Figure 4-8: Diazepam content assay of 5 and 10% w/w ethanol canisters. 
Canisters were prepared and stored in a stability cabinet at 40°C/75% RH for three months.  Thereafter  a single 
spray of the canister content was actuated into a DUSA, washed with ethanol and the recovered diazepam assayed 
using HPLC-UV. 
 
4.4.5. Nasal pMDI spray: droplet size distribution 
The 5% w/w diazepam formulation was prepared and attached to the 3M ‘Aardvark’ 
actuator.  Droplet size distribution was assessed using laser diffraction techniques.  The VMD 
(dv50) for the propellant alone was 18.89 ± 1.07µm with a significantly larger droplet size for 
BB of 45.11 ± 1.89µm, P ≤ 0.001 (Figure 4-9).  The VMD for diazepam was similar to that of 
the propellant, 19.25 ± 0.25µm.  The relative span of diazepam was similar to that of propellant 
alone (3.2 ± 0.12), however the span was significantly smaller (P ≤ 0.001) for BB, 1.43 ± 0.09. 
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Figure 4-9: Spray particle size distribution. 
Spray Particle size distribution for canisters filled with propellant alone (white bars), brilliant blue dye (BB, blue bars) 
and diazepam (red bars). Dv10, Dv50 and Dv90: particle diameter corresponding to 10, 50 and 90% cumulative 
undersize particle size distribution; data is represented of mean ±SD, n=6 replicate spray actuations per formulation 
 
4.4.6. Nasal pMDI spray deposition within a nasal cast model: brilliant blue 
visualisation 
To assess the distribution of the plume following deposition into the nasal cavity, brilliant 
blue (BB) dye was used as a visual indicator and incorporated into the pMDI system.  The 
deposition as assessed under static and dynamic air flow.  Under static air flow, a narrow angle 
orientation (30°) nozzle results in more posterior deposition within the nasal cast, with 
deposition increasing more towards to the olfactory region as the angle increased to 40° and 
50° (Figure 4-10 A)
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Figure 4-10: Nasal cast deposition of BB pMDI under static and dynamic airflow. 
Brilliant blue (BB) canisters were prepared and actuated into a nasal cast model under static (A), low (10L/min) (B) and high (30 L/min) (C) air-flow and at 30,40 and 50° to the 
plane.  The deposition of BB was visually assessed. 
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Figure 4-11: Nasal cast deposition of BB pMDI under static air flow and with the ‘short’ and ‘long’ nozzle attachments. 
Brilliant blue (BB) canisters were prepared and actuated into a nasal cast model using a short (A) and long (B) nozzle attachment angled at 30,40 and 50° to the plane.  The 
deposition of BB was visually assessed. 
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Under conditions of low flow, the deposition followed a similar pattern with a greater 
distribution within the nasal vestibule, particularly at 40° (Figure 4-10B).  Under high flow, the 
distribution within the nasal cast was generally diffuse, with no specific localisation in the 
olfactory region regardless of the spray angle adopted (Figure 4-10C).  With the inclusion of 
the short or long nozzle attachment (Figure 4-11A and B), spray deposition patterns generally 
followed a similar trend to that without the use of the attachments (Figure 4-10A). However, 
the localisation within the nasal cavity was less pronounced when using the attachments 
compared to the absence of the attachments, however the intensity of localisation (as 
assessed by the visual density of colour) was increased on the olfactory regions for the long 
attachment at 40° and 50°. 
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4.4.7. Diazepam deposition in a nasal cast model 
To assess the deposition of diazepam from 5% w/w ethanol canisters, a single actuation 
of prepared canisters was deposition within the nasal cast at an angle of 40° using static, low 
and high airflows but with no attachments.  The deposition of diazepam in the olfactory regions 
quantified by HPLC-UV.  The overall deposition within the olfactory region under static airflow 
as 6.45% ± 0.12% with low flow resulting in a similar deposition of 6.78% ± 0.58%.  However, 
under high flow, the olfactory deposition was significantly smaller 3.15% ± 0.8% (P < 0.01) 
(Figure 4-12). 
 
Figure 4-12: Olfactory deposition of diazepam. 
Diazepam was dissolved in 5% w/w followed by the addition of the propellant HFA134a.  A single actuation was 
administered into the nasal cast at an angle of 40° and under static, low and high air flow. Data represents mean ± 
SD. N=4 replicate sprays from 2 batches. ** P ≤ 0.01. 
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4.4.8. Cellular toxicity of diazepam 
To investigate the toxicity of diazepam towards OBGF400 cells, a cell viability assay was 
conducted with diazepam exposed to OBGF400 for 24 hours over a concentration range of 
0.001-1000µM.  Cell viability was generally maintained over a concentration of 0.001-100µM 
with a calculated IC50 of 213.2 ± 0.15µM (Figure 4-13). 
 
Figure 4-13: Cellular toxicity of diazepam on OBGF400 cells. 
Cells were grown on a 96-well plate at a density of 5 x103 cells per well and exposed to various concentrations of 
diazepam (0.001 – 1000µM). After 24 hour incubation 20 µL MTT in PBS (5mg/mL) added to each well & incubated 
for 4 hours. The MTT-formazan produced was solubilised in DMSO and quantified colorimetrically using a UV-
spectrophotometer at 570nm.  The control cell (without drug) corresponded to a cell viability of 100%. Data is 
reported as mean ±SD with up to 8 replicates per compound in at least 3 independent experiment. . 
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4.5. Discussion 
 
The BBB provides an insidious barrier to the effective delivery of drugs to the brain (Abbott, 
2005, Abbott et al., 2010b, Abbott and Romero, 1996, Pardridge, 2007b).  Interest in the nose-
to-brain (olfactory transfer) routes as a mechanism to bypass the BBB has recently gained 
attention with an increasing larger body of evidence in human volunteer studies to demonstrate 
the validity of this transfer route.  Despite this increase in interest in the olfactory mucosa as a 
potential target site for therapeutic delivery to attain brain penetration, no clinical translation of 
a direct nose-to-brain device exists.  However, recently a number of medical devices 
manufacturers have developed viable adaptation of traditional pulmonary pMDI actuators to 
allow targeted nose-to-brain drug delivery, e.g. ArhcerFIsh® N2B 
(www.mysticpharmaceuticals.com), ViaNase® (www.kurvetech.com), POD 
(http://impelnp.com/). 
The application of nose-to-brain delivery would benefit therapeutic conditions requiring 
rapid clinical interventions such as epilepsy, where the duration of seizures could be life 
threating and where administration of the therapeutic would likely not be conducted by the 
patient themselves.  The use of benzodiazepine therapy is widespread for seizures and the 
speed of delivery is important in reverse the seizures episodes.  However, the lack of apparent 
nasal deliver systems provides a novel therapeutic target group to exploit for nose-to-brain 
delivery and has been demonstrated for midazolam through nasal (systemic) delivery 
approaches (O'Regan et al., 1996, Mahmoudian and Zadeh, 2004, Mittal et al., 2006).  
This chapter is presented as a short feasibility study to explore the use of a novel nasal pMDI 
actuator system termed ‘Aardvark’ and developed by 3M® for the purposes of olfactory drug 
delivery.   
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To formulate a diazepam pMDI system, the identification of a suitable solvent and its 
miscibility with the propellant HFA134a was required.  The solubility of diazepam in ethanol, a 
common solvent system incorporating into pMDI systems to aid drug solubility, was found to 
be 36.36mg/mL and provided a suitably high concentration, considering most pMDI systems 
required smaller doses administered due to their targeted effect and the maximum 
recommended dose of diazepam for status epilepticus, 30mg (Sirven and Waterhouse, 2003). 
The filling of the canister vials with a mixture of HFA134a and ethanol (5 and 10% w/w) 
with diazepam, also resulted in no formation of crystal growth or precipitates over a 3 week 
period, indicating the suitability of ethanol as a co-solvent and the stability of the final formation.   
Ethanol is fully miscible with HFA134a but can impact upon the vapour pressure and hence 
the aerosol respirable fraction as well as inducing crystal growth of drug particles (Byron and 
Patton, 1994, Williams Iii and Liu, 1999), however this was not observed with our studies.  The 
confirmation of the final canister composition was then followed on by assessment of the long-
term stability, in terms of content assays, on diazepam within the formulated canisters.  It was 
found that both 5 and 10% w/w canisters maintained the stability of diazepam over the month 
period with no significant degradation of diazepam (Figure 4-8). 
To ensure the lack of pulmonary deposition following nasally administration of a drug 
formulations, the droplet size distribution is key in determining the potential for pulmonary 
deposition and it is usually accepted that a VMD of < 5µm (Stuart, 1973, Hatch, 1961a) will 
lead to significant pulmonary deposition. Having confirmed the stability of diazepam within the 
canisters when stored over 3 months, we next assessed the droplet size distribution from the 
actuators (Figure 4-9).  The dispersion of a drug into the propellant increased the eventual 
droplet size, and the inclusion of both BB (for visual indication of deposition) and diazepam 
results in an increase in size distribution fraction (Figure 4-9).  The dv10, indicating the fraction 
of which the spray volume is made up of droplets of equal or less diameters, is an important 
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measure of the fine particle fraction having the potential for pulmonary disposition.  In all three 
formulation development the dv10 was generally larger than the traditional cut-off for 
pulmonary delivery 3-5µm vs 2µm. Furthermore, the VMD (dv50) was similar between the 
propellant alone and the final diazepam formulation (Figure 4-9).  The relative span between 
formulation was similar expect for BB, which demonstrated significantly smaller span and 
hence narrower particle size distribution.  This may be a result of the extensive milling of the 
BB granules, which was not required with diazepam.  Furthermore, the median droplet size 
(dv50) was similar to that reports elsewhere for optimal nasal depositions (Newman et al., 
1988, Foo et al., 2007).  As a pMDI system is actuated, the formulation exits the spray orifice 
and becomes broken down into atomized droplets containing a proportion of each excipient 
used within the formulation, and when formulated with a drug, the droplets will also contain an 
identical proportion of drug.  The propellant is designed to rapidly evaporates and results in an 
intermediate droplet that consist of the co-solvent (any further non-volatile excipients) and the 
drug.   Furthermore, as the co-solvent evaporate the residual particles contain the non-volatile 
elements (i.e. drug) of the initial spray, which deposits at the target site.  It is important to note 
that these residual particles are often significantly smaller than their initial droplets following 
actuation (Sheth et al., 2015). 
Having demonstrated the suitability of a final diazepam formulation along with appropriate 
droplet size distribution, we next assessed the important administration properties to ensure 
olfactory delivery using BB formulation as a visual indicator for olfactory deposition.  Static, low 
and high air flows were used to simulate application with differing levels of inhalation (Foo et 
al., 2007) (Figure 4-10).  It was demonstrated that optimal olfactory deposition was achieved 
under static (Figure 4-10A) and low flow (Figure 4-10B) when the spray was administrated at 
an angle of 40° or 50°. The impact of air-flow is i mportant as the administration of nasal spray 
systems is often associated with a natural ‘inhalation’ activity which can significantly alter the 
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particle distribution through the air flow (Kimbell et al., 2007).  Indeed, when comparing low to 
high flow (Figure 4-10C), the dispersion of the droplets is evident by the lack of any 
homogenous blue deposition regions.   
Nasal pMDI systems, unless specifically designed for olfactory delivery, will often come 
associated with a nozzle that has not be defined to provide localised olfactory delivery, in lieu 
of a wider spray plume angle and hence more wide spread nasal delivery.  To investigate this, 
we adapted the ‘Aardvark’ actuator to include an attachment that would better angle the spray 
plume (Figure 4-11).  Although the attachments provided some ‘focussing’ of droplets within 
the olfactory region, the narrowing of the orifice may have resulted in impaction of the spray 
plume on the sides of the attachment preventing complete delivery of the actuated dose into 
the nasal cast.  However, existing nose-to-brain devices often employ such attachment, 
presumable to enhance the targeting of the spray plume towards the olfactory mucosa, e.g 
Optinose (Optinose US Inch, USA) (http://www.optinose.com/). 
As the attachments resulted in reduced olfactory targeting, the deposition of diazepam to 
the olfactory region was assessed at 40° in the abs ence of any attachments.  Static and low 
air flows gave similar depositions within the olfactory regions (6.4-6.8%) (Figure 4-12), with a 
significantly reduced deposition, 3.15% ± 0.8% (P < 0.01), under high air flow (Figure 4-12).  
Indeed, both the plume angle (not determined in this study) and administration angle have 
previously been reported as critical parameters for effective nasal deposition with decreasing 
turbinate deposition with increasing administration angle (Foo et al., 2007). 
The deposition onto the olfactory mucosa was relatively low, however it has previously been 
demonstrated that ≤ 5% (Foo et al., 2007) of any nasal administered formulation will reach the 
olfactory mucosa, and coupled with the smaller area within the human nasal cavity (3-10% of 
the total nasal surface area (Morrison and Costanzo, 1990b)), it is important to consider the 
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potency of the selected compound towards target receptors.  With non-efficient olfactory 
targeting, the choice of API must be associated with knowledge of it being a potent chemical, 
whereby minimal levels of deposition onto the olfactory mucosa would provide sufficient 
delivery to ensure a positive response at the target site within the CNS. 
The compatibility of the diazepam content within the spray system with OBGF400 cells 
was further assessed through a cellular viability assay.  Cell viability was maintained over a 
broad concentration range of 0.001-100µM with an IC50 of 213.2 ± 0.15µM (Figure 4-13).  The 
total canister content of diazepam was approximately 2.2-2.5mg/mL, equating to 
approximately 10mM. However, the content assay from a single actuation provides details of 
the actual total nasal deposition, 0.15-0.20mg/mL equating to approximately a 10-fold lower 
molar concentration (1mM).  Furthermore, deposition of diazepam was reported to be 
approximately 6-8%, therefore the expected olfactory mucosa exposure would be 60-80µM, 
and therefore would not be toxic to the olfactory cells. 
4.6. Conclusion 
In conclusion, this short study has demonstrated the potential to adapt existing pulmonary 
pMDI formulations systems to develop a novel olfactory-targeting nasal pMDI system.  
Diazepam was selected as a model candidate based on its potency and relatively ease to 
formulate (i.e. solubility in ethanol).  Furthermore, the use of a nasal cast model has aided in 
identifying the spray administration angles to obtain optimal olfactory deposition and the 
potential lack of any toxicity with the administrated dose that would deposition on the olfactory 
mucosa. 
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Chapter 5 
Conclusion 
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5. Conclusions 
The overall aim of this work was to evaluate possible formulation approaches that would 
be exploitable to overcome the physiological barriers present in the nasal cavity to deliver 
therapeutics directly to the brain. To consider this challenge, we investigate three potential 
formulation systems (i) thermoresponsive mucoadhesion nasal gels sprays; (ii) mesoporous 
silica nanoparticles and (iii) nasal pMDI devices. 
Chapter 2 focussed on the development of a simple but effective formulation for water-soluble 
drugs, with the anti-Parkinsonian drug amantadine selected as our model candidate. Hence 
each formulation was subjected for assessment based on gelation time, rheological properties, 
mucoadhesiveness, drug release, spray deposition in a nasal cast model, droplet size 
characterisation, toxicity and storage stability. We identified FCS and FPEG as optimal 
formulation systems with the slowest drug release from FPEG and the greatest from FCS.  A 
key obstacle for intranasally administered drugs is the retention time within the nasal cavity, 
and the inclusion of both a thermosensitive and mucoadhesive polymer would improve the 
residence time of the formulation in the nasal cavity and thereby increasing the window for 
drug absorption across the nasal and olfactory mucosa. Since gelation time and mucoadhesion 
was crucial for residency, different mucoadhesives were analysed for their impact on the 
efficiency of the formulations. It was also important to evaluate these formulations for their 
overall efficiency in delivering the drug.Whilst we did not utilise in-vivo or ex-vivo approaches 
to assess mucoadhesion, the measurement of mucoadhesion was conducted by both tensile 
strength measurement using texture analysis and an inclined agar mucin gel ramp was used 
for evaluation. This was not only very simple method, but was also more reproducible and 
hence reliable than tensile strength measurement. The results demonstrate the superiority of 
FCMC and FCS compared to FPEG. Out of the formulations we studied, overall the formulation 
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FCS stood out among the others because it was not only stable for the longest period but also 
showed better mucoadhesive properties and release profile.  
An eight-week stability study demonstrated that none of the formulations were stable at room 
temperature but were stable under refrigerated conditions, and hence these formulations could 
be developed as drops or in the form of liquid spray when stored under these conditions.  
Furthermore, our optimal formulations were screened for their cellular toxicity towards nasal 
epithelial and olfactory mucosa cells and demonstrated no significant cellular toxicity, 
demonstrating their compatibility in-vivo.  With a well-designed spray system, targeting the 
olfactory region will be more efficient. Hence formulations were also analysed using a spray 
device for their droplet size, and spray pattern in the nasal cast. All the formulations showed 
particle sizes greater than 5µm, as required to avoid entry into the lungs and the nasal cast 
results showed that FCMC covered the highest olfactory region (0.91cm2), and furthermore 
the use of the nasal cast allowed for a semi-mechanistic understanding of the administration 
techniques required to achieve optimal olfactory delivery.   
To address the delivery of poorly soluble drugs, Chapter 3 focussed on the development 
of mesoporous silica nanoparticles as carrier systems for curcumin and chrysin, two poorly 
soluble phytochemicals with a range of CNS cellular and molecular target sites. MSNP were 
selected due to their highly porosity and ability to enhance the solubility of loading molecules.  
MSNP were synthesized using three published different methods and compared on the basis 
of their morphological properties. We identified that Fan-MSNP had better PDI and smaller 
size (~216nm) as compared to the other methods. BET surface analysis confirmed that the 
obtained nanoparticles were mesoporous/microporous in nature. Cellular uptake of FITC 
loaded fan-MSNPs in OBGF400 cells confirmed the compatibility of these nano-systems for 
the intranasal route. Curcumin and chrysin were chosen to load in these system. Loading 
efficient for both curcumin and chrysin were between 12-15% and confirmed through HPLC, 
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TGA  and FTIR approaches with DSC analysis confirming that the loaded curcumin and chrysin 
were in amorphous form. Release studies conducted at pH 5.5 and pH 7.4 demonstrated more 
significant release for curcumin at pH 5.5.  Furthermore MSNP were generally non-toxic to 
OBGF400 cells over 10-100µg/mL for 24 hours. These results were also supported by the 
images obtained by live cell imaging Cell IQ. Thermosensitive gels can be a possible vehicle 
for these MSNPs in the nasal cavity hence we incorporated bare MSNP in the gels we 
optimised in the Chapter 1, and observed no significant rheological changes apart from a slight 
reduction in the initiation of gelation, as compared to the original formulations and suggesting 
that thermoresponsive gels may provide a suitable carrier for MSNP.Lastly, we also evaluated 
the feasibility of adapting pulmonary pMDI delivery devices for the targeted olfactory delivery 
of diazepam in collaboration with 3M. A stability study was conducted where diazepam was 
dissolved in ethanol and filled with HFA 134a kept at 40°C/75% relative humidity for 3 weeks. 
After confirming the stability of the formulation in the glass vials, these formulations were filled 
in 3M canisters and stability (diazepam content assay) assessed over a 3 month duration 
studied, which resulted in no significant decrease in diazepam content over 3 months in the 
prepared pMDI canisters.  Using the 3M nasal actuator, the deposition of the spray plume 
with a nasal cast model was assessed through the formulation of canisters containing brilliant 
blue dye as a visual indicator of deposition and the optimal administration techniques 
determined.  The resultant assessment of diazepam deposition onto the olfactory mucosa was 
quantified as 5-6% of total dose from a single actuation of the canister. Furthermore, the use 
of an actuator nozzle attachment demonstrated a more focussed targeting of the spray plume 
onto the olfactory mucosa, however it resulted in the significant deposition of the spray plume 
onto the internal walls of the attachment.  As some existing N2B pMDI system utilise extended 
actuator nozzles, further work is warranted on the design of an appropriate actuator nozzle 
attachment which would limit internal spray plume deposition and enhance the targeting ability 
onto the olfactory mucosa. 
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A clear challenge in targeting the olfactory mucosa is the correct administration angles of 
the device. Using both a nasal gel and pMDI system, this was still challenging, and therefore 
N2B delivery would, at present, be more appropriate for highly potent APIs where the 
deposition of < 10% of the administrated dose would result in a clinically significant response.  
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Apendix A 
 
 
Figure : Effect of PF127 concentration on gelation temperature  
1g of solution was weighed in a glass vial and placed in a dry block and heating initiated at 20 °C an d increased 
by 1°C after every 5 minutes of equilibration time.  The Tsol-gel point was defined as the temperature whereby the 
upper meniscus of the gel did not move upon tilting the vial by 90 °. n=3 
 
 
 
